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Oncogenes are now recognised to be fundamentally
important in regulating cellular proliferation and
differentiation, and alterations in their expression have
been described in spontaneous human neoplasms. This study
has sought to identify changes in ras and myc oncogene
expression during the process of human colorectal
carcinogenesis. The introduction presents a review of
current knowledge of oncogenes and their involvement in
neoplasia, and relates this information to the context of
colorectal carcinogenesis. The original work of the
thesis examines techniques of demonstrating oncogene
expression in tissue sections. Immunohistochemical
methods using specific antibodies to oncogene proteins
were compared with in situ hybridisation techniques using
radioactively labelled DNA probes containing oncogene
sequences. The latter methods were found to have many
problems and disadvantages compared with
immunohistochemistry. Provided that the specificity of
the antibodies was confirmed, that fixation conditions
were optimised, and that a sensitive detection system was
used, specific localisation of ras and myc oncogene
proteins could be consistently demonstrated in human
colorectal tissues by immunohistochemistry.
The monoclonal antibody Y13-259 was used to study ras
gene expression. Its specificity was confirmed by
immunoblotting, and by its use in immunohistochemistry
with a positive control cell line (FH05T1) which was
genetically manipulated to express Ha-ras at artificially
high levels. In a series of human colorectal tissues
studied by frozen section immunohistochemistry, it was
found that ras gene expression was increased in the early
(adenoma) stage of carcinogenesis, but that this increase
was not consistently sustained in carcinomas. These
results were confirmed in a larger series of tissues,
fixed by the specialised fixative PLPD, which offered
improved morphology with retention of optimal
immunoreactivity.
c-myc expression was investigated using the monoclonal
antibody Mycl-9E10 to the myc protein product. Tissue
fixation conditions were found to have an important
effect on staining distribution. 50 colorectal carcinoma
resection specimens were specially handled to optimise
fixation. Positive staining was observed in all
epithelial tissues, but a significant difference occurred
in subcellular distribution of stain. Nuclear staining
predominated in non-neoplastic mucosa whilst carcinomas
consistently showed cytoplasmic staining. The findings
suggest that an alteration occurs in the cellular
processing of the c-myc oncogene protein during the
process of colorectal carcinogenesis.
It is suggested that cooperation of ras and myc oncogenes
may occur at an early stage in colorectal carcinogenesis,
and play an important role in the generation of the
malignant phenotype. This suggestion is discussed in the
context of existing knowledge of oncogene invovement in
colorectal carcinoma.
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1.1 ONCOGENES - AN OVERVIEW
1.1.1 Retroviruses and oncogenes
It is a central belief of modern oncology that genetic
changes are fundamental to carcinogenesis. Evidence for
this belief comes from a wide variety of different
sources - from the study of cancer in populations to the
analysis of DNA of individual cells. We are now at a
stage in the study of cancer where the techniques and
resources exist to analyse these genetic changes at the
molecular level.
Recently oncological research has witnessed a remarkable
convergence of two apparently unrelated avenues of
investigation, which has led to important advances in the
understanding of genetic events of carcinogenesis. The
first of these concerns the work of tumour virologists.
Viruses have for long been suspected of playing a
critical role in the development of at least some human
cancers. It was many years before the full significance
was realised of the early observations of Rous, who
showed that a cell-free filtrate from tumours of fowl
could induce similar tumours in recipient birds. It was
subsequently shown that the agent responsible is a virus
of the retrovirus family.
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Retroviruses are unusual in several respects. Their life
cycle involves integration of their genome into the host
cellular chromosome by the unique process of reverse
transcription, in which the viral enzyme reverse
transcriptase allows the synthesis of a DNA copy of the
viral genome, which is then integrated into the host
cell's DNA. A subgroup of the retroviruses - the
oncogenic retroviruses - is able to cause transformation
of appropriate recipient animal cells in culture
(Duesberg, 1983). Transformation in this context refers
to a heritable change whereby affected animal cells lose
growth restraints of normal cells while adopting some of
the characteristics of malignant cells, including in some
cases the ability to induce tumours when injected into
syngeneic animals. Dissection of the genome of the
oncogenic retroviruses led to the identification of a
group of genes which were necessary for the initiation
and maintenance of transformation. This group is termed
the oncogenes, one genes or transforming genes, and in
the retroviruses is quite separate from the viral genes
controlling integration and replication.
The first of these genes to be characterised was the sre
gene of the Rous sarcoma virus (Stehelin et al, 1976),
which is the gene enabling the virus to transform chicken
fibroblasts in culture, and to induce sarcomas in vivo.
These workers made the tantalising discovery that sre is
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not a bona fide viral gene at all, but is a close copy of
the coding seguence of a gene found in all normal chicken
cells.
The full significance of these observations to the
context of human carcinogenesis was initially obscure.
Formal proof was still lacking that any virus could cause
a human malignant neoplasm, and indeed the mode of action
of the acutely-transforming oncogenic retroviruses
causing tumours in experimental animals seemed
incompatible with the natural history of the majority of
human malignant tumours. The retroviruses seemed to
transform cells to the malignant phenotype in a single
step, whereas many of the spontaneously-occurring human
cancers appeared to occur by the accumulation of several
changes, occurring step-wise, leading to a progressive
loss of growth control, apparently without the assistance
of viruses.
1.1.2 Oncogenes identified by transfection
A new and different approach to the investigation of the
cancer-causing genes of transformed cells was provided by
experiments involving the transfer of functional genes
between different cell types. There are a number of
different methods of performing this procedure which is
known as transfection. In the most commonly-used
technigue, a non-transformed embryonic rodent fibroblast
cell line was exposed to a calcium phosphate precipitate
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of high molecular weight DNA derived from transformed
cell lines (Cooper, 1982). The recipient cell line most
frequently used was the cell line NIH/3T3. When DNA from
control untransformed cells is used, there is no
observable effect, but with DNA from transformed cells,
the NIH/3T3 recipients sometimes undergo transformation.
It was possible by the techniques of molecular cloning to
identify the genes responsible for the change. Some
workers anticipated that these would emerge as an
unfamiliar, previously uncharacterised group of genes,
but they were at least partly mistaken. Examination of
nucleotide sequences defined very close homologies
between the transforming genes identified by transfection
and the already familiar oncogenes of the oncogenic
retroviruses (Bishop, 1983). The earliest reports of such
work include those of Parada et al (1982) and Santos et
al (1982), who showed the transforming genes of the EJ
and T24 human bladder carcinoma cell lines to have very
close homology with the oncogene carried by the Harvey
strain of the murine sarcoma virus. Subsequently, many
further similar types of homology were demonstrated
between transforming genes of cell lines and the
oncogenes of retroviruses.
1.1.3 Cellular oncogenes
Clues to the evolutionary origin of the retroviral
oncogenes were initially supplied by the work of Stehelin
et al (1976), and Spector et al (1978), who demonstrated
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the DNA of avian and mammalian cells to contain sequences
of very close homology to the src gene of the Rous
sarcoma virus. Analysis of cellular RNA also showed
transcripts of this gene to be present in uninfected
normal cells. Further work along similar lines showed
that each retroviral oncogene possesses a close homologue
in normal cells. Significantly, the oncogene sequence
found in normal cells possesses no adjacent viral
sequences such as the gag, pol or env genes, nor does it
contain the viral long terminal repeat sequences (LTR's)
whose presence would have been expected if the oncogene
sequence was of viral origin. In addition, the cellular
gene has the characteristic structure of alternating
exons (sequences coding for the final protein product)
and introns (intervening sequences not represented in the
protein product) which distinguishes eukaryotic genes
from viral genes which do not possess introns. These are
compelling pieces of evidence that the cellular oncogenes
are the progenitors of the viral oncogenes, and were
presumably picked up by the viruses during the processes
of integration and replication. Whilst such transduction
is a rare event, the oncogene confers the property of
inducing increased cellular proliferation, and hence
presumably gives the carrier virus a selective advantage.
The cellular oncogene sequence is termed a cellular
oncogene (c-onc) or proto-oncogene, to distinguish it
from the viral oncogene v-onc.
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Molecular cloning techniques have allowed
characterisation of c-oncs from many species, widely
separated in evolutionary terms, and a most remarkable
degree of inter-species conservation of gene structure is
observed. Creatures as different as man and the
Drosophila fruit fly share c-oncs of striking homology.
Indeed it has now been shown that baker's yeast
(Saccharomyces cervisiae) possesses genes whose structure
and protein products are remarkably similar to
corresponding genes in mammals (Papageorge et al, 1984).
Such fidelity of conservation across aeons of
evolutionary time is truly extraordinary, and argues
strongly for some crucial function basic to cellular
homeostasis. Furthermore, transcription from c-oncs
occurs in a variety of tissues, and in every vertebrate
species that has so far been examined, albeit often at
very low levels (1-10 copies per cell). However,
expression does not occur coordinately, and each oncogene
may have its own specific function in different tissues
and at different stages in development (Bishop, 1983).
The speculation follows quite naturally that oncogenes
are central to the regulation of cellular proliferation
and differentiation, functions which are manifestly
deranged in tumours. The cellular progenitors of the
retroviral oncogenes are clearly likely to be direct
instruments in the process of carcinogenesis.
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1.1.4 Oncogenes and control of cellular proliferation
All proliferating cells progress through a highly ordered
sequence of events referred to as the cell cycle, during
which protein and DNA synthesis occur followed by
mitosis. Evidently controls are exerted at certain
critical points in the cell cycle. In normal cells, such
controllers are sensitive to environmental stimuli, and
complex transmembrane and intracellular signalling
systems exist to transfer information from the
extracellular environment to the cell nucleus in the
induction of cell division. Accumulating evidence
indicates that oncogene products may have important
functions as links in these systems.
Growth stimulation of quiescent non-transformed cells in
culture leads to elevated expression of c-myc only in the
first cell cycle following stimulation, whereas c-Ki-ras
shows cell-cycle dependent levels of expression, the
relative abundance of ras mRNA increasing in mid-to-late
G /G . Conversely, a teratocarcinoma cell line (F9),
0 1
induced to undergo terminal differentiation to non-
proliferating endoderm, shows markedly diminished c-myc
expression, but unchanged levels of ras (Campisi et al,
1984). The c-fos oncogene shows elevated transcription
following growth stimulation of 3T3 cells in culture
(Greenberg & Ziff, 1985).
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In vivo, there is some evidence that oncogene expression
shows regulated variation at different phases of
embryonic development, and in adult tissues in varying
physiological states. In the mouse embryo, there are 2-5
fold increases in mRNA transcripts of c-myc, c-erb-A and
c-src during late gestation, whilst c-Ha-ras appears to
be transcribed constitutively (Muller et al, 1982; Slamon
et al, 1984) . In human placenta, there is evidence of
significant increases in c-myc mRNA levels in
cytotrophoblast during early gestation (Pfeifer-Ohlsson
et al, 1984). c-Ha-ras transcription has been observed to
increase 3-fold during hepatic regeneration induced by
partial hepatectomy in rats (Goyette et al, 1984).
Elucidation of the biochemical functions of the protein
products of oncogenes initially resisted straightforward
definition, partly because of the difficulty in isolating
the proteins in any quantity. With the advent of
techniques allowing efficient expression of cDNA in
bacteria and yeasts, it has become evident that a variety
of different functions are subserved, the products of the
different oncogenes segregating into a number of major
groups.
The first to be identified was the protein encoded by the
well-studied retroviral transforming gene v-src, a 60 kDa
protein termed pp60-v-src (Brugge and Erikson, 1977).
Soon, the uncommon enzymatic function of protein-tyrosine
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kinase activity was demonstrated for this product
(Collett and Erikson, 1978). Whilst phosphorylation had
already been recognised as an important regulator of
protein function, it had only infreguently been observed
to involve tyrosine in more than a small proportion of
total residues. Soon, the same tyrosine kinase activity
had been shown for the proteins of a number of retroviral
oncogenes as well as for their corresponding c-oncs
(Hunter and Cooper, 1985). All were found to share a
recognisably similar domain of around 30 kDa in which
resides the specific catalytic activity. This group of
proteins is generally associated with the plasma membrane
of cells, some spanning the membrane, others being
cytoplasmic proteins, closely apposed to the inner face.
The strategic location of this group of proteins at the
plasma membrane of the cell is suggestive of a role as
receptors in signalling systems analogous to those shown
by endocrine cells, in which cellular proliferation is
triggered by the action of an extracellular stimulus on a
membrane receptor. The epidermal growth factor (EGF)
receptor of normal cells was shown to have tyrosine
kinase activity (Buhrow et al, 1983), and later it was
shown by Downward et al (1984) that the protein product
of the v-erb-B oncogene shows very close amino acid
sequence homology with the sequence of the intracellular
part of the EGF receptor. The v-erb-B product appears to
be a truncated version of the receptor, the retained
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portion being the transmembrane and intracytoplasmic part
of the molecule. The intracytoplasmic domain is the part
likely to be responsible for the delivery of the signal
to the cell to proliferate. In its truncated form, the
receptor protein is no longer under the influence of
extracellular EGF, and presumably delivers a continuous
unregulated signal to the cell to proliferate.
A family of oncogene products exists without known
membrane receptor function, but which also show tyrosine-
kinase activity (abl, fes and fps). In addition to their
tyrosine kinase activity (the exact significance of which
remains to be determined), the protein products of the
src and ros oncogenes have been shown to have inositol
lipid kinase activity, having the ability to convert
phosphatidyl inositol to phosphatidyl inositol
biphosphate (Ptdlns(4,5)P2). The latter has emerged as
playing a central part in an important intracellular
signal transduction system (Berridge and Irvine, 1984).
In this system, binding of an agonist to a receptor on
the cell membrane leads to the diversion of Ptdlns(4,5)P2
from a 'futile cycle' of phosphorylation and
dephosphorylation by kinases and esterases in the cell
membrane, towards a phosphodiesterase which splits it
into inositol triphosphate (IP3) and diacyl glycerol
(DAG). Both of these molecules function as intracellular
second messengers, mediating stimulation of cellular
proliferation by mobilisation of sequestered
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intracellular calcium, and enhancement of protein kinase
C (PKC) activity respectively.
The downstream target of the ras proteins has recently
been identified (Trahey & McCormick, 1987) (see section
1.2.4), and it appears to couple a membrane receptor for
growth factors to the phosphodiesterase phospholipase C
which cleaves Ptdlns(4,5)P2 to IP3 and DAG (Berridge,
1986).
Further links have been demonstrated between oncogene
products and previously described pathways controlling
cellular proliferation. Sequence analysis of the 28kDa
protein product of the v-sis oncogene showed close
homology to one of the subunits of the well-studied
growth factor, platelet derived growth factor (PDGF)
(Waterfield et al, 1983). The attractive implication of
this finding is that cells transformed by this oncogene
escape the influence of normal growth restraints by
autocrine synthesis of growth factor.
The protein products of the oncogenes described above
appear to exert their action either at the cell membrane
or within the cytoplasm of the cell. There is however a
functionally separate group whose action appears to be
exerted in the nucleus. Some members of this group, whose
members include myc, myb, fos and erbA, show some
structural homology with each other, and their functions
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are also similar. As a group, the most conspicuous of
their actions is that of immortalisation of cells in
culture, whilst they are much more limited in their
ability to induce anchorage-independent growth (Weinberg,
1985). This is in contrast to the larger group of
oncogenes whose action is exerted in the cytoplasm.
The mechanisms of action of these 'nuclear oncogenes',
and their roles in normal cellular homeostasis, are
largely unknown. It is apparent that many of their
products are reversibly bound to nuclear structures, and
transcription of myc increases in growing cells shortly
before the S-phase of the cell cycle. Cells transfected
with myc appear to acquire an enhanced ability to express
other cellular genes, including artificially introduced
genes (Kingston et al, 1984). It is speculated that myc
may exert effects on transcription itself, or on the
apparatus responsible for it regulation or specificity.
1.1.5 Activated oncogenes in carcinogenesis
Cellular oncogenes, which after all are normal cellular
genes, do not in their native form cause neoplastic
transformation of cells. How then do they become
activated? Their structural and functional heterogeneity
becomes further manifest in the variety of ways in which
activation takes place. As a generalisation, oncogene
activation involves alteration from the normal
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physiological state either by enhanced transcription or a
structural change in the gene itself.
The first of the mechanisms to be described involved the
experimental ligation of strong transcriptional promoting
sequences to oncogene DNA sequences (Blair et al, 1981).
Oncogenes which were previously non-transforming acquired
activity when transcribed at artificially high levels.
This experimentally contrived mechanism was soon found to
have several close parallels in vivo. A rather perplexing
problem was posed to the tumour virologists by a group of
retroviruses, of which the avian leukosis virus (ALV) is
an example, which repeatedly induce specific neoplasms in
animals, yet do not carry a v-onc. This puzzle was
elegantly resolved when it emerged that the viral DNA in
the tumours caused by ALV is specifically integrated in
close proximity to the c-myc oncogene, whose expression
is greatly increased as a consequence of the action of
viral promoter or enhancer sequences in the long terminal
repeat (LTR) (Payne et al, 1982). A similar mechanism has
been shown to exist for other oncogenes in animal
tumours, including erb-B, but there is little evidence
that this mechanism is of major importance in human
carcinogenesis.
A second mechanism, with some points of similarity to the
first, emerged from study of oncogenes in the process of
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chromosomal translocations. Translocations are common in
tumour cells, and certain types of neoplasms repeatedly
show the same ones, the most familiar example being the
distinctive Philadelphia chromosome of chronic myeloid
leukaemia. Human Burkitt's lymphoma cell lines in the
majority of cases show a translocation in which the
distal portion of chromosome 8 is transferred to a
chromosome bearing an immunoglobulin gene which is active
in the initial tumour (usually chromosome 14). The c-myc
oncogene has been mapped to a position near to the break
point on the translocated portion of chromosome 8, and it
seems to come under the influence of neighbouring
powerful gene regulator sequences involved in
immunoglobulin production (Dalla Favera et al, 1982).
Again, inappropriately high expression leads to cellular
transformation.
Gene amplification is yet another means whereby oncogene
expression may be sufficiently boosted to cause
transformation. Distinctive chromosomal abnormalities
have been described which signify DNA amplification,
namely double minute chromosomes, and homogeneously
staining regions (HSR) (Alitalo, 1984) . Amplification of
c-myc has been mapped to HSR of chromosomes in the colon
carcinoma cell line COLO320 (Alitalo et al, 1983) and c-
Ki-ras amplification is described in double minute
chromosomes and HSR in a mouse adrenocortical tumour
cell line (Schwab et al, 1983). Amplification of the
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oncogene N-myc has been reported in unmanipulated human
tumours (principally of neuro-endocrine histogenesis
small cell undifferentiated carcinoma of lung, and
childhood neuroblastomas). The level of amplification of
N-myc broadly reflects the clinical aggressiveness of the
tumour (Schwab, 1985). The Ki-ras oncogene has been
reported to be amplified in ovarian carcinoma (Filmus &
Buick, 1984).
A very different mechanism of activation is shown by a
number of oncogenes, most notably the members of the ras
gene family. In this group, an alteration in gene
structure by mutation leads to important conformational
and functional changes in the protein product. This was
first discovered by analysis of DNA from EJ and T24
bladder carcinoma cell lines, and accumulating evidence
indicated activation of ras oncogenes to occur by
mutations at the specific points 12 or 61 in their coding
sequences (Varmus, 1984). Tumours induced by the action
of chemical carcinogens on rodent fibroblasts
consistently show point mutations at these specific
sites, the distribution of mutations suggesting
interaction of the carcinogen with the ras gene directly
(Balmain, 1985; Barbacid, 1987).
The epidemiology and natural history of most human
cancers indicates that the process of carcinogenesis
occurs in a stepwise fashion involving sequential
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acquisition of ever-greater deviations from the normal
controls of cells' growth, differentiation and behaviour.
It is a complex dynamic sequence which occurs over many
cycles of cell replication affecting successive
generations of cells. Moulding the processes of evolution
in the cell population is the natural selection of those
cells best fitted for autonomous replication. This is
clearly a very different situation from experimental
models in which cells acquire the transformed phenotype
in a single step, either by infection with an acutely
transforming retrovirus or by transfection with a single
oncogene.
Activated oncogenes are often detectable in unmanipulated
human cancers, but several observations indicate that
they are rarely sufficient on their own to induce tumour
formation, and probably represent only one component in a
complex chain of alterations. There is good evidence that
single oncogenes have limited powers. When early passage
cells are used as recipients of transfection, single
oncogenes do not on their own effect neoplastic
transformation. They may, however, confer isolated
components of the transformed phenotype - Land et al
(1983a) observed changes in cells transfected with the
ras gene indicating acquisition of cellular functions
such as reduced anchorage dependence. Recipients of myc
in contrast showed immortalisation in culture but were
not transformed. Under experimental conditions in which
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cellular maturation could be studied, Kahn et al (1986)
showed that myc alone could maintain self-renewal and
block terminal differentiation. When the ras gene was
introduced together with the active v-myc oncogene, the
cotransfected cells underwent vigorous morphological
transformation (Land et al, 1983a). Similar results were
obtained when ras was cotransfected with the large T gene
of the oncogenic DNA polyoma virus. This is one of three
true viral genes which evolved in the polyoma virus
genome, and which cooperate to induce the transformed
phenotype in infected cells. The large T gene on its own
confers decreased serum dependence and increased life
span, but when it is cotransfected with ras, complete
conversion to the transformed phenotype results (Land et
al, 1983b).
Further evidence for the limited powers of a single
oncogene come from experiments using transgenic mice. In
this system, a gene is injected into a fertilised ovum,
and typically within a few cell divisions, integrates
into a host chromosome. Usually all tissues acquire the
newly-inserted gene, although expression is often tissue-
specific, directed by regulatory elements of the gene.
Transgenic mice produced bearing the c-myc oncogene
develop neoplasms in only a minority of cells expressing
myc, indicating that further events are required for
tumourigenesis (Adams et al, 1985).
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The first cooperating pair of oncogenes recognised were
Ha-ras and c-myc, but several others are described. The
broad concept of cooperation was refined by Weinberg
(1985) who introduced the idea of 'complementation
groups' of oncogenes. Replacement of ras or myc in the
cotransfection experiments with other oncogenes allowed
the definition of two functionally different classes of
oncogene, based on the nuclear or cytoplasmic (including
plasma membrane) localisation of the gene product. He
pointed out that whilst there are few examples of
transformation of early passage cells by either a single
oncogene or two oncogenes of the same functional type,
there are many examples of nuclear and cytoplasmic
oncogenes cooperating to produce transformation. In some
of the few examples of apparent transformation by a
single oncogene, a variety of chromosomal aberrations are
observed in transformants (Spandidos and Wilkie, 1984),
which could conceivably lead to activation of additional
genes. Indeed, there is recent evidence indicating that
insertion of an extraneous oncogene can lead to increased
expression of endogenous oncogenes (Wyllie et al, 1987).
It seems likely that the transformed phenotype results
from a complex interaction of different oncogenes,
different growth signals and different cell receptors. A
system such as this with overlap and interplay between
the various components may allow proliferation to be very
finely controlled, and this may also explain why multiple
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genetic changes are needed for tumorigenesis (Land,
1986). The individual features which characterise the
transformed phenotype, such as growth factor
independence, reduced adhesiveness, immortalisation and
metastatic potential, are often independent of each
other, and it is likely that their acquisition by
different routes and in different chronological orders
may not affect the ultimate arrival of the cell at the
end point of the fully transformed phenotype (Balmain,
1985).
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1.2. THE RAS FAMILY OF ONCOGENES
1.2.1 ras genes identified by transfection
The NIH/3T3 cell line is a continuously passaged line of
murine fibroblasts which has been widely used in
transfection experiments in the identification and
characterisation of transforming genes (Cooper, 1982).
DNA from a number of sources including cultured cell
lines, chemically induced animal tumours and
unmanipulated primary human tumours, can elicit
transformation of the recipient NIH/3T3 cells. DNA from
corresponding normal tissues of the same tumour-bearing
hosts has no such effect, suggesting that a qualitative
change has taken place in the DNA of the tumour.
Collective experience of the NIH/3T3 assay system has
provided two striking observations. Firstly, transforming
activity is detected in only 10-20% of human tumours of
widely varying histogenesis, and secondly, regardless of
the tumour type, the activated c-ras oncogene is by far
the most frequently detected transforming gene in this
assay (Santos et al, 1985).
The NIH/3T3 cell line is considered to be an abnormal
cell line, already immortalised or 'rescued from
senescence', and which appears to be particularly
sensitive to transformation by activated c-ras oncogenes.
Neoplastic transformation of the recipient cells in the
assay appears to depend on the acquisition from the
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tumour DNA of a mutant allele acting in a dominant
manner. The NIH/3T3 cell is insensitive, however, to many-
other activated oncogenes, whose presence is almost
certainly concealed in the 85% or so of human tumours
which are negative in the assay. An important flaw in the
transfection assay is therefore in its insensitivity
success of transfection requires a dominant effector;
some active oncogenes may show limitations of species
specificity; and the earliest steps in the acquisition of
the transformed phenotype are unlikely to be detected in
this system.
Despite these shortcomings, the transfection assay has
provided valuable information. The availability of
retroviral DNA probes allowed investigators to seek - and
find - homologies between the previously known viral
oncogenes and the cellular transforming genes of the
NIH/3T3 transformant clones. The human EJ and T24 bladder
carcinoma cell lines were first found to have an
activated form of the ras oncogene carried by the Harvey
strain of the murine sarcoma virus v-Ha-ras (Parada et
al, 1982; Santos et al, 1982) and soon other human cell
lines were found to possess the corresponding v-ras gene
of the Kirsten strain (v-Ki-ras) (Der et al, 1982). A
third member of the ras family - N-ras - was also
detected as a functionally transforming gene in the
NIH/3T3 assay, but this has no retroviral homologue
(Shimizu et al, 1983).
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1.2.2 Molecular structure of ras oncogenes
In the human genome, Ha-ras and Ki-ras are each
represented by two loci, one with introns and one without
(Ellis et al, 1981; DeFeo et al, 1981; Chang et al,
1982b). The genes with introns show a higher degree of
inter-species conservation and are thought to represent
the functional genes. For historical reasons, they are
referred to as c-Ha-ras-1 and c-Ki-ras-2, and are located
on the short arms of chromosomes 11 and 12 respectively.
N-ras has been assigned to the short arm of chromosome 1.
Precise nucleotide sequence data are available for the
three human ras oncogenes (Capon et al, 1983a; McGrath et
al, 1983; Taparowski et al, 1983). There are wide
divergences in the size and complexity of the non-
transcribed intron sequences, but all three have four
exons of the same size with closely homologous nucleotide
sequences, and precisely corresponding splice points.
(Ki-ras has an additional diverged fourth exon, and may
code for two alternative products). Due to variations in
intron length, the three genes have very different sizes
approximately 40 kb, 6.6 kb and 14 kb for c-Ki-ras-2,
c-Ha-ras-1 and N-ras respectively. Each gene codes for
proteins of 188 or 189 amino acids, with a molecular
weight of 21,000.
There is evidence that the ras genes are members of a
larger evolutionarily-conserved 'super-family7 of related
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genes which have been termed rho (ras-homologous)
(Madaule & Axel, 1985). Significant homologies occur
between the amino-terminal sequence of the ras proteins
and a group of mammalian proteins termed G proteins,
whose role is transduction of signals from extracellular
stimuli into a variety of cellular responses (Hurley et
al, 1984; Gilman, 1984). A chance finding during the
screening of a cDNA genomic library prepared from the
abdominal ganglion of the mollusc Aplysia was that of an
open reading frame of 192 amino acids encoding a protein
of predicted molecular weight of 21,000 (Madaule & Axel,
1985). Computer-assisted search of the NIH protein
database allowed identification of several regions of
close homology between the deduced protein and the three
members of the ras family. Analysis of many different
species subsequently confirmed rho genes to be
universally present in all eukaryotes examined. There is
a striking conservation in size of the protein products
of ras and rho, all having a molecular weight of 21,000.
(The implications of this are discussed in section
1.2.4) .
1.2.3 Activation of ras oncogenes
ras genes are clearly present in an activated form in the
genome of tumours which are positive in the NIH3T3
transfection assay, yet transfection in their native form
from normal tissues fails to induce neoplastic
transformation (Cooper et al, 1982; Chang et al 1982a).
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What changes in the structure or expression of the gene
constitutes such activation? Comparison of the structures
of normal and activated ras genes initially indicated
subtle genetic changes of small physical proportions
which were not detected by restriction mapping.
Accumulating nucleotide sequence data from a number of
different laboratories demonstrated that the transforming
activity of the gene is the consequence of a point
mutation occurring at one or other of two critical
locations - codon 12, located in the first exon, or codon
61 of the second exon (Reddy et al, 1982; Tabin et al,
1982; Taparowsky et al, 1982 and 1983; Capon et al, 1983;
Shimizu et al, 1983; Yuasa et al, 1983). Mutations at one
or other of these locations have been demonstrated for
all three ras genes from a wide range of cell lines and
spontaneous human tumours. Each mutation is a single base
change. By analysing experimentally mutated ras genes, it
has been demonstrated that substitutions at positions 12,
13, 59, 61 and 63 can lead to activation (Levinson,
1986). By constructing Ha-ras genes bearing all possible
mutations at codon 12, Seeburg et al (1984) showed that
only one amino acid (proline) other than the glycine
which is normally present, fails to lead to activation.
Proline and glycine when they occur in alpha-helical
polypeptide chains both tend to act as hinge points, so
their substitution in the activated gene product may lead
to an important conformational change in the polypeptide.
This is supported by the fact that the p21 products of
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the mutated ras gene show altered electrophoretic
mobility (Seeburg et al, 1984).
Most reports have indicated that ras is activated by
mutation, but this may reflect the inherent insensitivity
of the NIH3T3 transfection assay. It is possible that
activation from gene amplification may not be detectable
in this assay. Amplification of non-mutated ras genes has
been reported in a few spontaneous tumours, but it seems
that this is a relatively inefficient way of inducing
malignant change. Driven by its own cellular promoters,
which are relatively weak, the normal ras gene is unable
to induce transformation of transfected fibroblast cell
lines. However, by placing the normal Ha-ras oncogene
under the powerful enhancing influence of viral long
terminal repeat sequences, Chang et al (1982a) were able
to effect transformation in the NIH3T3 system, but not in
primary embryo fibroblast cultures. Spandidos and Wilkie
(1984) demonstrated single step transformation of early
passage embryonic fibroblasts by the mutated T24 human
Ha-ras oncogene ligated to strong viral promoting
sequences. The normal non-mutated ras gene under the same
promoting influence induced immortalisation but not
transformation.
Over-expression of normal ras, whilst clearly
demonstrated in several experimental systems, has less
commonly been reported in authentic human tumours.
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However, elevated expression of ras has been detected at
the RNA level in a number of spontaneous human
malignancies of different types (Spandidos & Kerr, 1984;
Spandidos & Agnantis, 1984; Spandidos, 1985).
1.2.4 ras p21 structure and function
The product of the ras gene family is a protein of
molecular weight 21,000 daltons termed p21 (Shih et al,
1979) . It has been the subject of intensive investigation
since ras was first identified as the transforming gene
of the murine sarcoma virus. The foundations of this work
involved the use of specific antisera against the viral
transforming protein. Rodents inoculated with syngeneic
virally transformed cells produce antibodies to the
product of the viral oncogene (Shih et al, 1979), and
antisera produced in this way allowed partial
purification and biochemical characterisation of p21.
Each ras gene encodes a product of 188 or 189 amino
acids, and the three members show greatest divergence
from each other between amino acids 121-140 and 165-180.
In contrast, the amino terminal domain of the first 80
amino acids shows virtual identity of sequence between
the three proteins, and the middle domain of 80 amino
acids shows approximately 85% homology between any pair.
The sites at which activating mutations occur (positions
12 and 61) are within domains of homology between the
three proteins.
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The primary translation product is present in the cytosol
of the cell where it undergoes post-translational
acylation (Sefton et al, 1982), and is subsequently to be
found on the inner aspect of the plasma membrane
(Willingham et al, 1980) where it is bound with lipid
(Capon et al, 1983b; Yuasa et al, 1983). Amino acids
located at or near the carboxy terminal end of the p21
molecule are required for cellular transformation,
membrane association and lipid binding (Willumsen et al,
1984) .
The ability to efficiently express cDNA's encoding normal
and activated p21 polypeptides in Escherichia coli has
permitted more detailed biochemical and functional
analysis of the ras products (Lautenberger et al, 1983;
Feramisco et al, 1984; McGrath et al, 1984). Scolnick et
al (1979) had previously demonstrated GTP-binding
activity of p21, but the larger quantities of purified
protein yielded by the bacterial expression system
permitted the significant observation that in addition to
guanine nucleotide binding ability, the normal p21
proteins have GTP'ase enzymatic activity, and that this
is selectively impaired by 4 - 10 fold by the critical
mutation at position 12 which activates the oncogenic
potential of the gene (Gibbs et al, 1984; McGrath et al,
1984; Sweet et al, 1984). This was the first indication
of a functional difference between the normal and
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oncogenic forms of the protein.
The GTP-binding and GTP'ase activities of p21 prompted
speculative comparisons with previously-described
proteins with these properties, notably the mammalian G
proteins (Gilman, 1984) and the bacterial elongation
factor protein EF-Tu. Fascinating parallels emerged
between these proteins of widely differing origins. Like
p21, the G proteins are membrane-associated and catalyse
GTP hydrolysis, a function performed in response to a
variety of extracellular stimuli as diverse as photons
and hormones. X ray crystallographic data are not
available for p21 or G proteins as crystallisation has
not been achieved, but such data is available for EF-Tu,
which has 42% homology with p21 (McCormick et al, 1985).
These data were used to generate a model of the tertiary
structure of the p21 molecule. A striking finding was
that the four loops of maximum homology between the ras
gene products and those of the related homologous
proteins constitute the proposed guanine nucleotide
binding site. Significantly, amino acids 12 and 61 are
located in this phosphoryl-binding loop. This is
supported by the finding that an antibody raised against
a synthetic peptide of amino acids 5-18 (ie spanning
position 12) abolishes GTP binding by p21 (Clark et al,
1985) .
It seems clear that the structural similarity between
29
GTP-binding domains of ras p21 and the G proteins
indicates a similar function, namely that of a membrane-
associated switch. Mutations at positions 12 or 61 do not
affect GTP binding, but decrease hydrolysis by up to 10
fold. The GTP-bound form of p21 represents the active
conformation of the protein with respect to signal
delivery, and it appears that the oncogenic form of p21
when GTP-bound provides the cell with an unregulated
proliferation signal.
Whilst GTP hydrolysis is the function of the constant
domains of p21, the variable domains are likely to serve
to link the protein to several different receptor or
effector proteins. A flexible system of this kind may
allow a single cell to respond identically to different
stimuli, or alternatively allow two different cells to
repond differently to identical ligands (Madaule & Axel,
1985). The striking conservation in size of the ras and
rho gene products (21,000 kDa) may indicate that they are
interchangeable units in an interacting system of
proteins subject to strict constraints of size of
individual units.
Very recently, a protein has been identified by Trahey &
McCormick (1987) which is a strong candidate to be the
target for action of the p21 protein in mammalian cells.
This cytosolic protein termed GTP'ase activating protein
(GAP) interacts with the normal p21 protein to stimulate
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its GTP'ase activity by 100 fold. Significantly, GAP has
no apparent effect on the GTP'ase activity of the
mutationally activated p21 protein. The biologically
active GTP-bound form of p21 is hence permitted to
persist (Sigal, 1988).
In a different approach to the functional analysis of
p21, Stacey & Kung (1984) micro-injected purified
recombinant p21 proteins into various cell types. Micro¬
injection into NIH/3T3 cells led to morphological
transformation. When quiescent NIH/3T3 cells were
injected with non-mutated p21 they started to synthesise
DNA? when injected with mutationally activated p21, such
cells underwent rapid proliferation. Conversely, micro¬
injection of transformed cells with a monoclonal antibody
to p21 can lead to temporary reversal of the transformed
phenotype (Mulcahy et al 1985). Furthermore, such
antibodies also block the transforming ability of a group
of oncogenes with membrane-associated protein products
(src, fes and fms), an observation in keeping with the
proposal that p21 proteins act as transducers of
receptor-mediated signals (Smith et al, 1986).
Thus, whilst the details of the physiological function of
p21 remain unclear, a framework is beginning to emerge.
It is speculated that the p21 proteins mediate signals
from peptide growth factors such as EGF and PDGF. In
support of this is evidence that p21 interacts with the
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EGF receptor (Kamata & Feramisco, 1984). This leads to
binding of GTP by p21 resulting in a conformational
change, initiating interaction with an effector protein.
Whilst the nature of the effector protein is also
unclear, an obvious candidate is phospholipase C, a
phosphodiesterase playing a central role in the
generation of IP and DAG from Ptdlns(4,5)P2 (see
3
section 1.1.4). IP and DAG act as 'second messengers'
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in the control of proliferation. Some evidence for the
ras proteins playing a role in this relay system comes
from observations of enhanced turnover of
phosphoinositides in cell lines transformed by v-ras
(Fleischman et al, 1986). Termination of activation of
the normal p21 follows the hydrolysis of GTP, but mutants
defective in this activity undergo a prolonged
interaction with the effector protein, resulting in a
continuous signal to the cell to proliferate.
The p21 protein product of ras has also been shown to
possess important properties influencing cell
differentiation. The cell line PC12 is derived from a rat
phaeochromocytoma, and under the influence of nerve
growth factor, its cells undergo morphological
differentiation towards neuronal cells. Transfection of
the mutationally activated ras gene into PC12 recipients
reproduces this morphological differentiation, as does
micro-injection of the oncogenic p21 protein. The non-
mutated ras gene does not induce the change unless its
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expression is artificially enhanced, and micro-injection
of the normal p21 protein is followed by no observable
effect (Bar-Sagi & Feramisco, 1985; Satoh et al, 1987).
Observations such as these suggest that, in addition to
their role in the control of proliferation, the p21
proteins have a part to play in the induction of
differentiation in certain cell types.
Immunohistochemical observations of p21 expression in
different tissues support this suggestion. Furth et al
(1987) observed abundant p21 expression in certain fully
differentiated cell types, notably neurones of brain. It
was suggested that in these tissues, p21 proteins
subserve specialised membrane functions unrelated to
proliferation.
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1.3 THE MYC ONCOGENE
The cellular oncogene c-myc is the eukaryotic genomic
homologue of the transforming sequence v-myc first
identified in the MC29 avian retrovirus, an acutely
transforming retrovirus which causes a variety of
neoplasms in birds. It is expressed in many different
mammalian tissues, and abnormalities of its expression
have been described in a variety of mammalian and avian
tumours. The protein product of v-myc was one of the
first transforming proteins found to be localised to the
cell nucleus, and it has been proposed to function as a
regulator of gene expression, and to control the entry
and progression of cells through the cell cycle.
In the human, the single locus encoding c-myc has been
mapped to chromosome 8q. It contains a single copy of the
gene, consisting of three exons, only two of which (exons
2 and 3) encode a protein product. Exon 1, although non-
coding, shows a high degree of evolutionary conservation,
and it is therefore believed that regulatory elements are
situated in this part of the gene. Exons 2 and 3 encode a
polypeptide product of 62-64 kDa (Hann & Eisenmann,
1984), which has been localised to the nucleus in
immunofluorescent and biochemical studies. The protein is
labile, with a half-life of approximately 15 minutes, and
in vitro it shows DNA-binding properties (Beimling et al,
1985), a property which is impaired in the proteins of
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non-transforming mutant forms of v-myc (Donner et al,
1983) . These features of the p62 protein product of myc
are suggestive of a regulatory role in gene expression.
An early model proposed that p62 exerted a repressor
function by binding to exon 1, but more recent evidence
indicates that the situation is more complex, as the
translation efficiency of c-myc has been found to be
independent of the presence or absence of exon 1 (Cole,
1985; Butnick et al, 1985).
Expression of c-myc has been investigated in
untransformed cells and their transformed counterparts by
studying the effects of growth stimulation of mouse
fibroblasts (Kelly et al, 1983; Campisi et al, 1983;
Greenberg & Ziff, 1984; Muller et al, 1984). Within 1
hour of growth factor stimulation, levels of c-myc mRNA
showed a 20-fold increase, returning to basal levels by
18 hours. In this situation, it appears that the
concentration of c-myc mRNA is enhanced more by post-
transcriptional mechanisms (ie enhanced messenger
stability) than by transcriptional activation, although
the relative contributions are still uncertain.
While cells participate in the cell cycle, levels of c-
myc mRNA transcription appear to be constant, whether the
cell is of normal or transformed phenotype (Kelly et al,
1983) . However, when growth is arrested by depletion of
growth factors, levels of c-myc transcript fall
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dramatically in normal cells within 2 hours, but remain
high in chemically transformed counterparts (Campisi et
al, 1984). The levels of c-myc transcript also decrease
during terminal differentiation, for example HL60 cells
induced by dimethyl sulphoxide or the tumour promoter TPA
to undergo differentiation towards the macrophage or
neutrophil (Westin et al, 1982). The p62 protein product
appears to be gualitatively normal in most transformed
cells.
Deregulation of the normal pattern of c-myc expression in
a number of transformed cell lines and authentic tumours
is associated with structural changes involving the gene.
Mechanisms so far recognised in which there is loss of
regulatory control are chromosomal translocations,
retroviral insertions and gene amplification. In
chromosomal translocations and retroviral insertions, the
c-myc gene appears to come under the influence of
constitutively active gene enhancing sequences which
subvert the normal controls of expression. The avian
leukosis virus, for example, integrates close to c-myc
and lymphomas develop in infected birds as a result of
this mechanism (Payne et al, 1982).
Chromosomal rearrangements of a characteristic type are
often associated with distinctive tumours, and consistent
translocations are seen in Burkitt's lymphoma cell lines.
The commonest involves translocation of a terminal
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fragment of chromosome 8 to the distal part of the long
arm of chromosome 14. Molecular analysis has shown that
this characteristic rearrangement leads to the
juxtaposition of c-myc to close proximity with sequences
of the immunoglobulin heavy chain locus. The
translocation may transfer c-myc intact, and it is
proposed that in this case, the constitutive activity of
the immunoglobulin locus leads to uncontrolled expression
of myc. In different tumours, the c-myc-carryinq
chromosome may break within the first exon or the first
intron, but never within exon 2 or 3. It has been
suggested that exon 1 of c-myc may come under the
influence of the mechanism (as yet largely not
understood) which generates somatic mutations in the
variable region of the immunoglobulin gene in the process
of generation of antibody diversity (Taub et al, 1984).
Such mutations would lead to disruption of control
sequences, but retention intact of exons 2 and 3. The
implication is that an intact c-myc protein is required
for transformation, but that the presumed regulatory
function of exon 1 (and perhaps other upstream sequences)
is lost in tumour cells.
Gene amplification as a mechanism of oncogene activation
has been described in section 1.1.5. Many cellular
oncogenes are capable of undergoing amplification, but so
far, myc genes account for more than 90% of
amplifications described (Schwab, 1986). In most cases of
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amplification, despite relocation of the oncogene-
containing sequences to diverse positions on other
chromosomes, structural alterations of the gene itself
are relatively infrequent. However, it was during the
analysis by low-stringency probing of double-minute (DM)
chromosomes and homogeneously staining regions (HSR) for
the presence of amplified oncogenes that two previously
undescribed structural variants of the myc gene were
discovered. N-myc was found amplified in neuroblastoma
cells (Schwab, 1985), and L-myc in small cell lung cancer
(Nau et al, 1985). The complete structure of these genes
awaits elucidation, but they show a similar 3-exon
structure to c-myc with only exons 2 and 3 translated,
and there are regions of close sequence homology with c-
myc. In human neuroblastomas, there is a correlation
between the presence of amplified N-myc and advanced
tumour stage and aggressiveness (Seeger et al, 1985).
Again there is evidence that terminal differentiation (in
this case to ganglion cells) is associated with decreased
expression of N-myc (Schwab, 1985) . Amplification of myc
seems to be one of the mechanisms leading to the
emergence of clones of cells with increasingly malignant
properties, and is unlikely to be the initiating event in
carcinogenesis.
The reason is unknown for selective amplification in
tumours of c-myc as opposed to other cellular oncogenes.
A selective advantage appears to be conferred, as myc-
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rich double-minute chromosomes which lack centromeres
would be expected to disappear in the absence of
selection pressure. It is possible that amplification of
cellular oncogenes other than c-myc confers decreased
survival ability to most cell types.
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1.4 PATHOGENESIS OF COLORECTAL CANCER
There are striking differences in the incidence of
colorectal cancer in different parts of the world. In
Northwest Europe, North America and Australia, the large
bowel is amongst the three commonest sites of
carcinogenesis, whereas in Africa, Asia and South America
it is uncommon. Within high risk populations, distinct
variations in incidence occur which are largely
unexplained. Migrant studies indicate an environmental
factor or factors to be of importance, and with the
exception of a few uncommon conditions discussed below,
hereditary factors appear to play a lesser role. Broadly
speaking, populations at high risk enjoy an affluent
lifestyle (Japan is an exception), and the speculation
follows that diet has an influence on the development of
the disease.
There is a small number of conditions which are known to
predispose to the development of large bowel cancer, most
notably long-standing ulcerative colitis. There is reason
to believe, however, that cancer occurring in this
situation differs in several important respects from the
much commoner sporadic variety; such tumours are usually
poorly differentiated histologically and exhibit
aggressive, diffusely infiltrative behaviour. They appear
to take origin from flat, dysplastic mucosa, which is in
marked contrast to sporadic cancers which are believed to
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arise by malignant transformation of a pre-existing
adenoma, and are frequently well or moderately well
differentiated histologically.
1.4.1 Bile, bacteria and bowel carcinogens
Much effort has been spent attempting to identify
potential dietary carcinogens of the colorectum, and it
is clear that a complex interaction occurs between the
components of the diet and the resident bacterial flora
of the large intestine. It has for long been suspected
that metabolites of bile acids are potential carcinogens,
and it is postulated that bacterial flora of the large
intestine are responsible for converting benign
substrates into carcinogens. The composition of the diet
has an influence both on the concentration of the bile
acids in the intestinal lumen, and on the composition and
activity of the bacterial flora. High levels of meat
(particularly beef) consumption in a population correlate
with the incidence of colorectal cancer, and it has been
proposed that carcinogens are formed in situ by microbial
modification of dietary neutral sterols, or of bile
acids, increased by the presence of high levels of fat in
the diet. In vitro mutagenicity assays have been used to
investigate carcinogens in the faeces, and have
identified a potentially important group of substances
termed fecapentaenes, which are polyunsaturated
derivatives of glycerol, probably of bacterial origin
(Gupta et al, 1983). Whilst carcinogenic activity has not
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yet been formally demonstrated, the fecapentaenes are
very potent mutagens. Animal studies have also indicated
that bile acids may act as tumour promoters, and
microbial mutagenicity testing has shown that, although
they are not mutagenic by themselves, bile acids and
their metabolites act as co-mutagens, significantly
potentiating the mutagenic activity of other substances.
Recently, a mechanism has been postulated which may
explain the toxic effect of bile acids. This proposes
that mucosal damage occurs as a conseguence of the
calcium-binding action of these substances, and that the
increased cell turnover reguired to replace cells lost
through this effect may result in an increased chance of
alterations in DNA and mutant progeny leading to
neoplasms (Newmark et al, 1984). Human studies have shown
a correlation between the mean faecal bile acid
concentration and the incidence of colorectal cancer in a
population. Whilst there is no evidence that bile acids
can initiate the carcinogenic process (by the formation
of adenomas), it has been postulated that their role may
be in the promotion of premalignant neoplasms into those
with the potential for invasive growth (Hill, 1983).
1.4.2 The adenoma-carcinoma seguence
There is a considerable body of evidence which, although
largely circumstantial, indicates that the great majority
of colorectal carcinomas arise by malignant
transformation of pre-existing adenomas. The evidence is
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principally derived from epidemiological and pathological
observations (Day, 1984). The prevalence of adenomas in a
population is not easy to study, and the most reliable
information comes from careful prospective autopsy
studies. (Radiological studies tend to underestimate the
incidence of small lesions, and there is a bias in many
of the surgical studies towards proximal lesions within
endoscopic range). A correlation has been shown to exist
between geographical areas of high carcinoma incidence
and high adenoma prevalence. The correlation is far from
absolute, however, and a difference of up to 70% in
carcinoma incidence has been observed in different
populations showing similar prevalence of adenomas (Vatn
& Stalsberg, 1982). Adenomas tend to show a relatively
even distribution throughout the colon and rectum,
although in populations with high risk of cancer,
adenomas tend to be larger in the sigmoid colon and
rectum, the favoured sites of development of carcinomas
in these groups. This suggests that different factors may
be involved in the causation of adenomas (iniation) and
their subsequent development into invasive carcinomas
(progression). It is clear from migration studies that
environmental influences are again important factors in
the initiation of adenomas, but genetic factors are known
to play a role in a proportion of cases. Excluding the
familial polyposis syndromes, 'cancer families' have been
identified in whom an increased susceptibility to
colorectal cancer, not accounted for by shared
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environmental factors, is accompanied by a high incidence
of adenomatous polyps in the large bowel, a trait which
shows an autosomal dominant mode of inheritance (Burt et
al, 1985). Inheritance of this trait may have a more
significant role in the pathogenesis of adenomatous
polyps and colorectal cancer than has hitherto been
appreciated.
In populations at high risk for carcinoma, adenomas are
very common, with autopsy incidence rates of up to 50%.
Clearly therefore, only a small minority of adenomas
undergo malignant transformation. Much effort has been
spent on the important task of identifying selective
markers of high risk, both within the individual lesion
and in subsets of patients. Adenomas are histologically
divisible according to the predominant pattern of
glandular architecture, into tubular, villous and mixed
tubulo-villous types, but the three represent variants of
the same neoplastic process, and cytologically they are
very similar. All have the potential for malignant
transformation by undergoing the progressive changes of
dysplasia, in which histological changes of increasing
cellular atypia, architectural disorder and aberrant
cellular differentiation occur. All adenomas can, by
these criteria, be regarded as circumscribed foci of
dysplastic epithelium (Jass, 1987), and by convention,
histopathologists often attempt to assess the degree of
dysplasia in order to predict the risk of malignant
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transformation, The highly subjective nature of this
assessment has been emphasised by Brown et al, (1985),
but the fact remains that those lesions showing severe
dysplasia have a higher risk of progression to
malignancy. The fact that dysplasia can occur in flat
mucosa, for example in long-standing ulcerative colitis,
has led to the concept of the 'dysplasia-carcinoma'
sequence, advocated by some to supersede that of the
adenoma-carcinoma sequence, (Jass, 1987).
In addition to dysplasia, two other factors have been
identified which are associated with malignancy in
adenomas. Firstly, the size of an adenoma correlates
closely with the risk of malignancy - lesions less than 1
cm in diameter show less than 2% risk, whilst those
greater than 2 cm carry up to 50% risk. Secondly, the
architectural pattern of villous diferentiation carries a
risk of approximately 40% of malignancy compared with 5%
for pure tubular adenomas, and an intermediate level of
risk for mixed tubulo-villous lesions. Villous adenomas
are in general larger than the tubular forms, but even
when this influence of size is taken into account, their
tendency for malignant change is significantly higher. In
a large series of adenomas studied colonoscopically,
adenomas of 5mm or less showed a relatively even
distribution throughout the large bowel, whereas there
was a significantly higher incidence of larger lesions in
the sigmoid colon (Morson et al, 1983). Indeed, when
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size, growth pattern and degree of dysplasia are
considered, a close correlation occurs between the
distribution in the colon of 'high risk' adenomas and
colorectal cancer (Matek et al, 1986).
Adenomas and carcinomas coexist not only within the same
populations but frequently in individual patients. 30% of
surgical resection specimens for carcinoma show the
presence of one or more adenomas, and such patients are
at higher risk of development of metachronous carcinomas
(Bussey et al, 1967). When adenomas coexist with
carcinoma, they show a higher degree of dysplasia than
those seen in patients without carcinoma (Heald & Bussey,
1975).
Further strong histopathological evidence for the
adenoma-carcinoma sequence is provided by the occurrence
of residual benign elements within colorectal carcinomas.
This feature is seen in approximately 15% of cases
overall, but significantly more frequently in lesions at
an early clinical stage, which have not penetrated the
bowel wall (Dukes' stage A). Histologically, the residual
adenomatous elements show approximately equal occurrence
of tubular, villous or mixed tubulo-villous morphology.
However, as the incidences of these respective patterns
in adenomas not associated with carcinoma are 75%, 15%
and 10%, this is a further indication of the apparently
greater propensity of villous lesions to undergo
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malignant transformation (Morson, 1984).
If carcinoma of the colorectum were to arise de novo from
normal colonic mucosa with any degree of frequency, one
would expect there to be descriptions of incidentally
discovered small carcinomas of less than 0.5 cm in
diameter, both in surgical resection specimens and in
autopsy studies. This is not the case, and in contrast,
early invasive carcinoma is commonly seen occurring
within a pre-existing adenoma. This is regarded as
supportive evidence that the great majority of cancers
arise by this mechanism.
Perhaps the strongest evidence for a direct transition
from adenoma to carcinoma comes from study of the
uncommon hereditary condition familial adenomatous
polyposis (FAP). There are a number clinical variants of
this condition, but all show autosomal dominant mode of
transmission. Patients develop hundreds of adenomatous
polyps throughout the gastro-intestinal tract, but most
notably in the large intestine. Adenomas usually become
clinically apparent in adolescence and early adulthood,
and without treatment invariably carcinoma supervenes in
the large bowel, usually by the age of 40 years. Whilst
this condition is uncommon, it is a most valuable model
for the study of colorectal cancer in general, because
apart from their occurrence in large numbers, there are
no discernible clinical or pathological differences
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between the lesions of FAP and their sporadic
counterparts. The various histopathological types of
adenomas are found in very similar proportions to those
occurring sporadically. The evolution of lesions can be
traced histologically from the earliest changes affecting
a single crypt, through the formation of an adenoma with
increasing degrees of dysplasia to the development of a
typical invasive adenocarcinoma. Study of individual
lesions in patients with this condition (as well as the
rare cases of sporadic adenomas in which treatment is
refused) has allowed an approximate estimate to be made
of the time scale of the adenoma-carcinoma sequence. Most
adenomas never develop malignant change, but in those
which do, the transition seems to occur over a protracted
time scale of at least 5 years.
1.4.3 Genetic mechanisms
Over the years, many attempts have been made to identify
early changes in the colonic mucosa which may relate to
the development of neoplasia. Examination of mucosa
adjacent to carcinomas has revealed a range of
alterations in antigen expression (Skinner and Whitehead,
1981), type of mucin secretion (Williams, 1985), mitotic
activity (Romagnoli et al, 1984) and pattern of DNA
synthesis (Lipkin, 1974), but the associations may be
coincidental or consequential to neoplasia rather than of
aetiological significance. Recently, technological
advances in the field of molecular biology have been
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applied to the study of the fundamental genetic
mechanisms of colorectal carcinogenesis. Investigations
have focussed on the genome at various levels, from the
identification of cytogenetic abnormalities in tumour
cells, to investigation of the role of oncogenes and the
alterations which can occur in their regulatory
mechanisms.
Analysis of ploidy in adenomas and carcinomas by flow
cytometry of paraffin-processed tissues has shown that
approximately 60% of colorectal carcinomas show DNA
aneuploidy compared with around 10% or less of adenomas
(Quirke et al, 1986). Cytogenetic analysis of individual
tumours has identified non-random chromosomal
abnormalities in carcinomas, in particular involving
deletions of 5q (Herrera et al, 1986), and 17p (Muleris
et al, 1986). In 1971, Knudson proposed that both
dominantly-inherited cancer susceptibility of the FAP
type and the sporadic form of carcinoma may be due to
recessive mutations occurring at the same gene. For
cancer to develop, both alleles must be lost - in
sporadic cases both by somatic events, whilst in familial
cases one allele already carries a mutation through the
germ line, and only one somatic change is needed in the
homologous allele. There is recent evidence to support
this hypothesis. Bodmer et al (1987) have mapped the FAP
gene to a locus on chromosome 5q, near bands 5q21-q22,
and in an accompanying paper, Solomon et al (1987)
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demonstrated partial or complete loss of an allele in the
5q31-q34 locus in 20% of sporadic colorectal cancers.
These authors have proposed that becoming recessive for
the FAP gene at this locus is a key event in the
development of both the sporadic and familial forms of
cancer.
A similar approach reported by Fearon et al (1987)
yielded important results which are, however, to some
extent discordant. Following several reports of non-
random chromosomal deletions involving chromosome 17p in
sporadic colorectal cancers, these workers discovered
clonal loss in tumour cells only of one allele of 17p in
76% of a series of 34 such sporadic carcinomas.
(Polymorphic gene probes for a number of other
chromosomes were used, but chromosome 5 was not included;
less frequent deletions were occasionally observed on
other chromosomes). Interestingly, the 17p deletion was
only found in 1 out of 30 benign adenomas and 1 out of 3
areas of residual adenoma from frank carcinomas. It was
concluded that loss of a 17p allele occurs relatively
late in the multi-stage process of colorectal
carcinogenesis.
The same workers also reported in their paper results of
experiments investigating the clonality of colorectal
neoplasms. Using a Southern blotting technique with a
methylation-dependent restriction endonuclease, they
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studied restriction fragment length polymorphisms in DNA
from colonic tumours of female patients heterozygous for
a polymorphic locus on the X chromosome, and demonstrated
inactivation of the same X chromosome in all neoplastic
cells of the same individual tumours, including both
adenomas and carcinomas. This is good evidence for the
clonal nature of both adenomas and carcinomas.
There is evidence from a variety of sources which
indicates that oncogene expression is abnormal in
colorectal cancer. At present, much of the evidence is
fragmentary and its significance uncertain, but there
seems little doubt that both qualitative and quantitative
abnormalities of ras family oncogene expression occur.
Pulciani et al (1982) used the NIH3T3 transfection assay
to demonstrate the presence of Ki-ras transforming
sequences in DNA derived from 2 unmanipulated human
colonic carcinomas. Such transforming activity was absent
from the DNA from normal tissues of the same patients.
Whilst it was recognised that the NIH3T3 assay was an
insensitive technique, particularly for the detection of
oncogenes other than activated ras, other pieces of
evidence accumulated indicating a specific role for ras.
Spandidos and Kerr (1984) demonstrated a significant
elevation in the levels of ras mRNA transcripts in both
carcinomas and premalignant adenomas of colon compared
with normal colonic mucosa. Similar results were reported
by Slamon et al (1984) in a systematic survey of a large
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number of different human tumours including colorectal
adenomas and carcinomas.
Increased ras transcript levels do not appear to be a
consequence of gene amplification. Pulciani et al (1985)
found no evidence of amplification of ras DNA sequences
in 13 adenomatous polyps and 22 colonic cancers. However,
there is evidence for increased expression at the protein
level. Using immunoblotting techniques, Gallick et al
(1985) detected elevated levels of the ras p21 protein
product in extracts of colonic cancers compared with
those from adjacent uninvolved mucosa. They also noted
that levels of p21 appeared to be higher in carcinomas at
an earlier clinical stage compared with advanced lesions
which had metastasised.
A generalised decrease in the methylation state of DNA in
both adenomas and carcinomas of colon has been reported
(Goelz et al, 1985). DNA methylation occurs almost
exclusively at cytosine-guanine dinucleotides. Its role
is not fully understood, but it appears to be associated
with down-regulation of gene expression, and conversely,
a decrease in methylation is associated with gene
activation. Methylation changes are a normal feature of
cellular differentiation, and also occur in neoplasia,
but it is uncertain whether they are an invariable
property of tumours. Hypomethylation has been shown to
inhibit chromosomal condensation, and may lead to mitotic
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non-disjunction, resulting in a loss or gain of
chromosomes. Clusters of hypomethylated sequences
upstream of actively-transcribed genes (termed 'HTF
islands7) have been identified, and are believed to
contain regulatory elements controlling gene
transcription. Changes in the methylation state of these
regions may have effects on levels of gene expression. It
is perhaps significant in this regard that the Ha-ras
oncogene shows a much higher transforming activity in the
hypomethylated state (Borrello et al, 1987).
Mutational activation of ras has been sought by a variety
of methods of varying sensitivity. Early studies relied
on the NIH3T3 assay, and mutational activation detected
relatively infrequently (reviewed by Barbacid, 1987).
Alexander et al (1986) examined DNA derived from 9
primary colorectal carcinomas, and using a Southern
blotting technique to detect restriction fragment length
polymorphisms showed no evidence of mutations occurring
at codon 12 of Ki-ras or N-ras. There was no evidence of
rearrangement of either of these genes, but in one of
their cases, deletion of a Ha-ras allele was reported.
Heterozygosity of Ha-ras was also mentioned in a study by
Yokota et al (1986) who reported apparent loss of one c-
Ha-ras allele in a number of colonic cancers; it is not
specifically stated in their report how commonly this
abnormality was detected.
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Recently, more sophisticated and sensitive methods have
been applied to the detection of mutational activation of
ras. Simultaneous reports from Bos et al and Forrester et
al (1987) highlight a high incidence of activating
mutations at codon 12 of the Ki-ras gene in colorectal
cancers. Despite some remaining limitations to the
sensitivity of both of the techniques applied, both
studies reported a 30 - 40% incidence of the activating
mutation. Furthermore, a similarly high occurrence of
this mutation was present in dysplastic villous adenomas
and residual adenomatous elements of the carcinomas
studied. This suggests that the activating mutation
occurs early in the development of malignancy.
Evidence for the primary involvement of other cellular
oncogenes in colorectal cancer is less abundant, and
although there are many indications of alterations in
oncogene expression, some caution must be used in the
interpretation of these data, particularly with regard to
genes whose expression is cell cycle related. Increased
expression may simply relate to increased growth fraction
in tumours compared with normal mucosa (Torelli et al,
1987) .
Several groups have reported alterations of c-myc
expression - significantly elevated levels of c-myc mRNA
transcript occur (Slamon et al, 1984; Erisman et al,
1985; Alexander et al, 1986; Sikora et al, 1987; Meltzer
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et al, 1987), but only in a small minority of cases has
gene amplification been identified, and gene
rearrangement also seems to be uncommon. At the protein
level, immunoblotting and immunohistochemical studies
have described increased levels and altered distribution
of the p62 c-myc protein product in colorectal carcinomas
(Stewart et al, 1986; Sikora et al, 1987; Sundaresan et
al, 1987). Bolen et al (1987) described increased
tyrosine kinase activity of the protein product of the c-
src oncogene, pp60-c-src, in colorectal carcinomas
compared with normal colonic mucosa. It was suggested
that this alteration may have a direct role in colonic
carcinogenesis.
The current state of understanding of the processes of
human colorectal carcinogenesis is far from
comprehensive, but some parts of the puzzle are falling
into place. The neoplastic process appears to commence
with a clonal expansion from a single cell of the crypt,
escaping from normal growth controls, and forming a small
adenoma. Specific gene deletions on chromosome 5q and
probably other loci may be important in initiating the
process, and luminal carcinogens may play a potentiating
role. By the stage of adenoma formation, a generalised
diminution has occurred in the methylation state of DNA
in the lesion, consequences of which may include an
increased incidence of mitotic non-disjunction leading to
gain or loss of chromosomes, and increased expression of
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many genes, including oncogenes. During adenoma
development, an infrequent but important event is the
development of an activating mutation of the Ki-ras gene,
probably a consequence of increased cell turnover and the
further action of luminal carcinogens. Adenomas acquiring
the activating ras mutation may increase in size and
degree of dysplasia. Acquisition of the malignant
phenotype may be associated with loss of tumour
suppressor gene activity by deletion of chromosomes 5q or
17p.
This sequence of events is certain to be an
oversimplification. For example, less than 50% of
carcinomas have been shown to possess the activating
mutation of Ki-ras, and only a similar proportion show
the 5q deletion. It is likely that a considerable degree
of heterogeneity exists between individual lesions at the
detailed genetic level, but the techniques are now in
place to examine the molecular pathology in experimental
systems. The implications for diagnosis and treatment are
likely to be far-reaching.
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1.5 AIMS OF THE STUDY
Colorectal neoplasia is common in the UK and its high
incidence poses problems in population screening and
patient management. The detailed events of colorectal
carcinogenesis are unknown, but the adenoma-carcinoma
sequence is generally accepted in the large intestine,
and the availability of appropriate surgical resection
specimens affords the opportunity to study lesions at
various stages in the evolution from normal mucosa to
invasive adenocarcinoma. Increasing evidence of the
important roles of oncogenes in carcinogenesis has
accumulated, and activation of individual oncogenes at
different stages may account for the multi-step process
of colorectal carcinogenesis.
Several studies have indicated alterations in oncogene
expression in neoplasms of the large intestine, but most
have studied established malignant tumours, and have
often involved investigation of DNA, RNA or proteins
extracted from homogenates of solid tumours. The results
of such studies represent an overall picture of
expression in the total cell population in the tumour,
but may be misleading. All tumours consist of highly
heterogeneous populations of neoplastic cells and stromal
cells, and it would be of great interest to determine any
alterations in oncogene expression which might occur
within individual cells of the tumour.
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An important aim of this study was to develop reliable
methods of identifying oncogene expression at the
individual cell level in tissue sections of colorectal
neoplasms. It was of interest to compare two potentially
useful methods, in situ hybridisation and
immunohistochemistry. In situ hybridisation is a
technique of great potential value in which messenger RNA
transcripts of an expressed gene are detected in tissue
sections by the hybridisation of a labelled complementary
nucleic acid strand, making use of the highly specific
nature of such interactions between the two strands.
Appropriate DNA probes containing oncogene sequences were
available. Immunohistochemistry is a longer established
technique which utilises the specificity of binding of
antibodies to particular epitopes in tissues, with
subsequent detection usually by enzyme-linked methods.
The availability of monoclonal antibodies with
specificity to oncogene protein products allowed
investigation of this method to be undertaken.
A flexible positive control system was also available in
the form of rodent cell lines in culture which had been
genetically manipulated to express certain oncogenes at
artificially high levels.
Accumulating evidence for the importance of involvement
of ras and myc oncogenes in the carcinogenic process in
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general, and in colorectal tumours in particular,
prompted special attention being paid in this study to
analysis of their patterns of expression. It was of
particular interest to attempt to define alterations at




IMMUNOHISTOCHEMICAL DETECTION OF RAS ONCOPROTEIN
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SUMMARY
The monoclonal antibody Y13-259 was used to investigate
ras p21 distribution in human colorectal tissues by
immunohistochemistry. The specificity of Y13-259 was
confirmed by demonstration of its reactivity with a
control cell line (FH05T1) which had been genetically
manipulated to express the mutationally activated human
Ha-ras oncogene at high levels. Reactivity was
significantly lower in the unmanipulated progenitor cell
strain (CHL). Immunoblotting experiments also confirmed
the specificity of Y13-259, demonstrating reactivity with
a single protein band of MW 21kDa in protein extracts of
FH05T1 cells which was absent from extracts of CHL cells.
Formaldehyde fixation of tissues resulted in loss of Y13-
259 reactivity, so a series of acetone-fixed cryostat
sections of human colorectal tissues was investigated
using the ABC immunohistochemical technique. Colorectal
carcinomas showed a similar low intensity of staining to
normal mucosa, but adenomas showed consistently higher
staining intensity. A further series of similar tissues
was examined using periodate-lysine-paraformaldehyde-
dichromate (PLPD) fixation, which allowed use of paraffin
sections with improved morphology and retention of
immunoreactivity. Results of the frozen section series
were confirmed by titration experiments in which staining
was compared on serial sections at a range of
concentrations of Y13-259. The results suggest that
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elevated ras expression may be a significant early stage
in the process of colorectal carcinogenesis, but that
high levels of expression need not be sustained in the
subseguent conversion to invasive carcinoma.
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2.1 MATERIALS AND METHODS
2.1.1 Cell lines and tissues
Cell lines
A variety of cell lines were maintained in culture in
which oncogene expression had been augmented by genetic
manipulation. The cell lines were maintained in
Dulbecco's modification of minimum Eagle's medium
containing 10% newborn calf serum, and penicillin and
streptomycin. The cell lines were originally produced by
insertion of oncogenes in high expression vectors into
non-transformed early or late passage rodent fibroblast
cell lines by the calcium phosphate transfection
technigue (Spandidos & Wilkie, 1984). The non-transformed
parental cell strains are contact-inhibited, non-
tumourigenic and in the case of early passage cells,
diploid or near-diploid, whilst the transfectants are
transformed, aneuploid and give rise to rapidly-growing
tumours in immune-deprived animals.
The ras-expressing transformed cell line FH05T1 was
derived by transfection of an early passage fibroblast
cell strain from Chinese hamster lung, designated CHL,
using the plasmid construct pH05Tl (Spandidos and Wilkie,
1984). This plasmid has the mutationally-activated human
T24 Ha-ras oncogene (originally derived from bladder
carcinoma cells) flanked by transcriptional enhancing
sequences derived from the SV40 virus, ensuring a high
63
level of transcription of the oncogene. The resulting
FH05T1 cells are fully transformed, lack contact
inhibition and are aneuploid. They induce rapidly-
growing, infiltrative metastasising tumours when
inoculated into immune-deprived mice. Histologically,
these tumours have the appearances of undifferentiated
spindle-cell tumours of fibrosarcoma type. Estimation of
relative guantities of oncogene mRNA by dot-blot
hybridisation has shown 20-50 fold increased Ha-ras
transcript in FH05T1 cells compared with the parental
untransformed CHL cells (Spandidos and Wilkie, 1984;
Wyllie et al, 1987).
Cytocentrifuge preparations
Monolayer cultures of cell lines were gently disrupted by
treatment with 0.02% EDTA and 0.1% trypsin. The resulting
cell suspension was washed in culture medium containing
10% newborn calf serum followed by a further wash in
serum-free medium. The cells were counted, and their
5
concentration adjusted to 1x10 cells per ml. lOOul of
cell suspension was placed in each chamber of the
cytocentrifuge. The suspension was spun onto gelatine-
coated slides for 5 mins at 60 rpm. The slides were air-
dried, then fixed in the appropriate fixative (see
section 2.1.3). Slides were either used immediately or
o
stored in sealed polythene bags at -20 C.
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Cell pellets for paraffin processing
Monolayer cultures were gently disrupted with 0.1%
6
trypsin and 0.02% EDTA as above. Approximately 5x10
cells were used for each preparation. The cells were
suspended in 5 ml of the appropriate fixative, and
o
allowed to fix for 15 min at 4 C. After washing in
phosphate-buffered saline, the cells were resuspended in
lOOul PBS and lOOul 4% low-temperature melting agarose at
o o
40 C. After the pellet had set (5 minutes at 4 C) it was
finally fixed for a further 15 mins in fixative, washed
in PBS and processed to paraffin wax.
Animal tumours
FH05T1 cells inoculated into immune-deprived mice
engender rapidly-growing malignant tumours which are a
valuable source of authentic tumour tissue which is known
to express the T24 ras oncogene at high levels. The
regime of immune deprivation and inoculation is described
in detail by Wyllie et al (1987). Briefly, 6 week old
mice were thymectomised, irradiated and treated with
cytosine arabinoside. 0.1 ml of a cell suspension
7
containing 1-2x10 FH05T1 cells was inoculated
subcutaneously. Animals were killed when tumours of 1 cm
or greater were present (usually within 1-2 weeks). At




Human colorectal tissues were received on ice within
minutes of resection in the operating theatre. Resection
specimens were opened and examined immediately, and
samples of tissue taken from tumour and normal mucosa.
Samples were placed in plastic vials and 'snap7 frozen in
liquid nitrogen. Special attention was paid to the
presence of polyps of the colonic mucosa. If present and
of sufficient size, they were bisected, one fragment
retained for diagnosis by paraffin section histology, the
other frozen. In some cases, blocks were taken for
fixation in special fixatives at this stage. The
remainder of the resection specimen was pinned onto a
cork board, allowed to fix in formalin, and blocks
subsequently taken for paraffin section histology in the
usual way. This allowed confirmation of the diagnosis,
histological assessment of tumours, Dukes7 staging , and
was a source of paraffin sections for various techniques.
Frozen tissues aimed to include a block of the tumour-
normal interface for frozen section immunohistochemistry.
For protein extraction, samples were taken which aimed to
consist entirely of viable tumour tissue. Frozen sections
(6um) were cut, mounted on gelatine-coated slides, fixed
in acetone for 15 minutes at room temperature and air
dried. If necessary, sections were stored at this stage
o
in sealed polythene bags at -20 C.
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2.1.2 Immunoblotting for ras oncoproteins
Protein extraction
15-20 ml 0.02% EDTA was added to cell culture bottles
containing cell monolayers and the cultures were gently
agitated to detach the cells. After washing once in
phosphate-buffered saline (PBS), the supernatant was
decanted and 1 ml of lysis buffer was added (25mM TRIS pH
8.0, 50 mM NaCl, 0.5% NP40 (Nonidet p40), 0.1% SDS, 0.02%
PMSF (phenylmethylsulphonylfluoride)) and refluxed
vigorously through a 21 gauge needle. The lysate was then
o
centrifuged at 10,000 rpm for 30 min at 4 C, and the
supernatant collected. Although it was often necessary to
o
store the lysate (200ul aliquots at -20 to -70 C), best
results were obtained with freshly prepared specimens. It
was noted that levels of immunoreactive p21 diminished
very significantly in lysates stored for more than a few
weeks.
Specimens of human colorectal tissues sampled as soon as
possible after removal in theatre were 'snap' frozen in
o
liquid nitrogen, and stored at -70 C for variable
periods. A fragment of frozen tissue (approximately 1
gram) was rapidly chopped as finely as possible with a
scalpel, and the fragments immediately transferred to a
glass homogeniser with 1 ml of lysis buffer as above.
After homogenisation, the lysate was centrifuged as
above, and the supernatant collected.
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Measurement of protein concentration
Protein concentration of lysates was measured using the
Bio-Rad assay system. Dye reagent was freshly prepared
and filtered according to the manufacturer's
instructions. A range of known protein standards was
prepared from stock bovine serum albumin solution
(lmg/ml). To lOOul of standards and unknown samples was
added 5ml of dye reagent, and the mixture vortexed.
Samples were held at room temperature for 5 mins to 1 hr,
and optical density measured at 595nm by
spectrophotometry.
SPS-PAGE (SDS-Polyacrylamide gel electrophoresis)
A 15% acrylamide separating gel and 5% stacking gel were
prepared as described in Appendix 2. Equal volumes of
protein lysate and sample buffer (4% SDS, 40% glycerol,
125mM TRIS pH 7.0, lOmM EDTA, 10% B-mercaptoethanol,
0.04% bromophenol blue) were mixed, and the samples
denatured by boiling for 5 mins. Variable amounts of
protein up to 500ug were loaded onto each track of the
gel. One or more tracks of the gel were reserved for a
mixture of molecular weight standards, either as
unconjugated proteins (Sigma MW markers kit) or as
proteins conjugated to dyes of different colours
('Rainbow Markers', Amersham). Each electrode of the
vertical Bio-Rad electrophoresis apparatus was immersed
in electrode buffer (0.01% SDS, 0.05M TRIS pH 7.0, 0.4M
glycine). Separation was allowed to occur at 10 mA
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current until the sample fronts had entered the
separating gel, after which it was increased to 30mA.
Transfer to nitrocellulose
After electrophoretic separation had occurred in the
polyacrylamide gel (usually approximately 3 hours) the
gel was removed from the electrophoresis apparatus and
washed for 30 minutes with gentle agitation in transfer
buffer (0.01M TRIS, 0.1M glycine, 20% methanol). A
nitrocellulose sheet was cut to size (approximately 14x14
cm), and soaked in transfer buffer with two similar sized
pieces of Whatman chromatography paper (thickness 0.92
mm) . The nitrocellulose filter was applied to the gel,
and air bubbles excluded by gentle rolling with a glass
rod. The gel and nitrocellulose were sandwiched between
the two sheets of chromatography paper, with a sponge pad
on each outer side. This assembly was held in place in a
perspex clip, and inserted into the transfer apparatus. 3
litres of transfer buffer were added, and electrophoretic
transfer allowed to occur overnight at 50V, with constant
stirring.
Staining of gel (total protein)
1. Kenacid blue method.
After electrophoretic transfer, the gel was stained for a
minimum of 2 hours (or overnight) in kenacid blue
solution (2g/l kenacid blue, 10% glacial acetic acid, 45%
methanol). Destaining was performed overnight in 7%
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glacial acetic acid, 45% methanol.
2. Silver staining method
The gel was washed thoroughly, preferably overnight, in
at least 5 changes of DDW, then stained in ammoniacal
silver nitrate solution, freshly prepared as follows. 2.8
ml ammonia AR solution (specific gravity 0.88), and 3.75
ml 1M NaOH was made up to 100ml with DDW. 8 ml of
freshly-prepared 20% silver nitrate solution were added
dropwise with stirring, and the solution made up to 200
ml with DDW. The gel was stained for 15 minutes with
rapid stirring, after which it was extensively rinsed in
DDW through 3 changes over 30 minutes. Staining was
developed in formaldehyde/citric acid solution (0.5ml 40%
formaldehyde, 50 mg citric acid to 1 litre DDW). Bands
developed over a 10 minute period after which the
reaction was stopped by immersion in tap water.
Immunostaininq of nitrocellulose
After transfer, the nitrocellulose filter was washed in
TRIS-buffered saline (TBS), 3 changes, 10 minutes each.
Non-specific protein-binding sites were blocked by
incubation in 3% milk protein solution (Cadbury's Marvel)
in TBS for 30 minutes. The filter was then washed in TBS,
o
and if necessary could be stored at -20 C in a sealed
polythene bag at this stage. Incubation with 5ml of the
appropriate primary antibody took place in a sealed
polythene bag, at the appropriate dilution (most commonly
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1 in 100) in TBS containing 5% heat-inactivated neonatal
calf serum (HINCS) and 0.5% Tween 20. After 2 hours
incubation at room temperature, it was washed in excess
TBS/HINCS/Tween, 3 changes over 15 minutes. The filter
was then incubated with the appropriate biotinylated
secondary antibody 1 in 100 in TBS/HINCS/Tween for 1-2
hours and washed as before.
Horseradish peroxidase detection system
The filter was then incubated with 5 ml biotinylated
preformed complex of streptavidin-peroxidase (Amersham) 1
in 100 in TBS for 30 mins. After final washing in TBS (3
changes) the reaction was developed with diaminobenzidine
(DAB) solution (as in section 2.1.3). When complete
(usually within 5 minutes), the reaction was terminated
by washing in DDW. Nitrocellulose filters were then dried
and stored in the dark in a sealed polythene bag.
Alkaline phosphatase (Bluegene) detection system
The filter was incubated with 5 ml AP-streptavidin (BRL),
1 in 1000 in TBS pH 7.4 for 15 minutes, in a sealed
polythene bag. After washing in TBS pH 7.4 (3 changes, 15
minutes), the filter was washed in TBS pH 9.5 containing
50mM MgCl , for 15 minutes. It was then incubated in a
2
sealed polythene bag containing 5ml of fresh development
buffer prepared according to the manufacturer's
instructions (BRL). After 30 minutes incubation at room
temperature in the dark, the reaction was terminated by
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washing in DDW. In practice, staining of bands was
usually complete within 5 minutes. Stained filters were
then dried and stored in the dark in sealed polythene
bags.
125
I-Protein A autoradiographic detection system
125
The I-Protein A autoradiographic detection system was
adopted particularly for tracing p21-ras in immunoblots
from human colorectal tissues, and was used for its
increased sensitivity over the enzyme-linked detection
systems. Immunostaining of nitrocellulose filters was
slightly altered from the method described above in order
to conform more closely with the method of DeBortoli et
al (1985). This method differed in using an overnight
incubation of the nitrocellulose filter with Y13-259 at 1
o
in 200 dilution at 4 C, and replaced TBS/HINCS/Tween with
NTE-NP40 (50mM TRIS pH 7.4, 150mM NaCl, 2mM EDTA, 0.1%
NP40). Washing and incubation stages were carried out in
an ice-cold shaking water bath. The secondary antibody
(unconjugated goat anti-rat IgG - Sigma) was applied at 1
in 500 dilution in NTE-NP40 containing 3% BSA for 90
mins. After washing in NTE-NP40 (2 changes, 10 mins),
125
I-protein A (Amersham), specific activity
approximately 30 mCi/mg, 30ul in 30ml NTE-NP40 + 3% BSA
was added and incubated for 1 hr. After washing twice in
NTE-NP40 as before, the filters were air-dried, wrapped




2.1.3.1 Use of monoclonal antibody Y13-259 to p21ras
Monoclonal antibody Y13-259
Y13-259 is a monoclonal antibody prepared from rats
bearing tumours induced by the Harvey strain of the
murine sarcoma virus (Furth et al, 1982). It precipitates
p21 protein species encoded by both Harvey and Kirsten
strains of the virus, and reacts with Ha, Ki and N-ras
p21 products of the cellular oncogene. It reacts with the
products both of the normal and mutationally-activated
ras gene.
The hybridoma cell line was a gift from Dr D.A.
Spandidos. The antibody was prepared from culture
supernatants by ammonium sulphate precipitation as
described by Furth et al (1982). The protein
concentration of such preparations was measured by the
Mancini radial immunodiffusion method, and was generally
around 2.5 mg/ml (J. Going, personal communication).
o
Aliquots of 200ul were prepared and stored at -70 C. Care
was taken to ensure that aliquots were frozen and thawed
only once before use for immunohistochemistry.
Fixation conditions and tissue processing
The following fixatives and fixation conditions were used
for post-fixation of cryostat sections and cytocentrifuge
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preparations in an effort to optimise immunostaining
while retaining good morphology of cells and tissues:
1. Acetone (100%), 15 minutes, room temperature.
2. Formaldehyde (4% in PBS), 15 minutes, room
temperature.
3. Glutaraldehyde (0.1% in 0.1M sodium cacodylate pH
o
7.4), 15 minutes, room temperature or 4 C.
4. Methanol (100%), 15 minutes, room temperature.
Paraffin sections of FH05T1 tumours and human colorectal
tissues were prepared according to routine histological
methods. Tissues were fixed in 4% formaldehyde for 24
hours, dehydrated through graded alcohols, cleared in
o
chloroform and wax-impregnated at 56 C over a 20 hour
processing schedule. 5 micron paraffin sections were cut,
o
mounted on glass slides and air dried at 56 C.
In an attempt to unmask antigens by proteolytic
digestion, dewaxed rehydrated sections were incubated in
0.1% trypsin, 0.1% calcium chloride in 10 mM TBS pH 7.6
o
for 15 minutes at 37 C before applying antibody.
PLPD fixation
Periodate-lysine-paraformaldehyde-dichromate (PLPD)
fixative was prepared using a modification of the method
described by McLean and Nakane (1974). It contains 5mM
sodium metaperiodate, 37.5mM lysine-HCl, 1%
paraformaldehyde, 18mM phosphate buffer pH 7.4 and 5%
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potassium dichromate. It was freshly prepared from stock
on the day of use (see Appendix 3). Tissue blocks
approximately 5mm thick were fixed for a minimum of 18
o
hours at 4 C in the dark. They were then washed in
running tap water overnight to remove dichromate pigment.
Tissue blocks were then dehydrated, cleared and embedded




For the indirect immunoperoxidase technique, horseradish
peroxidase (HRP)-conjugated sheep anti-rat Ig (Amersham)
and HRP-conjugated rabbit anti-rat Ig (Dako) were used,
with very similar results. For the peroxidase anti-
peroxidase (PAP) method, unconjugated rabbit anti-rat Ig
and monoclonal rat PAP-complex (Sera Lab) were used. For
the streptavidin-biotin-peroxidase (ABC) method, the
secondary antibodies employed were biotin-conjugated
rabbit anti-rat Ig (Vector) or biotin-conjugated goat
anti-rat Ig (Sigma). Faint anti-human activity
encountered in the latter antibody was abolished by
absorption with acetone-dried human liver tissue, and
human immunoglobulins (Cohn fraction II, Sigma). For
immunogold silver staining, 5nm gold particle conjugated
rabbit anti-rat IgG (Janssen) was used.
Indirect immunohistochemical methods
Cytocentrifuge preparations, acetone-fixed cryostat
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sections or rehydrated PLPD-fixed paraffin sections were
washed in TRIS-buffered saline pH7.6 (TBS) for 5 mins.
Non-specific binding of primary antibody was blocked by
application of 10% normal human serum in TBS (NHS/TBS)
for 5 mins. Monoclonal antibody Y13-259 was applied at
concentrations varying from 5ug/ml to lOOug/ml in
NHS/TBS. In general, 25ug/ml was most satisfactory for
tissue sections (a dilution of 1 in 100 of purified
culture supernatant) whilst 5ug/ml was used for
cytocentrifuge preparations. The antibody was applied for
a minimum of 1 hour (lengthier incubations including
overnight incubation conferred no appreciable advantage).
After washing in TBS and blocking as above, the
appropriate secondary antibody was applied, diluted 1 in
50 in NHS/TBS for 1 hr. After thorough washing in TBS,
the final peroxidase-conjugated reagent (where
appropriate) was applied 1 in 50 in TBS for 30 minutes.
In the case of the ABC streptavidin-biotin complex
method, this was preformed complex of biotinylated
streptavidin-HRP (Amersham) and was applied 1 in 200 in
TBS for 15 minutes. After thorough washing the colour
reaction was developed with DAB solution (lmg/ml
diaminobenzidine in 50mM TRIS-HC1 pH 7.6, containing lOmM
imidazole, activated with lul/ml 100 vols H O
2 2
immediately prior to use). The reaction was allowed to
develop for up to 2 mins after which it was stopped by
washing in tap water. Thereafter, sections were
counterstained in haematoxylin, dehydrated through graded
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alcohols, cleared in xylene and mounted.
Immunoqold silver staining
Paraffin sections of PLPD- and formaldehyde-fixed tissues
were incubated with primary and gold-conjugated secondary
antibodies as described above. They were then washed
thoroughly in deionised distilled water, and treated with
250ul of silver enhancement solution (equal volumes of
IntenSE 2 enhancer and initiator solutions prepared
immediately before silver enhancement, according to the
manufacturer's instructions (Janssen)). The slides were
allowed to develop for up to 15 minutes, the reaction
being monitored visually by microscope. They were then
washed in tap water, counterstained, dehydrated and
mounted as previously.
Controls
Positive controls were included in early staining runs,
and negative controls in all runs. Positive controls
consisted of cytocentrifuge preparations of FH05T1 cells
fixed in acetone, or acetone-fixed frozen sections of
FH05T1 mouse tumours. For negative controls, each slide
was accompanied by one in which the primary antibody was
substituted by NHS/TBS and the remainder of the procedure
carried out as above.
2.1.3.2 Monoclonal antibody RAP-5
The monoclonal antibody RAP-5 is one of a series of
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murine monoclonals raised against a synthetic octapeptide
composed of amino acids 10 - 17 of the mutated Ha-ras
oncogene. Its originators described optimal reactivity in
immunohistochemical techniques with formaldehyde-fixed
tissues (Thor et al, 1984). RAP-5 was donated as ascites
fluid by Dr J. Schlom. Immunoblotting and
immunohistochemistry with RAP-5 were performed
essentially as described above. For immunoblotting, RAP-5
was applied at dilutions of 1:100 and 1:1000. For
immunohistochemistry, titration experiments indicated
optimal dilutions to be in the range between 1:10,000 and
1:20,000. The streptavidin-biotin HRP complex method was
used as above; the secondary antibody was biotin-
conjugated sheep anti-mouse IgG (Amersham) used at 1:50
dilution. Cytocentrifuge preparations of CHL and FH05T1
cells were prepared as described above, and post-fixed in
either acetone or 4% formaldehyde for 15 minutes.
Paraffin sections of formaldehyde-fixed FH05T1 tumours




2.2.1 ras expression in genetically manipulated cells
2.2.1.1 Immunoblotting for p21 with Y13-259
Protein extracts from FH05T1 and CHL cell lines were
separated by SDS-PAGE, transferred to nitrocellulose and
probed with monoclonal antibody Y13-259. Results are
illustrated in Fig. 2.1. Y13-259 detects a single protein
band of molecular weight approximately 21kDa present in
extracts of FH05T1 cells but either absent or detectable
at much reduced quantity in equivalent extracts from CHL
cells. Approximately equal amounts of protein were loaded
on each track of the gel, determined either by formal
protein concentration assay, or by demonstration of
approximately equal loading of gels by kenacid blue
staining.
The single 21kDa protein band was detectable when Y13-259
was used at 1:100 and 1:1000 dilution. Protein extracts
from FH05T1 tumours growing in immune-deprived mice
showed a major single band at the same position, but
there were also a number of fainter bands of higher
molecular weight proteins. The major protein was
detectable using either horseradish peroxidase or
alkaline phosphatase detection systems, at approximately
equal intensity. A formal comparison of the sensitivities
of the two detection systems was carried out.
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Fig. 2.1 Electrophoresis of proteins from FH05T1 cells
(F) and CHL cells (C). The left panel shows the original
polyacrylamide gel stained with kenacid blue, indicating
similarly loaded tracks. The right panel shows an
immunoblot stained with Y13-259 at 1 in 100 dilution,
detected by the alkaline phosphatase method. Mobility of
molecular weight markers is indicated. A single band of
21 kDa appears in the FH05T1 extract, but is absent from
the CHL extract.
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Comparison of HRP and AP detection systems
Duplicate sets of doubling dilutions of FH05T1 protein
extract were separated on the same polyacrylamide gel and
transferred to nitrocellulose. The nitrocellulose was cut
in two, and the immunodetection systems were compared.
The results are shown in Fig. 2.2. There was no
significant difference in the sensitivity of the two
systems. Both detected p21 in undiluted protein extract
and 1:2 dilution, but not at 1:4 or 1:8. The 'cut-off' at
1:4 was equally complete in both systems. In further
experiments, the AP system was usually selected, as the
stained filters showed less non-specific background, were
not light-sensitive, and were easier to photograph.
Immunoblots with RAP-5
Immunoblots of protein extracts of FH05T1 and CHL cell
lines were prepared as described and probed with the
murine monoclonal antibody RAP-5, at 1:100 and 1:1000
dilutions. The results are shown in Fig. 2.3. Multiple
protein bands were detected at the higher concentration,
but no specific band was detectable in the 21 kDa region,
where there was no difference observed between CHL and
FH05T1 protein extracts.
2.2.1.2 Immunohistochemistry
Fixation conditions for immunohistochemistry with Y13-259
are critical. Early experiments employing the fixatives
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Fig. 2.2 Comparison of horseradish peroxidase (HRP) and
alkaline phosphatase (AP) detection systems. Doubling
dilutions of a protein extract of FH05T1 cells were run
on PAGE and transferred to nitrocellulose in duplicate.
The immunoblots were stained with Y13-259 at 1 in 100
dilution, and HRP and AP detection systems compared. A
single band of 21 kDa is detected with both systems, but
a threshold is observed in which the band is barely
detectable at 1 in 4 dilution, and is absent at 1 in 8.
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Fig. 2.3 Comparison of Y13-259 and RAP-5 in the detection
of ras p21 product. Proteins from FH05T1 (F) and CHL (C)
were separated by PAGE. In (a) an immunoblot is stained
with Y13-259 at 1 in 100 dilution. The 21 kDa band is
present in FH05T1 but absent from CHL. In (b), RAP-5
staining of identical extracts is shown at 1 in 1000
dilution, and (c) at 1 in 100 dilution, (d) shows
similarly loaded tracks in the original PAGE gel stained
with kenacid blue. The positions of 14 kDa and 24 kDa
marker proteins are indicated by arrowheads.
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that the aldehyde-based fixatives formaldehyde and
glutaraldehyde almost completely abolished
immunoreactivity with Y13-259. This was true of
cytocentrifuge preparations of cell lines, paraffin
sections of agar-embedded cell pellets, and sections of
FH05T1 tumours from immune-deprived mice. Proteolytic
digestion of such preparations by trypsin failed to
restore useful amounts of immunoreactivity. It would
appear that Y13-259 is therefore not suitable for use
with routinely processed biopsy material. Similarly,
methanol and ethanol were unsatisfactory fixatives.
Acetone fixation was satisfactory in preserving
immunoreactivity with Y13-259, but often at the expense
of very poor morphological preservation of the tissues
for histology.
Using acetone post-fixation, all cells of the FH05T1 cell
line showed strong immunoreactivity with monoclonal
antibody Y13-259, both in cytocentrifuge preparations
(Fig 2.4) and in frozen sections of agar-embedded cell
pellets. Staining was completely absent from negative
controls in which Y13-259 was omitted from the
immunohistochemical method, and replaced by normal serum.
Staining of FH05T1 cells was readily obtained using the
less sensitive indirect immunoperoxidase technique, but
its intensity was amplified by the use of the ABC method.
In contrast, staining was absent from the great majority







Fig. 2.4 Acetone-fixed cytocentrifuge preparation of
FH05T1 cells stained with Y13-259. All cells show strong
immunoreactivity.
Fig. 2.5 Acetone-fixed cytocentrifuge preparation of CHL
cells stained with Y13-259. The great majority of cells
are negative, but a small proportion shows strong
staining.
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minority, variable between 5% and 15%, showed strong
specific staining which was absent from negative controls
(Fig. 2.5).
Positive staining of FH05T1 cells from cell lines in
culture in general showed a membrane-associated
distribution of stain, seen in frozen sections of cell
pellets, although some cytoplasmic stain was seen in some
cells in most cases, and staining was not as crisp as
seen in PLPD-fixed specimens (see below). Membrane
staining was not seen in acetone-fixed frozen sections of
FH05T1 tumours growing in immune-deprived mice. In these
tumours, strong staining of all tumour cells was
observed, showing a cytoplasmic distribution. This was in
marked contrast to the adjacent normal murine tissues
such as skeletal muscle which showed almost complete
absence of staining, thus serving as a valuable form of
in-built negative control in these sections (Fig 2.6).
PLPD fixation
The specialised fixative periodate-lysine-
paraformaldehyde-dichromate (PLPD) was initially used in
an effort to solve some of the problems encountered with
acetone-fixed frozen sections. The FH05T1 positive
control system was used to investigate the properties of
this fixative, both with respect to the pattern and
cellular distribution of immunoreactivity with Y13-259,
and to the preservation of optimal cellular and tissue
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Fig. 2.6 Acetone-fixed frozen section showing margin of
FH05T1 tumour in immune-deprived mouse; section stained
with Y13-259. The tumour cells show strong
immunoreactivity, whilst adjacent fibrous tissue and
skeletal muscle are negative.
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morphology. Paraffin sections of agar-embedded pellets of
FH05T1 and CHL cells fixed in PLPD were stained with Y13-
259 using the ABC immunohistochemical technique as
previously applied to frozen sections. As before, all
FH05T1 cells showed strong staining, whilst CHL cells
showed almost no staining. The FH05T1 cells showed a
distinctly cell-membrane associated pattern of staining
(Fig 2.7). Although this pattern of staining had been
previously observed in frozen sections of similar agar-
embedded preparations, the definition was much superior.
Paraffin sections of FH05T1 tumours in immune-deprived
mice also showed good retention of immunoreactivity with
Y13-259, with all the tumour cells showing strong
staining. Such staining was often clearly linear cell-
membrane associated, but usually some cytoplasmic
staining was also observed (Fig. 2.8). Such membrane-
associated distribution had not been previously seen in
frozen sections of such tumours. Background staining was
minimal with PLPD-fixed FH05T1 tumours, and histological
preservation was greatly superior to that of acetone-
fixed frozen sections, and in many ways comparable with
formaldehyde-fixed paraffin sections. However, shrinkage
artefact was slightly more prominent, and chromatin
clumping often occurred in the cell nuclei which stained
densely haematoxyphilic. PLPD can therefore not be






Fig. 2.7 Paraffin section of PLPD-fixed agar-embedded
pellet of FH05T1 cells stained with Y13-259. Distinct
membrane-associated staining is present.
Fig. 2.8 PLPD-fixed paraffin section of FH05T1 tumour in
immune-deprived mouse. Cell-membrane associated staining
is obtained with Y13-259.
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2.2.2 ras expression in human colorectal tissues
2.2.2.1 Immunohistochemistry with Y13-259
Frozen section technique
In contrast to the FH05T1 positive control system, Y13-
259 showed generally low levels of specific staining in
human colorectal tissues, and it was necessary to employ
the more sensitive ABC immunohistochemical detection
system. Fixation conditions for human tissues did not
vary from those found to be optimal in the control
system, and acetone post-fixed frozen sections of fresh
(or stored frozen) colorectal tissues were required.
Several methods of immunohistochemical staining were
compared in an attempt to optimise the sensitivity and
specificity of the technique. The details of the methods
are outlined in section 2.1.3.1. For each technique, a
range of concentrations of primary and secondary
antibodies was used, and the influence of variation of
incubation times was investigated. The conditions
described in section 2.1.3.1 are optimal.
The indirect method, in which a peroxidase-conjugated
secondary anti-rat IgG antibody is used, was
unsatisfactory, as rather faint staining was obtained
which was insufficiently distinct from the background
levels of staining to be meaningful. This was in contrast
to the situation in the FH05T1 system, in which this
method was perfectly adequate.
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The non-amplified streptavidin-biotin system, in which a
biotinylated anti-rat IgG secondary antibody was followed
by incubation with a simple peroxidase-conjugated
streptavidin stage, similarly produced insufficiently
distinct staining for reliable assessment.
The peroxidase-anti-peroxidase (PAP) technique, in which
an unconjugated anti-rat IgG secondary antibody provides
a bridge between the primary antibody and a peroxidase-
anti-peroxidase complex, was even less satisfactory, in
that background levels of staining were high, and no
specific staining could be observed, even after overnight
incubation with the primary antibody.
Most satisfactory was the amplified streptavidin-biotin-
complex (ABC) technique, in which a biotinylated
secondary antibody is followed by reaction with a pre¬
formed complex of streptavidin-biotin-peroxidase. With
ABC, specific staining could be obtained which was of
higher intensity than that of any of the other methods.
A recurring problem in acetone-fixed frozen sections of
human colorectal tissues, but which did not arise in the
FH05T1 control system in either cytocentrifuge
preparations or sections of mouse tumours, was that of
high levels of background staining of stromal and other
tissues. In early attempts this was so high as to render
assessment of specific staining impossible, and various
experimental strategies were employed in an effort to
reduce it. The normal serum of a variety of animal
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species was used as a blocking agent prior to incubation
of sections with both primary and secondary antibody.
Sera of swine, sheep, goat, rabbit and human were
compared, and human serum was found to significantly
reduce background staining. Absorption of the primary
antibody with acetone-dried human liver tissue was also
felt to offer some reduction in background levels.
Despite these measures, background staining varied to
some extent between staining experiments, and in some
cases remained unacceptably high. Staining of such cases
was repeated until it was judged that a reliable result
was obtained.
Staining patterns in human colorectal tissues
Frozen sections of human tissues were all obtained from
surgical resection specimens, the majority for neoplastic
disease, but some for inflammatory or diverticular
disease. Normal colonic mucosa from resections for non¬
neoplastic conditions showed very similar staining
patterns to uninvolved mucosa from surgical resection
margins and from directly adjacent to colorectal
neoplasms. Staining was generally of low intensity and
uniformly distributed throughout the cytoplasm of cells
at all levels of the crypt and at the epithelial surface
(Fig. 2.9). In many cases, such staining was of low
intensity, but judged to be specific.
Adenocarcinomas showed a variable staining pattern. In
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Fig. 2.9 Acetone-fixed frozen section of normal colonic
mucosa stained with Y13-259. Faint but specific
immunoreactivity is seen in all epithelial cells
throughout the crypt. (Macrophages in the lamina propria
show endogenous peroxidase activity).
Fig. 2.10 Acetone-fixed frozen section of colonic
carcinoma stained with Y13-259. This case shows faint
staining of carcinoma cells.
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the majority, staining was negative or indistinguishable
from background levels. A proportion showed specific
staining of moderate intensity (Fig. 2.10), and a small
number stained with high intensity. All carcinoma cells
showed staining of similar degree within the same
section, and the distribution was cytoplasmic.
Adenomas showed the highest intensity of staining (Fig.
2.11). This was cytoplasmic in location, and more intense
than that seen in the adjacent uninvolved mucosa,
although a sharp interface was never seen, and the
greatest intensity of staining was usually seen at the
centre of the adenoma.
Frozen section series
While recognising that immunohistochemistry can not be
regarded as a quantitative technique, the differences in
staining intensity described above were striking, and a
simple 3-stage grading system was devised. Staining which
was similar to the level of background was designated as
negative or equivocal (+/-); faint specific staining
was designated moderate (+); intense staining was awarded
++. A small series of assorted colorectal tissues was
stained with the Y13-259 ABC technique and assessed in
this way. Grading was performed independently by two
observers, and in more than 75% of cases, there was
agreement in assessment of staining intensity. Where
different assessments were made, the differences did not
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Fig. 2.11 Acetone-fixed frozen section of tubular
adenoma. Strong staining of epithelial cells is seen with
Y13-259.
Fig. 2.12 PLPD-fixed paraffin section of the interface
between an adenoma and non-neoplastic colonic mucosa,
stained with Y13-259. The cells of the adenoma show
strong immunoreactivity, whilst non-neoplastic mucosa is
negative.
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affect the statistical significance of the results. The
results shown in Table 2.1 are a consensus. The intra-
observer variability of the author was tested at an
interval of several months from the first assessment and
consistency was achieved in more than 80% of cases.
TABLE 2.1
Number of cases - staining
intensity with Y13-259
Tissue: +/" + ++
Carcinomas 14 10 2
Adenomas 0 2 5
Normal adjacent 8 9 1
to carcinoma
Normal adjacent 2 4 1
to adenoma
Normal non-neoplastic 4 3 0
Table 2.1. Adenomas show a significantly greater
intensity of staining compared to carcinomas (p<0.01) and
all normals (p<0.002)(Four-fold Table Test). Carcinomas
showed no significant difference in staining intensity
from normal mucosa.
There was no correlation found between staining intensity
and histological differentiation, Dukes' stage and site
of carcinomas, and histological subtype, degree of
dysplasia and site of adenomas.
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PLPD-fixed paraffin sections
Paraffin sections of human colorectal tissues fixed in
PLPD showed specific immunoreactivity with Y13-259 which
together with the superior definition of staining pattern
and tissue morphology represented a major improvement on
the frozen section method. Furthermore, background
staining which had been a continual problem was very
significantly diminished in comparison with acetone-fixed
frozen sections. For this reason, consistency of staining
between experiments was much improved. Best results were
obtained with fresh tissue trimmed to thin blocks and
placed immediately in fixative, but results were very
o
satisfactory with tissues which had been stored at -70 C
for up to 3 years and then placed in the fixative.
Immunoreactivity remained in tissues which had been fixed
for 6 weeks in PLPD and subsequently processed to
paraffin. No diminution in immunoreactivity was evident
in PLPD-fixed paraffin-embedded tissue blocks stored at
room temperature for several months.
The pattern of staining in colorectal tissues was in
general similar to that described in frozen sections. In
normal mucosa,staining was faint or absent; when present,
it titrated out rapidly (see titration experiments
below). In contrast adenomas showed strong specific
staining. This was cytoplasmic in distribution, and
convincing membrane-localised staining was not observed.
However there was a sharp transition between the
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Fig. 2.13 PLPD-fixed paraffin section of adenocarcinoma
of colon. All carcinoma cells show immunoreactivity with
Y13-259, clearly distinguished from the stroma which
shows very low levels of staining.
Fig. 2.14 PLPD-fixed paraffin section of rectal
adenocarcinoma. Heterogneity of staining of tumour cells
is seen, and some cells show nuclear staining.
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positively-staining cells of the adenoma and the negative
cells of the adjacent uninvolved mucosa (Fig 2.12). The
principal difference in staining reaction between PLPD-
fixed material and frozen sections was in the carcinoma
group. Almost all carcinomas showed specific
immunostaining which was cytoplasmic in distribution,
with occasional cases in which nuclear staining was
observed. Membrane staining was not observed. Staining
was usually quite intense, and clearly distinguished from
the low level of background staining (Fig. 2.13). In a
few cases, heterogeneity of tumour cell staining was
seen, the majority of cells showing staining but a small
proportion negative (Fig 2.14). This was an uncommon
pattern, and in most cases all carcinoma cells were
positive.
Titration experiments
The improvement in reproducibility of staining intensity
between experiments afforded by PLPD-fixed material
allowed a more quantitative approach to the assessment of
differences in staining between normal, adenomas and
carcinomas. In a limited series of cases, the primary
antibody Y13-259 was applied at a range of dilutions from
1 in 10 to 1 in 500. Sections were assessed independently
by two observers, and for each case the highest dilution
was recorded at which specific staining could still be
observed. In practice it was found that a sharp threshold
is generally observed, and agreement was reached in more
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than 75% of cases. In cases of disagreement, a consensus
was arrived at, and the results are shown in Table 2.2.
TABLE 2.2
Dilution of Y13-259
Tissue Total Neg 1:10 1:25 1:50 1:100 1:500
Normal 15 7 2 5 1 0 0
Adenoma 15 0 0 0 3 7 5
Carcinoma 19 0 0 4 10 4 1
Adenomas show positive staining to higher dilutions of
Y13-259 than carcinomas and normal mucosa (p<0. 01) .
Carcinomas show staining to higher dilutions than normal
mucosa (p<0.01) (Chi square test).
2.2.2.2 Immunoblottinq for p21 in colorectal tissues
Alkaline phosphatase detection system
Immunoblots of protein extracts from human colorectal
tissues were prepared as above, but the AP detection
system was insufficiently sensitive to detect p21 ras
with Y13-259 with any degree of reliability.
Occasionally, faint bands were obtained at approximately
21 kDa in some specimens, but in most cases were absent.
A range of higher molecular weight protein bands were
detected which were absent from extracts of FH05T1 and
CHL cell lines. Their nature is uncertain, but they may
include histone proteins and immunoglogulins. Detection
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of the smaller amounts of p21 present in spontaneous
human tumours required modification of the technique.
Immunoprecipitation of p21 from tumour extracts was
attempted using a modification of the technique of
Gallick et al (1985). Briefly, this method involved
reaction of protein lysates with Y13-259, incubation with
rabbit anti-rat IgG, followed by treatment with
Staphylococcal protein A. Precipitates were then washed,
and immunoblotting carried out as above. The technique
proved unsuccessful, and was not pursued.
125
I-Protein A detection system
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The I-protein A method was adopted for use with
extracts of human colorectal tissues because of its
reported increased sensitivity over enzyme-linked
methods. Initial experiments followed the method of
DeBortoli et al (1985), as described in section 2.1.2,
but this was subsequently modified to increase the
amounts of protein loaded on each track to up to 1 mg.
Using this method, bands were present in the 21 kDa range
in samples which had yielded no detectable p21 by the AP
detection system.
Protein extracts of FH05T1 cell lines and tumours showed
diminution in amounts of immunoreactive p21 when stored
o
at -70 C for more than a few weeks, although in some
cases p21 could be detected in reduced amounts after more
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than 12 months. Extracts of human tissues required to be
used within a few days of preparation, as p21 was
undetectable in samples of extract stored for longer.
Freshly prepared extracts of tumours which had been
stored as frozen whole tissues showed retention of p21
indistinguishable in amount from fresh tumours.
In protein extracts of human colorectal tissues, whether
from normal mucosa, adenoma or carcinoma, bands were
detectable in the 21 kDa region. There was some variation
in the intensity between different samples, but
consistently greater intensity was not found in extracts
of any particular tissue type. Protein extracts from
human colorectal tissues showed p21 bands as doublets, in
contrast to the single band observed in FH05T1 extracts.
Some variation in intensity of inividual components of
the p21 doublet was noted, but a consistent pattern was
not found to correlate with any particular tissue type.
Results of a typical experiment are shown in Fig. 2.15.
2.2.2.3 Immunohistochemistry with RAP-5 in colorectum
Paraffin sections of formaldehyde-fixed human colorectal
tissues were stained using RAP-5 with the ABC method. The
pattern of staining differed significantly from that seen
with Y13-259. Although normal mucosa generally showed low
levels of staining, its presence and intensity was
variable between cases and between different fields of
the same case. Adenomas and carcinomas showed positive
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Fig. 2.15 Immunoblot of protein extracts of human
colorectal tissues, separated by PAGE and detected on
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nitrocellulose by Y13-259 with I-protein A. Tracks
loaded with equivalent amounts of the following protein
samples: 1 - adenoma, 2 - carcinoma (same patient); 3 -
carcinoma; 4, 5 and 6 - normal mucosa, adenoma and
carcinoma respectively (same patient); 7 - extract of
mouse FH05T1 tumour (positive control for p21 ras). The
marker indicates the 21 kDa position. A single p21 band
is detectable in the extract of FH05T1 tumour; p21 bands
are present in all human colonic tissues, a faint doublet
appearance discernible in several specimens.
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staining, and although there was often a considerable
degree of heterogeneity of staining within individual
lesions, there was no differential staining between
infiltrative and non-infiltrative areas. Relatively high
levels of staining occurred in stroma and muscularis
propria, and serosal cells were consistently strongly
positive. A range of other human tissues including normal
skin, bronchial mucosa, cartilage, smooth and striated




Profound phenotypic changes follow the transfection of
transcriptionally enhanced mutationally-activated Ha-ras
oncogene into early-passage rodent fibroblasts. A
contact-inhibited non-tumourigenic diploid (or near-
diploid) cell strain (CHL) is transformed to a cell type
(FH05T1) giving rise to rapidly-growing infiltrative
metastasising aneuploid tumours (Spandidos and Wilkie,
1984). Quantitative RNA dot-blot analysis indicates such
transfectants to have up to 50-fold elevation in Ha-ras
mRNA transcript compared with the parental cells,
representing approximately 0.8% of total cellular mRNA
(Wyllie et al, 1987). The observation that T24 Ha-ras
transfectants derived from different parental cells (such
as rat fibroblast line 208F) acquire a similar range of
aggressive properties is in support of the proposal that
the constellation of phenotypic changes is a consequence
of elevated levels of ras expression, and not merely a
coincidental feature of individual clones studied. The
genetic manipulation which engendered the FH05T1 cell
line is of course an artificially-contrived situation,
and there may be few naturally-occurring analogues
amongst spontaneously-occurring human neoplasms. This
does not diminish from the fundamental interest in this
system as a means of investigating phenotypic changes due
to ras expression, or from its value as a positive
control system for immunohistochemical and other studies
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of ras p21 expression. One of the strengths of the system
is the opportunity it affords to study known ras-
expressing cells both in pure population in cell culture,
and growing as authentic malignant tumours in animals.
The monoclonal antibody Y13-259 was raised in rats
bearing tumours induced by the Harvey strain of the
murine sarcoma virus (Furth et al, 1982) and it has been
shown to immunoprecipitate human p21 ras products of Ha,
Ki and N-ras genes (Furth et al, 1987). Its specificity
for p21 has been documented in a variety of different
reports using different techniques (e.g. Gallick et al,
1985; Mulcahy et al, 1985) and the epitope it recognises
seems to be located in the region of constancy of the
three p21 species, probably amino acids 70-81 (Lacal and
Aaronson, 1986). Using the FH05T1 test system, the
present study has provided further confirmation of the
specificity of Y13-259 for the ras gene products by
immunoblotting and immunohistochemistry.
The major problem with the use of Y13-259 in
immunohistochemistry has been the apparent lability of
this epitope under conditions of strong aldehyde
fixation. In the experience of the writer and that of
others (Kerr et al, 1985; Ghosh et al, 1986),
formaldehyde fixation completely abolishes
immunoreactivity of paraffin sections of human tissues,
and no useful staining is restored after proteolysis by
trypsin. Some workers appear to have found differently
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(Furth et al, 1987; Chesa et al, 1987), but in neither of
these reports is sufficient detail provided of the
fixation conditions used with human tissues.
Most immunohistochemical studies with Y13-259 have
involved the use of acetone-fixed frozen sections. As
confirmed in this study, best results are obtained with a
highly sensitive immunohistochemical detection system.
Although elevations in ras transcription have been
reported in a number of human tumours, levels do not
generally approach the artificially high values of the
FH05T1 system. Mutational activation of ras may not
result in large increases in transcription, and it is
perhaps not surprising therefore to find lower levels of
p21 in human tumours.
Acetone-fixed frozen sections have yielded results
regarded as generally trustworthy, but there are many
disadvantages, some of which have already been mentioned.
An ideal solution to the problem would be to identify
another antibody to ras p21 of similarly restricted
specificity to Y13-259 but whose reactivity is retained
in formaldehyde-fixed tissues. Reports of the monoclonal
antibody RAP-5 seemed promising in this regard (Horan
Hand et al, 1984; Thor et al, 1984). It was raised by
immunisation of a mouse with a synthetic octapeptide
containing amino acids 10 - 17 of the mutated human Ha¬
ras oncogene, linked to thyroglobulin. The hybridoma was
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originally selected on the basis of differential binding
to the peptide reflecting the mutated gene product
compared to that of the non-mutated homologue. It was
subsequently found that RAP-5 binds to cells of normal
tissues and tumours (such as breast carcinoma) in which
mutated ras would not be expected. This has been assumed
to be due to cross-reaction of the antibody with the non-
mutated p21 product, but this assumption has not been
properly validated. Important claims were made for RAP-5,
notably its putative preferential binding to infiltrative
areas of carcinomas in breast and colon. This pattern was
reported to be present only in formaldehyde-fixed tissues
(Horan Hand et al, 1984; Thor et al, 1984). The results
of the present study failed to confirm the claims made
for RAP-5. Its inability to differentiate between FH05T1
and CHL cells, together with the wide range of proteins
detected on immunoblotting and the wide range of cell
types stained by immunohistochemistry cast serious doubt
on the specificity of RAP-5 for any ras-related protein.
This work demonstrates the necessity of stringent testing
of antibodies for use in immunohistochemistry, and
illustrates the value of an unequivocal positive control
system.
Apart from Y13-259, there are no widely available
antibodies to p21 of acceptable specificity, so
consideration was given to altering fixation conditions
in order to retain immunoreactivity while optimising
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morphology. These requirements are to some extent in
conflict. The quality of preservation of morphology of a
tissue is at least in part dependent on the degree of
cross-linkage between tissue constituents induced by a
fixative, whilst preservation of antigenicity is
inversely proportional to the number of cross-links and
the speed at which they are introduced. Paraformaldehyde
(methanol-free formaldehyde) has been found to provide
good morphological preservation, and although antigenic
denaturation occurs, it is less than that induced by
formaldehyde, and it can permit adequate retention of
immunoreactivity when used at optimal concentration.
McLean and Nakane (1974) conceived a fixative for immuno-
electron microscopy in which periodate and lysine were
added to paraformaldehyde. The theoretical basis for this
fixative (PLP) lies in the ability of lysine to cross¬
link carbohydrate moieties oxidised by the periodate,
thus providing better preservation of the conformational
structure of glycoprotein antigens. Potassium dichromate
was a later addition included for its membrane-
stabilising properties (Holgate et al, 1986).
Membrane localisation of p21 distribution was suggested
by the staining pattern of frozen sections of agar-
embedded FH05T1 cultures, and confirmed with similar
PLPD-fixed preparations, where localisation of staining
was much more precise. Membrane staining can also be
readily identified in sections of PLPD-fixed FH05T1 mouse
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tumours, although cytoplasmic staining is also present
and is often the predominant pattern. In contrast, the
localisation of stain in PLPD-fixed human tissues has not
been observed in the cell membrane. Cytoplasmic staining
predominates, but on occasion staining is also seen in
the cell nucleus. Other authors have also commented on
the differences in staining distribution between ras-
expressing cells in tissue culture, which showed membrane
staining, and tissue sections where diffuse cytoplasmic
staining was observed (Bizub et al, 1987; Brown et al,
1987) . Indeed the membrane staining seen in PLPD-fixed
mouse tumours in the present study is believed to be the
first description of membrane distribution of p21 in
tissue sections of tumours.
The cytoplasmic distribution of staining of human tumour
tissue may be an artefact of tissue sectioning as
suggested by the above authors, but there are possible
alternative explanations. Difficult to exclude is the
suggestion that perioperative ischaemia or hypoxia may
result in an alteration in the cellular distribution of
p21 before the tissue is fixed. In mouse FH05T1 tumours
handled in such a way as to simulate the conditions of
handling for human resection specimens, there was an
impression of redistribution of staining to the cytoplasm
from the membrane, but this was hardly conclusive.
Against this autolysis hypothesis is evidence which
indicates that once p21 is situated in the plasma
110
membrane, it is securely anchored there and very
difficult to remove in vitro either by proteolysis, salt
extraction, chelating and reducing agents, or detergents
(Grand et al, 1987). These authors have also provided
evidence that, at least for the product of N-ras, even
when produced in vast excess, all post-translationally
modified p21 locates in the plasma membrane. This is in
keeping with the observation of the present work that the
p21 of FH05T1 cells in culture locates only in the plasma
membrane.
Although it is possible that an artefact of tissue
sectioning or autolysis explains the cytoplasmic
distribution of staining, it may be authentic. ras
polypeptides are synthesised as cytosolic precursor
molecules, pro-p21 ras (Shih et al, 1982). Post-
translational modifications occur before attachment to
the inner face of the plasma membrane, and the critical
step is covalent palmitylation occurring at the conserved
cysteine residue at position 186 (Chen et al, 1985).
After this step, p21 is rendered highly insoluble, and
becomes firmly attached to the inner face of the plasma
membrane. It does not span the full thickness of the
lipid bilayer - only the C-terminal 4 amino acids are
integrated. It is possible that a derangement of the
post-translational modification of p21 may have the
consequence of cytoplasmic solubility and distribution of
the protein; p21 over-expressed in E. coli and not
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acylated after translation behaves as a soluble
cytoplasmic protein (Lacal et al, 1984).
The observation of nuclear staining in some PLPD-fixed
sections of human tissues may also be a genuine
reflection of p21 distribution in these cases, but if so,
its significance is quite uncertain. More likely, this
pattern is also artefactual. A possible explanation is
the observation by Grand et al (1987) and confirmed in
this study that Y13-259 appears to cross-react in
immunoblots with a protein believed to be of histone
origin.
Immunohistochemical staining is fundamentally a
qualitative technique, and when assessing results in
individual cases, ideal criteria should only take account
of the presence or absence of specific staining in the
section. Nonetheless there is no doubt that real
differences in the intensity of specific staining do
occur which are likely to reflect true differences in the
amount of antigen present. In devising the simple scoring
system used for assessing staining of frozen sections,
which essentially records whether specific staining, if
present, is faint or strong, it was considered that a
valid comparison could be obtained of the relative
proportions of p21 present in different tissues. It is
clearly important that such scoring is reliable and
reproducible, and the high degree of inter- and intra-
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observer agreement achieved confirms that consistent
results are obtainable by this method.
The principal result of the frozen section series is the
observation of consistently high levels of p21 expression
in adenomas, in contrast to the generally lower levels in
normal mucosa and most carcinomas. In the context of the
adenoma-carcinoma sequence, this suggests that ras
expression is elevated in the earlier stages of the
process, but that expression diminishes again as adenomas
evolve into carcinomas. However, concern about the
validity of the scoring system used led to attempts to
confirm these findings using a titration technique of
increasing dilutions of Y13-259 on serial paraffin
sections of tissues fixed in PLPD. As this fixation
technique became available later in the study, in only a
minority of cases were both techniques applied to the
same individual tissues. The titration method was not
applied to frozen sections as the high background
staining made assessment of specific staining impractical
at high dilutions of primary antibody.
Titration of Y13-259 concentration in the series of PLPD-
fixed colorectal tissues confirmed the major finding of
high expression of ras in adenomas compared with low
levels in normal mucosa. This approach has also revealed
expression of ras at intermediate levels in the great
majority of carcinomas - a finding confirmed by the high
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proportion of carcinomas staining positively in the
series stained using Y13-259 at the higher concentration
of 1 in 25. The similarity in results to the frozen
section series is illustrated by considering the
percentages of each tissue type showing positive staining
at 1 in 100 dilution of Y13-259.
TABLE 2.3
FS Series PLPD Series




ras activation may occur early in the carcinogenic
process in the colorectum, but high levels of expression
may be a marker rather than a cause of the active
proliferation of neoplastic cells. Cytokinetic data
indicate that adenomas have a shorter cell cycle time and
a higher proportion of cells in cycle than the normal
mucosa (Bleiberg and Galand, 1976; Deschner and Lipkin,
1976). Furthermore, adenomas have a shorter cell cycle
time than carcinomas and normal mucosa. The carcinogenic
process in colon may require that the cells of an adenoma
achieve a certain altered proliferative potential, a
marker of which is increased ras expression, and which
once achieved renders them vulnerable to the action of a
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further carcinogenic stimulus or stimuli which converts
the lesion to an invasive carcinoma. Once this has acted,
the requirement for ras expression is supplanted, and
levels fall. In keeping with this hypothesis are the
results obtained by Gallick et al (1985) who observed
higher levels of p21 detectable by immunoblotting in
colorectal carcinomas at an early pathological stage
(Dukes7 stage A) compared to more advanced lesions which
had metastasised.
The main purpose of immunoblotting in this study was
validation of antibody specificity and confirmation of
the presence of p21 in human colorectal tumours.
Additional points of interest have emerged from its
application to colorectal tissues. p21 was detected as a
doublet band in all human colonic tissues, whether normal
or neoplastic. This is in keeping with the findings of
Furth et al (1987) in a range of normal tissues, and
DeBortoli et al (1985) in a series of breast carcinomas.
It is most likely that the doublet band represents the
product of different members of the ras gene family (Ha,
Ki and N-ras) migrating at slightly different rates.
Although the p21 proteins of normal and mutationally
activated ras genes also show slightly different
electrophoretic mobilities, this explanation is less
likely as the same pattern was seen in normal and
neoplastic tissues. The single band detected in extracts
of FH05T1 cells represents the mutated Ha-ras gene
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product, present in vast excess over other ras gene
products in these cells.
Like immunohistochemistry, immunoblotting is essentially
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a qualitative technique. However, when using the IE-
Protein A detection system, it might have been
anticipated that if there were significant differences in
amounts of p21 between samples, these differences would
be revealed as bands of varying intensity. The finding of
p21 bands of only slightly varying intensity in normal
mucosa, adenomas and carcinomas was not the expected
result in view of the immunohistochemical findings, but
only a small number of cases have been investigated.
Similarly the observation of variation in the intensity
of one or other component of the doublet bands in
different specimens is intriguing, especially in the
light of recent reports of ras deletions in colonic
carcinomas. These findings await confirmation in a
larger series of cases.
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CHAPTER 3
IMMUNOHISTOCHEMICAL DETECTION OF C-MYC ONCOPROTEIN
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SUMMARY
c-myc expression in colorectal tissues was studied by
immunohistochemistry, principally using the monoclonal
antibody Mycl-9E10. Antibody specificity was investigated
by application of immunohistochemistry to myc-expressing
cell lines, and by immunoblotting of protein extracts of
cell lines and colorectal tissues. Immunoblotting
identified a single major protein band in both extracts
which is believed to represent the c-myc oncoprotein, but
its electrophoretic mobility was unexpectedly rapid,
indicating molecular weight of 40-45 kDa, and the
explanation of this is uncertain. Immunohistochemistry
showed positive staining in cell lines known to
transcribe c-myc at artificially high levels, but
positive staining of similar pattern was also present in
an unmanipulated progenitor cell line. This is believed
to indicate the endogenous c-myc expression expected in
proliferating cells in culture. Positive staining was
observed in tissue sections of all human colorectal
tissues. Conditions of fixation had an important effect
on staining distribution, with rapid fixation in
formaldehyde required for optimal results. A series of
50 colorectal resection specimens for carcinoma, fixed in
this way, showed differences in distribution of
immunoreactivity between normal mucosa, adenomas and
carcinomas. Nuclear staining predominated in normal
mucosa, but carcinomas showed diffuse cytoplasmic
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location of staining in all cases. Adenomas showed an
intermediate pattern, with both cytoplasmic and nuclear
staining patterns present. Cytoplasmic staining was
significantly more frequent in adenomas than in normal
mucosa (p<0.01). The results indicate that differences in
the cellular processing of the c-myc oncogene product may
occur during the evolution of colorectal neoplasms.
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3.1 MATERIALS AND METHODS
3.1.1 Cell lines
A cell line was used as a positive control in which c-myc
expression was augmented by transfection with the high
expression plasmid vector pMCGMl which contains the
entire c-myc gene linked to Moloney virus LTR seguence
(Spandidos, 1985). The cell line RFMCGM1 (referred to
subseguently as RFM) is a derivative of the 208F rat
fibroblast line, transfected with pMCGMl. RFM cells show
variable elevation of c-myc mRNA transcript levels up to
18-fold relative to the parental 208F line (Wyllie et al,
1987). The cell lines were maintained in culture as
described in section 2.1.1, and cytocentrifuge
preparations and cell pellets in agar prepared also as
described previously. 208F cells, although said to be
non-tumourigenic, engendered slowly-growing tumour
nodules when injected subcutaneously into immune deprived
mice. Approximately 50% of inoculations of RFM gave rise
to aggressive fibrosarcomas under similar conditions.
Such tumours were not suitable as controls for
immunohistochemistry because the anti-p62-c-myc antibody
Mycl-9E10 (see below) is of mouse origin, and the
immunohistochemical technigue reguires anti-mouse IgG as
a secondary antibody. Cross-reactions with endogenous
mouse IgG resulted in unacceptably high levels of
background staining.
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3.1.2 Human colorectal tissues
Methods of collection and handling of resection specimens
of human colorectal tissues have been described in
section 2.1.1. For immunohistochemistry, frozen sections
and paraffin sections were used, and the effects of
different fixatives compared. For frozen sections, post-
fixation in acetone or formaldehyde was carried out as in
section 2.1.3.1. Paraffin sections of formaldehyde-fixed
or PLPD-fixed tissues were also used. Special efforts
were made to minimise the delay in placing fresh tissues
in the appropriate fixative.
3.1.3 Immunohistochemistry
Antibodies to the p62-c-myc protein product
The monoclonal antibodies Mycl-9E10 and CT14 are two
members of a series of six monoclonals isolated from mice
immunised with synthetic peptide immunogens whose
seguences are derived from that of the human c-myc gene
product p62. Both were raised against the C-terminus
peptide residues 408-432. Unlike CT14, 9E10 fails to
immunoprecipitate native p62-c-myc, but it is a sensitive
probe for the protein on immunoblots, and binds to it
with high affinity (Evan et al, 1985). Both antibodies
have been used in .immunohistochemical studies and 9E10
has been reported to show a higher degree of sensitivity
for the p62 protein than CT14 (Sundaresan et al, 1987).
Mycl-9E10 and CT14 were prepared from hybridoma culture
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supernatants by ammonium sulphate precipitation, and
o
stored as aliquots of 200 ul at -70 C. The polyclonal
antibody anti-p62-c-myc was prepared by immunisation of
rabbits by whole recombinant p62-c-myc protein expressed
in bacteria (Watt et al, 1985), and was donated by Dr R.
Watt of Smith, Kline and French, Philadelphia.
Immunohistochemical technique
Immunohistochemical staining was performed using the
indirect (peroxidase-conjugated secondary antibody) or
the ABC (streptavidin-biotin peroxidase complex)
technique. In principle, the methods are exactly as
described previously (section 2.1.3.1); details of the
method vary as follows:
1. Endogenous peroxidase activity was blocked before
application of the primary antibody by incubating the
dewaxed rehydrated paraffin sections in 3% hydrogen
peroxide in methanol for 15 minutes, followed by washing
in TBS.
2. When using the murine monoclonal antibodies 9E10
and CT14, non-specific binding was blocked by application
of 10% normal rabbit serum in TBS. When using the rabbit
polyclonal anti-p62-c-myc antiserum, 10% normal swine
serum was applied.
3. All primary antibodies were applied at a dilution
of 1 in 100 for 1 hour.
4. For 9E10 and CT14, the secondary antibody was
biotin-conjugated rabbit anti-mouse IgG (Dako), applied
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at a dilution of 1 in 400 in 10% normal rabbit serum. For
polyclonal anti-p62-c-myc, biotin-conjugated swine anti-
rabbit IgG (Dako) was applied also at 1 in 400 dilution.
5. In some experiments, Amersham ABC complex was
replaced by Dako ABComplex, freshly prepared immediately
before use according to the manufacturer's instructions.
In all experiments, a negative control was provided for
each section in which the primary antibody was omitted
and replaced by 10% normal rabbit serum.
Immunoblotting
Protein extracts of cell lines and human colorectal
tissues were prepared as described in section 2.1.2, and
SDS-PAGE separation and transfer to nitrocellulose
carried out as previously. Immunodetection was carried
out using the alkaline phosphatase detection system as
previously, the only difference being the species-
specificity of the secondary antibody (anti-mouse IgG for




3.2.1 Immunoblottinq using Mycl-9E10
Protein extracts of the 208F and RFM cell lines were
separated on PAGE alongside extracts from colorectal
tissues and transferred to nitrocellulose. Using the AP
detection system, a major single band was detectable in
RFM cells, at approximately 40-45 kDa. This band was also
present at approximately equal intensity in 208F cell
extracts, also as a single major band. Colorectal tissues
showed a similar major band in this region , but multiple
bands of lower intensity were also present at both lower
and higher molecular weights. Although a faint band was
present in the 60-65 kDa range, this was of considerably
lower intensity than the band at 40-45 kDa, and was
absent from extracts of the known myc-expressinq cell
line RFM (Fig. 3.1) .
3.2.2 Immunohistochemistry
Cell lines
The 208F and RFM cell lines were used as a control
system to identify the optimal conditions of fixation and
tissue handling for immunohistochemical detection of the
c-myc oncoprotein. Fixation conditions were found to have
a significant effect on the ability to demonstrate
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Fig. 3.1 Immunoblot of protein extracts of RFM cell line
and human colorectal tissues, separated by PAGE and
detected on nitrocellulose with Mycl-9E10 with alkaline
phosphatase detection system. Tracks were loaded with
equivalent amounts of protein extracts from the following
specimens: 1 - RFM myc-expressing cell line in culture;
2, 3 & 4 - carcinoma, adenoma and normal mucosa
respectively from same patient; 5, 6, 7 & 8 - carcinomas
from separate patients; 9 - normal mucosa; 10 - molecular
weight markers (Amersham, 'Rainbow Markers').
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positive staining. The mouse monoclonal antibody 9E10 was
the anti-myc primary antibody used in most experiments.
Despite the observation that positive staining was
demonstrable using 9E10 with the indirect technique
(peroxidase conjugated secondary antibody), the ABC
streptavidin-biotin-complex technique was used because of
its increased sensitivity. Immunohistochemical staining
was performed on cytocentrifuge preparations of 208F and
RFM cell lines fixed in acetone or formaldehyde. All
cells of both lines showed positive staining when fixed
in acetone but were negative when formaldehyde-fixed.
Staining was most frequently localised diffusely
throughout nucleus and cytoplasm, but in some
preparations, exclusively nuclear staining of granular
pattern was obtained. The reason for this divergent
pattern of staining in apparently similar preparations
was never identified. Allowing for the fact that there
were some morphological differences between the two cell
lines, no discernible difference was seen in staining
pattern between 208F and RFM. Staining was absent from
negative controls.
The staining with 9E10 was compared with that obtained
using the two other anti-p62 antibodies, CT14 and
polyclonal antip62-c-myc. These reagents, produced in
very different ways, resulted in a closely similar
distribution of immunoreactivity in acetone-fixed
cytocentrifuge preparations. No significant difference in
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pattern or intensity of staining was demonstrated between
208F and RFM cell lines. Negative controls showed no
staining.
Paraffin sections of formaldehyde-fixed agar embedded
cell pellets were stained using the three anti-myc
antibodies. Positive staining was obtained with 9E10 in
sections from both cell lines. No difference in pattern
or intensity of staining was observed between them, both
showing diffuse immunoreactivity distributed throughout
nucleus and cytoplasm of all cells. Exclusively nuclear
staining was never observed in these preparations.
Morphological preservation was not good in these
preparations and accurate subcellular localisation of
staining was not possible. Staining with CT14 and
polyclonal anti-myc was significantly fainter but of
similar pattern.
Human colorectal tissues
A variety of fixation conditions were compared using
frozen and paraffin sections of human colorectal tissues,
and differences were observed in the quality,
localisation and intensity of immunoreactivity. The
antibody 9E10 was the principal antibody used in this
part of the study. Paraffin sections of formaldehyde-
fixed tissues showed retention of immunoreactivity, and
positive staining was obtained with sections of
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routinely-handled resection specimens of colorectal
tissues from the files of the Biopsy Service. However,
when these sections were compared with those from a
series of colorectal resection specimens which had been
specially handled to optimise fixation and minimise delay
in placing tissue blocks in formaldehyde, the latter
group showed a very clear improvement in terms of the
intensity and localisation of staining pattern. The
improvement was particularly seen in sections of normal
mucosa, in which distinct nuclear localisation was seen
in a significant proportion of epithelial cells, whilst
others were quite negative. This contrasted with the
pattern in normal mucosa of routinely-fixed tissues where
although positive staining was still observed, its
distribution was most frequently diffusely cytoplasmic,
and differences in staining between individual cells in
the mucosa were much less clearly defined.
Frozen sections of colorectal tissues, post-fixed in
acetone, also retained some immunoreactivity, but were
significantly less satisfactory in three respects. The
pattern of immunostaining was poorly localised, being
diffusely cytoplasmic or sometimes concentrated at the
adluminal aspect of the surface epithelium (Fig. 3.2).
The staining was significantly fainter than in formalin-
fixed sections, and morphological preservation was poor.
Paraffin sections of tissues fixed in PLPD showed
complete loss of immunoreactivity. These differences in
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Fig. 3.2 Acetone-fixed frozen section of colonic adenoma
stained with Mycl-9E10. Staining is faint and variable,
and localised to the adluminal aspect of the glandular
epithelium. (Endogenous peroxidase activity is seen in
macrophages in the lamina propria).
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staining patterns were shown to be a consequence of
fixation, in that tissue blocks from the same specimen
fixed in formaldehyde or PLPD, or subjected to frozen
section showed the different patterns of staining
described.
It was concluded that optimal fixation for
immunohistochemistry with 9E10 required minimum delay in
placing adequate-sized tissue blocks in formaldehyde.
Under such conditions, the theoretically predicted
nuclear localisation of immunoreactivity was consistently
obtained in a proportion of cells in sections of normal
mucosa.
Resection specimens
A series of 50 colorectal adenocarcinomas were stained
for p62-c-myc using monoclonal antibody 9E10. In all
cases, the resection specimens were specially handled for
optimal fixation as above; the average time interval
between resection and adequate fixation was estimated to
be approximately 30 minutes. Blocks of carcinoma were
selected to include adjacent uninvolved mucosa where
possible, and in 25 cases, blocks from the mucosa of the
resection margin were examined. When present, co-existent
adenomas from the resection specimens were sampled, and
in Dukes7 stage C carcinomas, examples of involved lymph
nodes were used.
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Figs. 3.3a & b. Normal colonic crypts from mucosa of
resection specimen rapidly fixed in formalin, stained
with Mycl-9E10. In the superficial part of the crypts,
most cells show nuclear staining, but on the surface
epithelium, a proportion of nuclei are negative. At the
crypt base, a proportion f cells show staining, but some
are negative. There is almost no cytoplasmic staining
throughout.
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Specific staining was always obtained in normal mucosa,
and in the majority of cases, a consistent pattern of
distribution was observed (Figs. 3.3a & b). The pattern
was similar in mucosa adjacent to adenomas and
carcinomas, and from resection margins of specimens.
Areas of exclusively nuclear staining of colonic
epithelial cells were observed in the great majority of
cases (93%), and in 39% of cases, exclusively nuclear
staining was the pattern of localisation in more than 90%
of positively-staining cells. The proportion of cells
showing such nuclear staining was lower at the bases of
the crypts than in the intermediate (maturation) zone,
where the majority of cells showed staining. Nuclear
staining was also usually seen in a proportion of cells
on the surface epithelium, variable up to approximately
50% of cells, while neighbouring surface cells which were
morphologically indistinguishable were negative. However
in many cases, cytoplasmic staining of surface epithelial
cells occurred, and when this pattern was seen, all cells
at the surface were stained (Fig. 3.4). Cytoplasmic
staining was present in 61% of blocks of normal mucosa,
but in only 7% was this pattern present in more than 90%
of positively-staining cells. Basal and intermediate
cells of the crypt only infrequently showed cytoplasmic
staining.
Adenomas showed a variable pattern of staining
distribution, but positive staining was observed in all
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cases. In 12 of 19 cases (63%), both nuclear and
cytoplasmic localisation of staining were observed in
different parts of the lesion (Fig. 3.5), but in 2 cases,
more than 90% of positively-staining cells showed nuclear
staining only, while in 5 cases, cytoplasmic staining was
similarly predominant. When exclusively nuclear staining
predominated, a proportion of cells were seen which
showed no staining, but when cytoplasmic staining was
predominant, all cells appeared to be stained. No
correlation was identified between the histological type
of the adenoma and the pattern of staining. The numbers
are small, but the impression was gained that nuclear
staining was more freguent in small adenomas, whilst
cytoplasmic staining was commoner in the larger lesions.
Areas of severe dysplasia in adenomas showed cytoplasmic
staining.
Primary carcinomas all showed positive staining, although
there was some variation in the intensity in different
areas of the same tumour, and between different tumours.
No attempt was made to quantify such differences. There
was no obvious correlation with the degree of
differentiation or any other histological property of the
tumour. In all carcinomas, staining was predominantly
cytoplasmic in distribution, and present in all cells
(Fig. 3.6). Exclusively nuclear staining was only rarely
observed in some areas of some carcinomas, and was never
seen in more than 10% of positively-staining cells. A
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Fig. 3.4 In some cases, cytoplasmic staining occurred of
epithelial cells at the surface of normal mucosa.
Fig. 3.5 Adenoma of colon stained with 9E10. Both nuclear
and cytoplasmic staining are present in epithelial cells;
a proportion of the nuclei are negative.
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Fig. 3.6 Infiltrating adenocarcinoma of colon stained
with 9E10. All cells of the adenocarcinoma show staining
which is diffusely localised throughout the cytoplasm.
Fig. 3.7 Interface between non-neoplastic colonic mucosa
(top) and carcinoma. Distinct nuclear staining is present
in normal mucosa; cytoplasmic staining is present in
carcinoma cells.
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clear difference in the cellular distributin of staining
occurred at the interface between normal mucosa and
carcinomas. Normal mucosa showed nuclear staining, whilst
the carcinoma showed cytoplasmic staining (Fig. 3.7).
Cytoplasmic staining of all carcinoma cells was seen in
all cases of metastatic carcinoma in lymph nodes.
An attempt was made to assess the differences in staining
distribution in different tissues in a semi-quantitative
way. 3 categories of staining distribution were defined
as follows:
1. N>C - exclusively nuclear staining present in 90%
or more of positively-staining cells.
2. ON - cytoplasmic staining present in 90% or more
of positive cells.
3. N=C - areas of exclusively nuclear and of
cytoplasmic staining both present in different parts of
the section, neither pattern accounting for 90% or more
of positive cells.
Table 3.1 shows the results of staining of each tissue
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Carcinomas show a highly significant predominance of the
cytoplasmic staining pattern compared with normal mucosa
and adenomas. Metastatic carcinoma in lymph nodes shares
this pattern. Adenomas show a significantly higher
frequency of cytoplasmic staining when compared with all
normal mucosae taken together (p<0.01 - Chi squared
test). There is no significant difference in distribution
of staining pattern between normal mucosa adjacent to
either adenomas or carcinomas compared with that derived
from surgical resection margins.
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3.3 DISCUSSION
3.3.1 Specificity of Mycl-9E10 for p62-c-myc
The monoclonal antibody Mycl-9E10 was shown by its
originators to recognise an epitope of the human c-myc
protein p62 (Evan et al, 1985), and although it did not
immunoprecipitate detectable amounts of native c-myc
protein from detergent extracts of Colo 320 HSR cells (a
cell line derived from a human colonic tumour in which
the c-myc oncogene is amplified) it was shown to be a
sensitive probe for p62-c-myc in immunoblotting
experiments, recognising a single protein band of deduced
molecular weight 62 kDa. Subsequent reports have
described the use of 9E10 in immunohistochemical studies
(Sundaresan et al, 1987; Jones et al, 1987), and although
it has not found such extensive use as the antibody 6E10,
which is yet another member of the same group of
antibodies produced by Evan et al (1985), it has been
reported to produce patterns of immunostaining consistent
with the predicted distribution of p62, and similar to
the patterns obtained with other anti-p62 antibodies.
Immunoblotting investigations carried out in this study
have provided an unexpected result concerning the protein
recognised by this antibody. It was shown that 9E10 binds
to a protein present in extracts of both RFM and 208F
cell lines. The protein forms a single homogeneous band,
and other bands are very much fainter, or absent in some
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preparations. The molecular weight of this protein,
deduced from its electrophoretic mobility on SDS-PAGE, is
in the region 40-45 kDa. This finding has been repeated
in separate experiments with separately-prepared extracts
of the cell lines. A protein of identical electrophoretic
mobility is also present in protein extracts of human
colorectal tumours, although in these preparations,
several other prominent bands occur. The explanation for
the apparently anomalous mobility of the protein is not
certain, and it has not yet been possible to compare the
pattern obtained with other anti-myc antibodies on the
same protein extracts. It is possible that the epitope
recognised is unrelated to the p62 protein, but the
originators of this antibody (Evan et al, 1985) have
described reactivity with a single protein band in the
60-65 kDa region in extracts of myc-expressing cells.
However, anomalous electrophoretic mobility for the c-myc
protein has been described previously, and it has been
noted that the precise proportions of acrylamide and bis-
acrylamide in the gel can have an important effect on the
rate of migration of the c-myc protein (Evan et al,
1985) . There is also one report of a 48kDa myc-related
protein detected by PAGE (Giallongo et al, 1983), which
may perhaps be explained by such technical
considerations.
The 208F and RFM cell lines have proven to be
considerably less satisfactory as positive controls for
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immunohistochemistry than the analogous ras-expressing
system described in chapter 2. Immunohistochemistry was
unable to show clear-cut differences in staining pattern
between 208F and RFM cells, despite evidence from
quantitative RNA dot blots on the same cultures of an
increase of between 6 and 20 fold of c-myc transcript in
the transfected RFM cell line. There are several
alternative explanations. Firstly, c-myc expression is to
be expected in all cells in cycle, and relatively small
quantitative differences in p62 would be detected poorly
by immunohistochemistry. Secondly, the 208F cell line
cannot be regarded as approximating to normal early
passage cells - the cells are aneuploid, and although
reputedly non-transformed, consistently gave rise to
slowly-growing nodules of low-grade tumours on
inoculation into immune-deprived mice (Wyllie et al,
1987) . The very similar patterns of immunohistochemical
staining obtained with the two other anti-myc antibodies
(CT14 and polyclonal anti-p62-c-myc), whose specificity
for p62 has been adequately documented by their
respective originators (Evan et al, 1986; Watt et al,
1985) supports the proposal that 9E10 indeed recognises
an epitope of p62 in both 208F and RFM cells.
3.3.2 Cellular localisation of immunoreactivity
Nuclear localisation of immunostaining for c-myc protein
is predictable on theoretical grounds. p62 has been shown
by immunofluorescence and cell fractionation studies to
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localise to the cell nucleus (Hann & Eisenmann, 1984;
Beimling et al, 1985), and more recently it has been
shown to have precisely the same pattern of distribution
within the nucleus as that of small nuclear
ribonucleoprotein particles (Spector et al, 1987).
Although in vitro, p62 shows non-specific binding to DNA,
in vivo the greater proportion of the protein does not
appear bound, as DNA'ase treated nuclei retain p62
immunoreactivity within the nuclear matrix (Spector et
al, 1987). The association of p62 with its nuclear
binding target appears to be dependent on a relatively
weak and reversible ionic interaction, as p62 can be
quantitatively extracted from isolated nuclei in
relatively low salt concentration (Evan & Hancock,
1985). It has emerged that experimental conditions of
extraction are critical - a temperature-dependent
irreversible process of insolubilisation of p62 occurs in
o
isolated nuclei at 37 C, in which p62 coprecipitates with
a number of other proteins (Evan & Hancock, 1985). This
explains previous descriptions of limited extractability
of p62 from the nucleus (Eisenmann et al, 1985).
During mitosis, myc proteins become dispersed throughout
the cytoplasm, and have no association with condensed
chromosomes (Windqvist et al, 1984). Apart from this
situation, however, only a small proportion
(approximately 5%) of p62 is found in the cytoplasmic
fraction of cultured cells subjected to detergent lysis
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at low ionic strength (Evan et al, 1985). The c-myc
protein is synthesised in the cytoplasm in around 7
minutes, but is rapidly transported to the nucleus
(Beimling et al, 1985). It has a short half life of
around 15 - 20 minutes, but the manner of its
inactivation or degradation is unknown. The protein is
present in more than one form within the cell, and there
are phosphorylated and non-phosphorylated forms.
Phosphorylation appears to occur identically in
transformed and non-transformed cells, and lack of
phosphorylation does not prevent nuclear localisation.
Recombinant bacterially-expressed p62 (which is non-
phosphorylated) , when micro-injected into the cytoplasm
of quiescent fibroblasts, is transported to the cell
nucleus within 15 minutes, where it localises with the
small nuclear ribonucleoprotein particles (Spector et al,
1987) . A specific amino acid sequence directing transport
of p62 to the nucleus has not been identified, but it
seems unlikely that such a sequence if it exists is
abnormal in transformed cells as p62 appears to be
qualitatively normal in most tumours in which c-myc is
elevated.
In the present study, under conditions of rapid fixation
in formaldehyde, nuclear localisation of staining was
consistently demonstrated in paraffin sections of normal
colonic mucosa from surgical resections, but cytoplasmic
staining was present to a variable extent in similar
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tissues in which fixation had been delayed. It seems
probable that an artefactual redistribution of p62 occurs
to explain this observation. Under conditions of tissue
hypoxia, such as occur in a surgical resection specimen
during the operation and after removal, ionic changes
occur in cells, including a significant fall in the
intracellular pH. This may be sufficient to interrupt the
non-covalent association of p62 with its nuclear target,
with consequent redistribution of the protein throughout
the cytoplasm. Rapidity of fixation is therefore believed
to be of importance with respect to the cellular
localisation of p62. It is also likely to be important
with respect to the presence of intact p62 itself. p62 is
a very labile protein with a short half life, and within
3 hours of a stimulus inducing cellular quiescence and
differentiation, the protein is virtually undetectable by
immunoblotting of cell extracts using 9E10 as probe (Evan
et al, 1985) .
Recently, Loke et al (1988) have reported an
immunohistochemical study which indicates that variations
in fixation procedure can lead to significant and
sometimes paradoxical differences in subcellular
distribution of the c-myc protein product in cell lines
and normal mouse tissues. In cytocentrifuge preparations
of the myc-expressinq cell line HL60, it was found that a
redistribution of immunoreactivity occurred from nucleus
to cytoplasm with increasing length of time in certain
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fixatives (acetone or formaldehyde). In paraffin sections
of normal mouse tissues fixed in formaldehyde, nuclear
staining was lost and occurred in the cytoplasm. Whilst
the findings of this study differ in detail quite
significantly from those of the present study, they
emphasise the fact that fixation conditions are very
important in immunolocalisation of myc product, and that
consistency of technique is essential.
The consistent observation of cytoplasmic localisation of
immunoreactivity in surgically resected carcinomas is
less easily explicable purely on the basis of artefactual
redistribution of p62. That such redistribution does
occur to some extent is suggested by the fact that
significant areas of nuclear staining were never seen in
carcinoma cells in resection specimens, whereas a
proportion of endoscopically-biopsied carcinomas (in
which fixation in formaldehyde can be assumed to be
almost instantaneous) sometimes showed distinct nuclear
localisation of staining. However, it was consistently
noted in resection specimens that distinct nuclear
staining occurred in normal mucosa directly adjacent to
carcinoma showing cytoplasmic staining. This would seem
to exclude a fixation effect, and implies a significant
difference in the cellular handling of p62 between normal
mucosa and carcinomas. It is relevant to this hypothesis
that adenomas from the same resection specimens showed a
significantly higher frequency of cytoplasmic staining
144
than normal mucosa, but less than carcinomas. It is also
worth noting the implications of these observations of
altered distributions of p62 for data provided by a
recently developed flow cytometric assay which quantifies
the protein in isolated cell nuclei derived from archival
paraffin blocks of pathological material (Watson et al,
1985) .
Different fixatives may have a different effect on the
ionic interaction between p62 and its nuclear ligand, and
this may explain some of the paradoxical patterns of
staining seen in cell lines and tissues with different
fixatives. Diffusion and disappearance of p62 during
fixation may explain the faint or absent staining in
acetone-fixed and PLPD-fixed tissue sections.
Formaldehyde fixation clearly does not denature the
epitope recognised by 9E10, but staining is absent from
cytocentrifuge preparations of cell lines because in
these, the cell membrane is intact and impermeable, and
p62 consequently inaccessible to antibody. Paraffin
sections of the same cell lines fixed in formaldehyde
show strong staining. Acetone fixation of cytocentrifuge
preparations results in permeabilisation of the cell
membrane to antibody which can enter the cell and react
with p62.
The cytoplasmic location of staining in 208F and RFM
cells is difficult to explain. Fixation delay is not the
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explanation, as the cell lines were freshly harvested and
rapidly fixed. It is possible that cytoplasmic
immunoreactivity is a true reflection of p62 distribution
in these cell lines.
3.3.3 p62 distribution in colorectal tissues
There are a number of published reports describing
patterns of immunohistochemical staining for p62-c-myc in
gastro-intestinal tissues including colorectal mucosa,
adenomas and carcinomas (Stewart et al, 1986; Ciclitira
et al, 1987; Sundaresan et al, 1987; Jones et al, 1987).
In all of these studies, the monoclonal antibody Mycl-
6E10 was used, a different member of the series of
antibodies raised by Evans et al (1985). In the study of
Jones et al, 9E10 was noted to give identical patterns of
staining to 6E10, and Sundaresan observed identical
staining patterns with CT14 and 6E10. Immunohistochemical
techniques of varying sensitivity were employed in these
studies, but all describe results of staining with
formaldehyde-fixed paraffin embedded tissue sections. As
far as can be judged, no special procedures were taken
for rapid fixation in any of these studies.
There is a considerable lack of uniformity in the results
described in these reports, although there are some
points of broad agreement. In the normal mucosa, Stewart
et al (1986) observed staining to be maximal in the
transition zone of the crypts between the crypt base and
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the surface epithelium. Staining was cytoplasmic in
location, an effect attributed solely to the fixation
procedure. Jones et al (1987) observed rather similar,
but faint staining of maturing crypt cells and surface
epithelium, but cells at the crypt bases were negative.
Sundaresan et al (1987) described exclusively nuclear
staining of the proliferative (basal) zone, mixed nuclear
and cytoplasmic staining in the maturation (transition)
zone, and exclusively cytoplasmic staining in the mature
(surface) zone. Ciclitira et al (1987) described very
weak staining of occasional superficial enterocytes in
normal mucosa which was otherwise negative.
A somewhat closer measure of consensus was achieved in
descriptions of the patterns of staining obtained in
colorectal carcinomas. Stewart, Jones and Sundaresan all
observed positive staining in all carcinomas which was
predominantly or exclusively cytoplasmic in location. In
their study of adenomas and carcinomas of patients with
familial adenomatous polyposis, Sundaresan and associates
claimed to be able to identify proliferative, maturation
and mature zones in these lesions, analogous to those of
the normal crypt. It is difficult to accept their
suggestion of increasingly cytoplasmic localisation of
staining with increasing cellular maturation, as they
provide no indication of how these zones were identified,
nor whether the cytokinetics of cells in their zones bear
any relation to those of the normal crypt.
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The results of the present study support the assertion of
increased c-myc expression in colorectal carcinomas, as
all cells showed staining in carcinomas, compared with
only a proportion of cells in the normal mucosa. There is
also reason to accept in part the observation of Jones et
al (1987) that the cytoplasmic distribution of staining
can in some circumstances be attributed to fixation
conditions. It appears however that there is a real
difference between normal mucosa and carcinomas in the
manner of association of the c-myc protein with the
nucleus, and further support for this comes from the
significantly increased frequency of cytoplasmic staining
in adenomas compared with normal mucosa. This suggests







Nick translated labelled whole plasmid DNA probes
containing oncogene sequences were used in an attempt to
develop an in situ hybridisation technique for the
autoradiographic detection of mRNA transcripts of
oncogenes in cell lines and human colorectal tissues.
Analysis of total RNA in extracts of cells and tissues
showed evidence of considerable RNA degradation in human
tissues, but despite this, the presence was confirmed of
hybridisable oncogene mRNA transcripts by dot blot
hybridisation on nitrocellulose. For in situ
hybridisation experiments, sections of cell pellets or of
human colorectal tissues were subjected to a range of
fixation conditions, pre-hybridisation treatments
including proteolysis and acetylation, and post-
hybridisation conditions. Specific hybridisation was
never demonstrated with any probe. Background grain
counts were significantly decreased by acetylation of
sections. Non-specific adherence of probes to cells in
tissue sections, provisionally identified as macrophages,
was abolished by fixation in ethanol-acetic acid. The
possible reasons for the failure of the method are
discussed. It was concluded that in situ hybridisation
techniques for demonstrating oncogene mRNA transcripts in
tissue sections have many problems and disadvantages
compared with immunohistochemical methods for detection
of oncogene proteins.
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4.1 MATERIALS AND METHODS
4.1.1 DNA probes
The following DNA plasmid probes were used in RNA dot
blotting and in-situ hybridisation techniques:
a) PT24-C3 (Shih et al, 1982), containing a 6.3 kbp
insert of the mutationally activated T24 human Ha-ras-1
gene.
b) PSP3K (McCoy et al, 1983), containing a 640bp
sequence of the 3' exon of Ki-ras-2 in SP65 vector.
c) PMC41C (Watson et al, 1983), containing an 8.4
kbp sequence including the entire human c-myc gene.
d) PHR281 (Erickson et al, 1981), containing a 6.7
kbp sequence of human ribosomal DNA.
e) PBR322 (Bolivar et al, 1977) - plasmid DNA
without inserts.
All probes were used as nick-translated whole plasmid
DNA, heat denatured by boiling for 5 minutes immediately
before use.
4.1.2 Nick translation of DNA probes
Nick translation was carried out using minor
modifications of the method described by Rigby et al,
32
(1977). Probes were labelled with PdCTP (preferred for
35
dot blotting) or SdCTP (for in situ hybridisation
3
experiments). Nick translation using H-dCTP yielded DNA
probes of significantly lower specific activity, and was
considered unsuitable for in situ hybridisation
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experiments. 0.5ug probe DNA was incubated with 10 ng/ml
of DNA'se I, 1% stock E. coli polymerase I and a mixture
of labelled dCTP and unlabelled dATP, dGTP and dTTP. The
o
labelling reaction was allowed to occur at 14 C for 3 hr
in 0.05M TRIS pH 8.0. It was stopped by the addition of
0.2M EDTA. Excess tRNA was added, and the unincorporated
nucleotides removed by Sephadex G50 chromatography. The
labelled DNA was precipated by standard methods
32 35
(Maniatis, 1982). Specific activity of P and S-
7 8
labelled probes varied from approximately 5x10 to 5x10
cpm/ug DNA.
4.1.3 RNA extraction from cell lines and tissues
RNA was extracted from cell lines , experimental tumours
and human colorectal tissues using a modification of the
method described by Chirgwin et al, (1979). Sterile
glassware and equipment were used throughout, and where
possible, stages were performed on ice. 1-2 g of frozen
7
tissue, or approximately 10 cells were used. Tissues or
cells were homogenised in a glass homogeniser in
guanidium isothiocyanate buffer until dissolved. After
centrifugation to remove solid particles, the supernatant
was ultracentrifuged on a caesium chloride gradient
overnight at 38krpm. The resulting pellet was extracted
through chloroform-butanol and the aqueous phase
containing RNA was ethanol precipitated and recovered by
centrifugation. RNA concentration was measured by
assessing optical density at 260 and 280 nm. The quality
152
of the extracted RNA was assessed by running samples on a
0.8% agarose gel containing 18% formaldehyde (prepared by
standard methods - Maniatis, 1982), which was stained by
ethidium bromide and photographed in ultraviolet light.
4.1.4 RNA dot blotting
Nitrocellulose filters were soaked in sterile DDW and
taken through graded SSC solutions to 20xSSC (lxSSC is
0.15 M NaCl, 0.025M trisodium citrate). RNA samples were
adjusted in concentration to 2.5ug/ul (and in some semi¬
quantitative experiments doubling dilutions from that
concentration). Samples were boiled for 10 mins and 2ul
applied to each dot location of the filter. Denatured
unlabelled probe DNA (1 ng) was used for positive
o
hybridisation control. Filters were baked at 80 C for 1
hr. For hybridisation, filters were soaked in 20xSSC,
then incubated with 10 ml pre-hybridisation buffer (50%
formamide, 5xSSC, 5xDenhardt's solution, 50 mM sodium
phosphate pH 6.5. 1% glycine, 250ug sheared calf thymus
o
DNA, 0.1% SDS) in a sealed polythene bag at 42 C for 1
hr. This was drained and replaced by 10 ml hybridisation
fluid, essentially the same as pre-hybridisation fluid,
containing 0.5 ug nick translated DNA probe, denatured by
boiling for 5 mins immediately before use. Incubation was
o
carried out overnight at 42 C. The filter was then washed
in 3 changes of 2xSSC, 0.1% SDS at room temperature,
o
followed by 3x15 minute changes of 0.1% SSC at 50 C. The
filter was then blotted dry, wrapped in cling film, and
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placed next to two pre-sensitised X-ray plates, and kept
o
at -70 C. Plates were developed at 2 and 5 days.
4.1.5 In situ hybridisation experiments
Frozen sections of the following tissues and preparations
were cut, ensuring that thawing did not occur at any
time:
a) agar pellets of CHL and FH05T1 cell lines,
prepared as described in section 2.1.1.
b) FH05T1 tumours from immune-deprived mice, with
corresponding normal mouse tissues - mounted together to
give a composite block.
c) human colorectal tissues, consisting of
carcinomas, adenomas and normal colonic mucosa.
Sections were mounted on gelatine-coated slides and
immediately fixed in one of the following fixatives:
a) 0.1% glutaraldehyde in 0.1M cacodylate buffer, 20
minutes, on ice.
b) 1% or 4% buffered formaldehyde, 20 minutes, room
temperature.
c) 4% freshly prepared paraformaldehyde, 20 mins,
room temperature.
d) 3:1 ethanol-acetic acid, 20 mins, room
temperature.
After fixation, sections were washed in PBS for 10 mins,
and were either dehydrated through graded alcohols for
o
storage at -70 C, or were taken directly to the next pre-
hybridisation stage.
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A variety of pre-hybridisation treatments were compared
with control untreated sections. Such experiments used
multiple serial frozen sections cut from the same tissue
block. Pre-hybridisation protocols were as follows:
a) Proteolytic digestion. Sections were incubated in
self-digested Pronase (lOug/ml) in 50mM Tris pH 7.4 at
o
37 C for 10 mins, or with Proteinase K (1.5ug/ml) in the
same buffer containing 3mg/ml calcium chloride, for 10
o
mins at 37 C For Proteinase K, the reaction was stopped
by the addition of glycine (2mg/ml in PBS). Sections were
then post-fixed in either 4% paraformaldehyde or 0.1%
glutaraldehyde.
b) Acetylation. Sections were immersed in 0.1M
triethanolamine buffer pH 8.0 to which acetic anhydride
was added within seconds of use, to 0.25%. Slides were
incubated for 10 mins at room temperature, then washed in
PBS.
c) Pre-hybridisation with unlabelled sheared salmon
sperm DNA. Sections were incubated overnight in
hybridisation buffer (see below) containing excess
(lmg/ml) sheared heat-denatured salmon sperm DNA, at
o
42 C. Thereafter, sections were washed twice in 2xSSC at
room temperature for 2 hrs, then taken to the
hybridisation stage.
Hybridisation conditions
The protocol for hybridisation was slightly modified from
the method of Akam (1983). Up to lug of nick translated
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DNA probe was added to 300 ul of hybridisation buffer
(50% deionised formamide, 0.6M NaCl, lOmM TRIS pH 7.2,
lmM EDTA, 0.02% Ficoll, 0.02% PVP, lmg/ml BSA, 0.1 mg/ml
salmon sperm DNA) and boiled for 10 mins immediately
prior to use. 8ul of the mixture was placed on the
section, and sealed under a cover slip with cow gum.
o
Sections were incubated overnight at 42 C. The coverslip
was then removed, and sections exposed to one of a
variety of post-hybridisation protocols:
a) wash in 4 changes of post-hybridisation buffer
(as hybridisation buffer, omitting probe and salmon sperm
o
DNA), at 37 C, over 24 hr.
b) wash in 2xSSC, 2hrs, room temperature; then in
o
6xSSC, 25% formamide, 39 C, 2x10 mins; then overnight in
o
2xSSC at 4 C.
c) wash in 2xSSC, 2 hr, room temperature; then 1 hr
o o
in O.lxSSC at 60 C; then overnight in 2xSSC at 4 C.
Sections were then dehydrated through graded alcohols,
and dipped in Ilford K2 emulsion for autoradiography.
After drying, sections were placed next to pre-sensitised
X-ray plates (which allowed a rapid visual screening of
results). X-ray plates were developed after 3 days.
Autoradiographs were developed after variable periods up
to 3 weeks, and were then stained with haematoxylin and
eosin.
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4.2 RESULTS AND DISCUSSION
Total RNA was extracted from cell lines, experimental
mouse tumours and freshly-frozen human colorectal
tissues, and in order to confirm the presence of RNA
hybridisable to the DNA oncogene probes, dot blot
hybridisation was carried out. RNA samples were first run
on a denaturing agarose gel, and particularly in the case
of human colorectal tissues, there was evidence of a
considerable degree of RNA degradation having occurred.
Although two major bands were usually discernible,
representing 18S and 28S ribosomal RNA components, a
continuous smear of RNA was present indicating degraded
fragments of a wide range of sizes within the samples.
Despite this, the extracts contained RNA in a
sufficiently intact form to allow specific hybridisation
on nitrocellulose, confirming the presence in the tissues
examined of transcripts complementary to probe DNA
sequences.
The results of one such dot blot hybridisation experiment
is shown in Fig 4.1. RNA from human colorectal tissues
and controls were spotted onto 4 identical nitrocellulose
filters and probed with PT24C3 (Ha-ras), PSP3K (Ki-ras),
PMC41C1 (c-myc) or PHR28-1 (human ribosomal sequence).
The latter is a ubiquitous sequence in all human cells,
and its transcript universally abundant. It served as a












Fig. 4.1 RNA dot blots of human colorectal tissues and
32
controls. 4 identical blots are shown, probed with -P
labelled nick-translated DNA probes containing sequences
of human ribosomal DNA, Ha-ras, Ki-ras or c-myc (see
text). Column 1 - RNA dots of normal mucosa (a), adenoma
(b) and carcinoma (c) from same patient; (d) - normal
mucosa from patient with diverticular disease. Column 2 -
RNA dots of (a) - Fh05Tl cells in culture; (b) - FH05T1
tumour in mouse; (c) - CHL cells in culture; (d) - normal
mouse liver. Column 3 - dots of probe DNA as positive
controls - (a) - PSP3K (Ki-ras); (b) - PT24C3 (Ha-ras);
(c) - PMC41C1 (c-myc).
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hybridisable form on the filters, and to confirm
approximately equal amounts of RNA in each dot location.
Quantitative differences in RNA can not be reliably
assessed using this experimental design, whose purpose
was confirmation of the presence of oncogene transcript
only. Nonetheless it is clear that there are differences
in the dot intensities of different samples probed with
the same probe. Investigation of such differences was not
pursued in this study. Differences in the intensity of
hybridisation of individual samples with different probes
are due to an even wider range of potential variables and
were not pursued.
In situ hybridisation to tissue sections was performed
with human colonic tissues in which dot blot
hybridisation had confirmed the presence of transcript.
Similarly, hybridisation was attempted with sections of
agarose pellets of FH05T1 cell line, and FH05T1 tumour,
for which more quantitative data were available on
abundance of Ha-ras transcript. Despite the use of a
range of experimental conditions encompassing the major
published methods, specific hybridisation was never
demonstrated.
The rationale for the various strategies is as follows.
In many instances, relatively high levels of background
grain counts were present on autoradiographs, and it was
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possible that a low level signal was being obscured. The
radioactivity responsible for this background was not
removed by extensive post-hybridisation washes of varying
stringency as described above. Pre-hybridisation with
heat-denatured salmon sperm DNA was designed to block
non-specific adherence of DNA to tissue sections. Its
effect was deleterious however, as background grain
counts were increased significantly, and this approach
was abandoned.
Most published methods for in situ hybridisation to
tissue sections include a pre-hybridisation stage of
proteolysis. The justification for this treatment is that
any RNA present in the tissue section may be physically
unable to hybridise with probe DNA as it is obscured by
cellular proteins. The effects of Proteinase K and
Pronase were compared with untreated control serial
sections. There was no consistent difference in labelling
of tissues, with no specific hybridisation demonstrable.
Morphological preservation was poorer in treated
sections, and a recurring technical problem was floating
of sections.
The possibility was considered that non-specific
background was due to probe DNA binding to local
concentrations of basically charged proteins, via a
charge effect. To investigate this, sections were
incubated with acetic anhydride, a procedure designed to
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acetylate basic groups, removing the charge effect when
hybridisation is subsequently performed (Hayashi et al,
1978) . Sections treated in this way showed a small but
significant decrease in background activity, but specific
hybridisation was still not detectable. The acetylation
stage was retained in further experiments.
An early observation in human colorectal tissues
submitted to in situ hybridisation techniques was of
binding of probe DNA to a population of cells,
tentatively identified as macrophages, in the lamina
propria of normal mucosa and in the stroma of tumours
(Fig. 4.2). Binding was non-specific in that it occurred
with all DNA probes, including 'irrelevant' DNA plasmids
such as PBR322 which contains no human sequences.
Treatment of sections with RNA'se prior to hybridisation
had no effect on binding, confirming that adherence was
not due to hybridisation with RNA. Acetylation of
sections before hybridisation also had no effect, and
similarly proteolysis had no observable effect. The only
experimental condition which abolished non-specific
binding of this type was fixation of sections in ethanol-
acetic acid after the pre-hybridisation stages.
There are many possible explanations for the failure of
the methods of in situ hybridisation which were used in
this study, and it is likely that a combination of
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Fig. 4.2 Non-specific binding of S-labelled DNA probe
PBR322 to cells in the lamina propria (probably
macrophages) of normal colonic mucosa. Binding is
unaffected by pre-treatment of sections with RNA'ase.
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hybridisable RNA was demonstrated in extracts of tissues
by dot blot hybridisation, the procedure of RNA
extraction by its very nature involves a many-fold
concentration of RNA from the relatively low levels in
the tissues. It is likely that the number of copies of
mRNA oncogene transcript in the tissues is sufficiently
low that the sensitivity of the method is surpassed. The
inability to detect ribosomal RNA, which is abundant,
comprising approximately 70% of total cytoplasmic RNA, is
difficult to explain on this basis, but colleagues have
subsequently shown heavy labelling of rRNA in frozen
sections of a variety of tissues. Their results emphasise
two additional features:
(i) RNA is 'smeared' out of the tissue by the act of
sectioning, appearing as an asymmetric 'shadow'
conforming to the path of the microtome blade, and
(ii) the rRNA probe used in the present work had an
affinity substantially less than optimal.
It is certain that copy number of oncogene transcript is
considerably lower than that of rRNA. Whilst quantitative
data are not available for human colorectal tissues,
Wyllie et al, (1987) have shown that even in the highly
ras-expressing cell line FH05T1, Ha-ras transcript
accounts for only approximately 0.8% of total RNA.
Degradation of RNA occurs very readily by endogenous or
exogenous nucleases, and there was evidence of
degradation having occurred in the RNA extracts,
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particularly those prepared from human colorectal
tissues. In collecting human clinical specimens,
particularly surgical resections of the large intestine,
there is inevitably a period of peroperative hypoxia and
ischaemia, followed by a variable delay until tissue
samples are selected and frozen. During this period, RNA
degradation occurs with a resulting diminution in the
quantity of hybridisable RNA transcript in the tissues.
Although all possible steps were taken to minimise delay
in tissue handling, it is likely that a considerable
degree of degradation occurred during this stage. The
problem is more readily dealt with in cell lines and
animal tumours, and the failure to demonstrate specific
hybridisation in these preparations suggests that other
factors are also important.
Fixation of tissue sections is necessary for a number of
reasons. The structure of tissues must be preserved for
subsequent morphological examination, and fixation
inactivates all enzymatic activity (including nucleases)
in the tissues, thus preventing endogenous degradation of
RNA. Fixation, however, may also affect the ability of
RNA to undergo hybridisation. This may involve direct
chemical modification of RNA itself, or RNA may be
physically obscured by proteins cross-linked in the
fixation process, rendering it inaccessible for
hybridisation.
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Proteolytic treatment aims to overcome this potential
problem by cleaving proteins and exposing the underlying
RNA for hybridisation. The treatment is empirical and can
be difficult to control, but its effectiveness has been
emphasised in a number of publications. Post-fixation
after protease treatment is said to prevent loss of mRNA
during the hybridisation stage (Jilbert et al, 1986). A
potential problem of contamination of enzyme preparations
by small quantities of RNA'ses can be avoided by 'self-
digestion' of the protease preparation before use.
The procedure of nick translation of probes yielded
7
labelled DNA with specific activities of between 5x10
8 32
and 5x10 cpm/ug DNA. P was used for dot blot
hybridisation, but high penetration of its emission gave
35
poor localisation on autoradiography and S was used,
which allowed generation of labelled probes of similar
specific activity, but with improved localisation.
Specific activity of labelled DNA of the levels achieved
are satisfactory for dot blot hybridisation, but may be
insufficiently high to allow hybridisation to be detected
at the cellular level in tissue sections. More recently
developed methods of DNA labelling, such as
oligonucleotide primer labelling allow higher specific
activities of DNA probes to be achieved, and may increase
the sensitivity of the technique. Biotin labelling of DNA
by nick translation or other techniques is another
approach; after hybridisation, sensitive enzyme-linked
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detection systems can be used.
One of the effects of nick translation is a reduction in
the single-stranded length of the labelled probe. The
effect is principally a function of the DNA'se I
concentration. Under the conditions used in this study,
DNA of a wide range of different sizes is produced. Probe
length is likely to have an important effect on the
signal produced in in situ hybridisation, with two
conflicting influences in operation. Shorter probes would
be expected to have improved access to hybridisable RNA,
but longer probes will show increased bound radioactivity
per hybridised mRNA molecule. This theoretical conflict
is reflected in the literature - Brahic & Haase (1978)
observed an increased signal with shorter probes; Gowans
et al, (1981) found little difference, and Hafen et al
(1983) described a stronger signal with longer probes. In
this study, it was assumed that the range of sizes of
probe generated by nick translation would minimise the
influence of this variable.
The rate and precision with which complementary nucleic
acid sequences hybridise is dependent on several factors
including the probe concentration, sequence complexity of
the probe, temperature, solvent concentration and salt
concentration. Hybridisation conditions were selected
which were similar to those considered optimal for RNA
dot blot hybridisation on nitrocellulose filters. Ample
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scope would have been present for optimising these
conditions had specific hybridisation been demonstrated
in tissue sections, but in its absence, the experimental
conditions were not varied in this study.
Double stranded DNA probes, nick translatd and heat-
denatured to single strands, have obvious disadvantages
for detection of specific sequences. Only one strand of
the duplex is complementary to the sequence being sought,
while its partner will tend to exert competitive
inhibition of the desired reaction. A labelled single-
stranded probe has theoretical advantages in this regard,
although in practice, colleagues using such single-
stranded RNA probes (generated by the SP6 or Riboprobe
system) for in situ hybridisation (K. Rose, A.H. Wyllie)
have met with only limited success.
In conclusion, the techniques used in this study for the
detection of oncogene transcripts by in situ
hybridisation were found to have many problems and
disadvantages compared with immunohistochemistry. In the
context of the qualitative demonstration of oncogene
expression in tissues, mRNA transcripts and oncogene
protein products are equally acceptable as targets for
specific probes. Immunohistochemistry using specific
antibodies to oncoproteins was therefore the method





5.1 The ras oncogene in human colorectal neoplasia
There is agreement from the work of several investigators
that expression of the ras oncogene is increased in
colorectal carcinomas compared with non-neoplastic
colonic mucosa (Spandidos & Kerr, 1984; Slamon et al,
1984; Gallick et al, 1985; Pulciani et al, 1985). The
immunohistochemical findings of the present study confirm
this, but provide additional evidence to show that ras
expression tends to be higher still in pre-malignant
colorectal adenomas. This observation has not been
previously recorded as few studies have specifically
examined ras expression at the adenoma stage. However,
Spandidos & Kerr (1984) demonstrated elevated levels of
ras mRNA transcripts in both adenomas and carcinomas, and
interestingly, some of the highest levels occurred in
adenomatous lesions. Gallick et al (1985) examined ras
expression in carcinomas by immunoblotting technigues,
and found that the highest levels of ras p21 protein
occurred in cancers at an early clinical stage (Dukes'
stage A), whereas more advanced lesions which had
produced metastases tended to have lower levels. Despite
this, no clear relationship has emerged between ras
expression and clinical or prognostic parameters. Kerr et
al (1986) found no correlation between levels of ras mRNA
and prognosis, and in the series of carcinomas examined
by immunohistochemistry in the present study, again no
relationship could be shown between ras expression and
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any clinical or pathological features of the tumours.
There are a number of studies claiming to examine p21 ras
expression and localisation in colorectal tumours by
immunohistochemistry, but most have employed the
monoclonal antibody RAP-5 (Horan Hand et al, 1984; Thor
et al, 1984; Czerniak et al, 1987; Michelassi et al,
1987) . The conclusions from these studies are at variance
with the results reported herein; RAP-5 staining is
reported to increase with increasingly malignant
phenotype during the process of colonic carcinogenesis.
Evidently, the pattern of staining with RAP-5 is of
interest and may have biological significance, but as
discussed in chapter 2, it is doubtful whether it bears
any relation to ras expression.
Immunochemical studies with other antibodies are scanty.
Kerr et al (1985) using Y13-259 obtained broadly similar
patterns of staining to the results of this study,
although increased expression in adenomas was less
obvious. In an immunoblotting study of a range of human
tumours, Tanaka et al (1986) used polyclonal antibodies
raised to synthetic peptides of p21. Single p21 bands
were detected in normal colonic mucosa in 7 cases, and in
3, expression was elevated in carcinomas relative to the
corresponding normal mucosa. The electrophoretic mobility
of the p21 detected in these carcinomas was the same as
that of the normal mucosa, and it was concluded that the
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codon 12 mutation was absent in these cases, as this
would have given a slower migrating protein. These
findings differ slightly from the immunoblotting data of
the present study (chapter 2) in which doublet bands of
p21 were found in extracts from both normal mucosa and
carcinomas. This is probably a reflection of the
different antibodies used.
Increased expression of ras in carcinomas seems not to be
a consequence of gene amplification. Pulciani et al
(1985) examined DNA from a series of unmanipulated
primary human tumours including 31 colorectal carcinomas
and 13 adenomas, and in no case was amplification of ras
genes detected. Similar results were reported by
Alexander et al (1986), Yokota et al (1986) and Meltzer
et al (1987), and the collective experience of these
studies also indicates that major ras gene rearrangements
are also uncommon.
However an interesting finding in these studies was the
identification of allelic deletion of Ha-ras occurring in
a small proportion of cases. The significance of this is
uncertain, and whilst it may represent random loss of
chromosomal material in genetically unstable tumours, it
may be indicative of a more specific event in initiation
or progression. A deletion of Ha-ras itself is unlikely
to be a primary event, but it may point to involvement of
another gene or genes in close proximity on chromosome 11
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whose deletion leads to development of malignancy.
The paradigm of this mechanism which has received most
attention is the hereditary form of retinoblastoma, in
which susceptibility to the tumour is inherited through a
germline mutation, and the neoplasm develops after a
somatic change (usually deletion) of the homologous
allele. It appears that loss or functional inactivation
of both alleles of a normal regulatory gene allows
development of malignancy (Klein & Klein, 1985). Almost
nothing is yet known about the functions of such genes
(sometimes referred to as 'anti-oncogenes'), but their
existence is not in doubt, and their role is coming under
intense scrutiny at present. As discussed in section
I.4.3 (chapter 1), the recent mapping of the FAP gene to
chromosome 5q21 (Bodmer et al, 1987) and the
demonstration of allelic loss at this locus in 20% of
sporadic cancers (Solomon et al, 1987) indicates that
this mechanism may operate on chromosome 5 in a
significant proportion of cases of colorectal cancer.
Similar events involving different genes also occur on
other chromosomes, notably chromosome 17p (Fearon et al,
1987), but probably also less frequently on chromosome
II.
ras genes appear to achieve transforming potential most
commonly by the acquisition of activating mutations of
codons 12 or 61, and recent evidence suggests that such
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mutations of Ki-ras occur in up to 40% of colorectal
cancers (Bos et al, 1987). In this study, 6 of the
carcinomas examined had residual adenomatous elements,
and in 5 of these, the activating mutation was also
present in Ki-ras in the adenomatous areas. Forrester et
al (1987) also reported Ki-ras mutation to be present in
a similar proportion of colorectal carcinomas, and also
in 7 out of 8 villous adenomas. This is compelling
evidence that mutational activation of Ki-ras is a
critical early event in the carcinogenic process in the
colon.
In vitro, mutational activation of ras is not always
reguired to confer the transformed phenotype, but
although the normal ras gene can be artificially driven
by powerful retroviral LTR sequences to effect
transformation, this is a relatively ineffective way of
activating ras. In primary cultures, the cooperation of
another cotransfected oncogene such as myc is required to
cause transformation (Land et al, 1983). In contrast, the
mutated ras gene much more readily induces properties of
the malignant phenotype, properties which are nonetheless
still modulated by the level at which ras is expressed.
Mutated ras genes driven by their own cellular promoters
fail to transform primary embryo fibroblasts, whist
consistently inducing transformation in established
fibroblast cell lines. However, when driven by powerful
retroviral enhancer elements, they transform both
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(Barbacid, 1986).
Mutational activation of ras has no effect on its
inherent rate of expression (Tabin et al, 1982) , and as
ras amplification or rearrangements are uncommon in
colorectal tumours, the elevated expression of ras in
colorectal adenomas and carcinomas may be secondary to
some other change in the neoplastic cells. The nature of
such a change is a matter for speculation, but the
influence of other expressed oncogenes may be important.
It is clear from the simplicity of the process by which
ras genes become activated that the full spectrum of the
malignant phenotype cannot be conferred in this single
step. There is good evidence from in vitro experiments
that single oncogenes, even in activated form, have
limited powers of transformation, whereas a number of
examples are known of different oncogenes cooperating to
produce oncogenic transformation. This is in keeping with
the nature of human cancer, a slowly-developing multi¬
stage disease.
In vitro models show that ras may cooperate with the myc
oncogene to induce malignant properties in cells, but
before considering the nature of such cooperation, it is
appropriate to examine what has emerged from this study
on the individual contribution of the c-myc oncogene in
the process of colorectal neoplasia, and how this relates
to the work of other investigators.
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5.2 c-myc and colorectal carcinogenesis
It is clear from a variety of sources that c-myc
expression is increased in colorectal carcinomas relative
to normal mucosa (Slamon et al, 1984; Erisman et al,
1985; Calabretta et al, 1985; Alexander et al, 1986;
Yokota et al, 1986; Sikora et al, 1986; Stewart et al,
1986; Jones et al, 1987). RNA dot blotting performed in
29 colon carcinomas by Erisman et al (1985) revealed 5-40
fold elevation of c-myc transcript compared to normal
mucosa in 72% of cases, but Southern blotting showed
absence of amplification or major rearrangements
affecting the gene in any case. Amplification of c-myc
has been detected by other groups however, but at low
frequency. Yokota et al (1986) described 3-8 fold
amplification in 2 out of 32 colon cancers; 2-5 fold
amplification was reported in 2 of 9 carcinomas by
Alexander et al (1986), and Meltzer et al (1987) reported
amplification in 3 out of 45 carcinomas. However, again
no major rearrangements involving the c-myc locus were
detected in any of these studies. Rothberg et al (1985)
noted that elevated expression of c-myc occurred
significantly more frequently in tumours arising in the
left colon than those of the right, and suggested that
this may relate to differences in epidemiology and
clinical behaviour between tumours at these two sites.
Immunohistochemical studies (previously discussed in
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section 3.3.3) also provide evidence for increased
expression of the p62 c-myc oncoprotein in colon
carcinomas, and in this regard at least, are in agreement
with the findings of the present study. The biological
significance of increased myc expression is a matter for
some debate. It has been pointed out by Calabretta et al
(1985) and Torelli et al (1987) that the increase in myc
expression in colonic carcinomas is accompanied by a
parallel increase in expression of other cell-cycle
related genes, including those for histones, whose
expression is restricted to the S phase. Increased
histone gene expression has therefore been cited as
evidence of an increased growth fraction in tumours, and
it was suggested that increased c-myc expression is a
non-specific reflection of the greater proportion of
cycling cells. It may, however, be erroneous to regard c-
myc as a cell-cycle related gene in the same sense as the
histone genes. There is no direct correlation between c-
myc expression and passage through the cell cycle - for
example, Campisi et al (1984) have described constitutive
high expression in quiescent chemically transformed cells
in culture, and more recently, Erisman et al (1988) have
shown constitutively high c-myc mRNA and protein levels
in cell lines derived from human colorectal carcinomas.
Normal cells do show increased c-myc transcripts in the
first cycle following growth stimulation (Kelly et al,
198 3) , but levels return to basal values in subsequent
cycles. Indeed c-myc mRNA transcript levels have been
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shown to be invariant throughout the cycle in actively
proliferating cells in culture (Hann et al, 1985;
Thompson et al, 1985). Rather than being associated with
proliferation per se, high levels of c-myc expression
appear to be associated with the ability of the cell to
enter the cell cycle from the G phase. However, as
0
mitogenic stimulation of asynchronously growing cell
cultures induces elevation of c-myc expression, a G -
0
arrested cell population is not required for this
elevation of c-myc expression to occur, and Erisman et al
(1988) have argued that activation of expression may be a
direct response to growth factor-receptor interaction. In
keeping with this suggestion is the observation that
serum (ie growth factor) depletion of asynchronous
cultures for short periods leads rapidly to decreased c-
myc expression. Continual presence of growth factors may
be required to sustain basal levels of c-myc expression.
In the light of such suggestions, it can be argued that
the enhancement of c-myc expression in colorectal
carcinomas is not a consequence of increased cell
proliferation in tumours, but a primary change specific
to the tumour, disrupting normal control of
proliferation, perhaps by preventing exit to the G
0
phase.
Until more is understood about the molecular function of
the protein product of c-myc, and the mechanisms by which
c-myc expression regulates cell proliferation, the
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significance of increased expression is likely to remain
a matter for speculation. The same applies to the
interpretation of the altered patterns of p62 c-myc
localisation between the nucleus and cytoplasm observed
in this study. It is clear that complex events occur at
several levels in the regulation of c-myc expression
which may influence the amounts and localisation of the
protein product. The rapid synthesis and transport of p62
to the nucleus, and its short biological half life
suggest that minor changes in the rate of synthesis,
transport to the nucleus or subsequent breakdown could
lead to relatively major changes in the quantity of p62
present in the cytoplasm at any one time. The main
conclusion which can be drawn from the
immunohistochemical results herein is that some change
occurs in the cellular processing of the p62 protein
during the adenoma-carcinoma sequence leading to its
accumulation in the cytoplasm in carcinomas. The nature
of the change is entirely unknown.
5.3 Cooperation of c-myc and ras oncogenes
Neither the activated cellular ras nor myc oncogenes can
transform normal cells singly, but in cooperation they
can achieve full transformation in vitro (Land et al,
1983) . Similar cooperation has been described between a
number of other oncogenes, and it appears that the two
cooperating genes may each elicit a limited range of
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cellular responses that act in distinct but complementary
ways. Weinberg (1985) has emphasised that although up to
40 different oncogenes are known, there is a much smaller
number of pathways governing cellular proliferation, and
that it may be possible to classify oncogenes according
to a limited range of functional properties. He has
divided oncogenes into two groups, 'nuclear' or
'cytoplasmic' according to the localisation of their gene
product, and such a simple classification correlates
quite well with what is known of the functions of their
proteins, and the effects produced when the oncogenes are
introduced into cell cultures by transfection. 'Nuclear'
oncogenes (such as c-myc) confer immortalisation in
culture and reduced serum requirements, but are poor at
inducing anchorage-independent growth. 'Cytoplasmic'
oncogenes (such as ras) tend not to induce
immortalisation, but promote anchorage-independent growth
and may induce growth factor secretion. In most
instances, activation of oncogenes from both nuclear and
cytoplasmic groups appears to be necessary to effect
transformation in vitro. This framework is certainly an
over-simplification, as there are several reported
exceptions to this scheme. It is also important to note
that these studies have involved fibroblasts rather than
epithelial cells which may behave quite differently.
Nonetheless, the concept of cooperating oncogenes is an
attractive one, and is consistent with the multistage
process of human carcinogenesis.
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The detailed mechanisms involved in oncogene cooperation
remain obscure, but a number of observations may be of
relevance. Cells transfected with the c-myc oncogene show
enhanced transcription of a number of resident cellular
genes as well as introduced genes (Kingston et al, 1984).
It has also been reported by Wyllie et al (1987) that
expression of certain endogenous cellular oncogenes (abl
and fos) can be substantially elevated in myc and ras
transfectants. Interestingly, in the transfected cell
lines with tumourigenic properties, elevated expression
of oncogenes of both nuclear and cytoplasmic groups
occurred, even in cells transfected with a single
extraneous oncogene. This is consistent with the proposal
that activation of oncogenes of both types is important
in the induction of transformation.
There is direct evidence of trans-activation of
transcription of certain oncogenes by other oncogene
proteins derived from the adenovirus early region 1A.
When introduced into cells, the cellular promoter
activities of endogenous c-fos and c-myc genes are
stimulated, and their transcription shows significant
elevation. On the other hand, transcription of Ha-ras is
unaffected (Sassone-Corsi et al, 1987). It is interesting
to note that segregation of behaviour is again seen
between the 'nuclear7 and 'cytoplasmic' oncogenes in this
situation.
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The hypothesis that multiple oncogenes may exert their
actions on a limited number of biochemical pathways to
transformation receives support from study of
transformation revertants. Zarbl et al (1987) selected
revertants of v-fos-transformed fibroblasts, and found
that these cells were resistant to subsequent
transformation by several oncogenes (v-fos, v-Ha-ras, v-
abl, v-mos). They proposed that mutation may occur in a
gene or genes lying on a cellular pathway common to
transformation by several oncogenes which need not
necessarily share obvious structural similarities.
Interestingly, these revertants were not totally
resistant to transformation - other structurally quite
dissimilar viral oncogenes could cause transformation of
these cells. It seems likely that such oncogenes either
use a different pathway, or act at a point downstream of
the block.
Clearly the complexities of interactions between
different oncogenes are difficult to unravel, especially
in human tumours in vivo, and distinguishing primary and
secondary events is a problem. However it may be
reasonable to concentrate on the potentially fundamental
role of c-myc in the process, as it appears that elevated
levels of the myc product may perturb regulation of the
cellular transcription apparatus. It has been suggested
by Weinberg (1985) that activation of c-myc may induce
transcription of a collection of cellular genes whose
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products are critical for growth and differentiation.
5.4 Other oncogenes
Data on the involvement of other oncogenes in colorectal
carcinogenesis are even scantier. Bolen et al (1987) have
described 5-8 fold increased tyrosine kinase activity of
the pp60-c-src oncogene product in all of 15 colorectal
carcinomas, and even higher increases in cell lines
derived from colonic cancers. This was not attributable
to increased abundance of the protein, and it was
suggested that the increased specific activity of the
phosphotransferase may contribute to the genesis of colon
tumours. In a study designed to detect oncogene
amplification or allelic deletions of oncogenes that are
heterozygous for restriction fragment length
polymorphisms (RFLP), Meltzer et al (1987) used 11
different oncogene probes to detect alterations in DNA
from a series of 45 colon carcinomas. In addition to
identifying 3 cases of c-myc amplification (referred to
above), c-erbB-2 amplification was detected in one case,
and allelic deletion of c-myb was found in 4 cancers and
1 of 15 adenomas. No abnormalities were detected with the
other oncogene probes. The study of Yokota et al (1986)
was of similar design, and in addition to finding c-myc
amplification in 2 out of 32 colon cancers, allelic
deletion of c-myb was also reported in one case. It is in
the nature of studies of this type that the experimental
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design is organised to detect a small number of specific
abnormalities, and when 'screening' for alterations in a
range of oncogenes in this way, the incidence is
inevitably underestimated. For example, the RFLP
technique can only identify allelic deletion in
heterozygotes, and then only if length polymorphism is
present in an oncogene cut by a particular restriction
enzyme. Moreover, many rearrangements and most point
mutations would be undetected by this method. The
relative infrequency of abnormalities detected and their
lack of uniformity suggests that they may be a
consequence rather than a cause of carcinogenesis.
In conclusion, it is evident that deregulated expression
of several oncogenes occurs in the process of colorectal
carcinogenesis, and that alterations of ras and myc
oncogene expression are particularly frequent. It is
tempting to conclude that ras and myc in cooperation are
responsible for important properties of malignant cells,
and play a direct role in the early stages of colorectal
carcinogenesis. However the malignant phenotype
represents the integration of the individual actions and
interactions of multiple genes, and it may be wrong to
imagine that the individual action of any one gene should
correlate very closely with behaviour. It is probable
that there are multiple routes by which cells may achieve
the malignant phenotype, and in a system of complex
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interactions between oncogenes and many other cellular
genes, we are faced with the familiar problem of
distinguishing the causes from the conseguences of
neoplastic change. However there is reason for optimism
that some of the fundamental molecular mechanisms of
carcinogenesis have now been identified, and the future
holds the challenging prospect of defining in detail the
molecular mechanisms by which normal cells acguire the
properties of malignancy. We are now in a strong position
to meet the challenge.
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APPENDIX 1
PUBLICATIONS FROM THESIS
Parts of the work described herein have been published;
photocopies of papers follow, (included by kind permission of
Macmillan Press Ltd).
1. A description of immunohistochemical detection of
ras p21 product in the FH05T1 cell line and in
colorectal tissues was published in the British
Journal of Cancer, 1985," 52_: 687-693, and
selected for publication in abstract in The Year
Book of Cancer, 1987, pp!44-146.
2. A report of evaluation of monoclonal antibody
RAP-5 by immunohistochemistry and immunoblotting
was published in the British Journal of Cancer,
1986, 54: 377-883.
3. Frozen section immunohistochemistry results with
monoclonal antibody Y13-259 in colonic tissues were the
subject of an oral presentation to The Pathological
Society of Great Britain and Ireland, in Cardiff in Juie
1985. An abstract was published in The Journal of
Pathology, 146: 249A.
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4. Immunohistochemical results with monoclonal
antibody Mycl-9E10 in colorectal tissues were
presented in poster form to The Pathological
Society in Southampton in July, 1987. An abstract
was published in The Journal of Pathology, 152,
234A.
5. A report of immunohistochemical demonstration of
ras p21 product in PLPD-fixed paraffin sections
has been accepted for publication in The Journal
of Pathology, (1988), 155.
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Immunohistochemical detection of the ras oncogene p21
product in an experimental tumour and in human colorectal
neoplasms
A.R.W. Williams1, J. Pins1, D.A. Spandidos2'3 & A.H. Wyllie1
1Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh EH8 9AG,
2Beatson Institute for Cancer Research. Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK
and 3Hellenic Institut Pasteur. Athens. Greece.
Summary The monoclonal antibody Y13 259 to the ras oncogene protein product p21 was used in an
immunohistochemical study of ras expression in human colorectal neoplasms. The ability of the antibody to
detect enhanced levels of ras expression was confirmed by its use with an experimental neoplasm known to
express ras at high levels. Human colonic adenocarcinomas in general showed a similar staining intensity to
that seen in normal mucosa. Adenomas however showed consistently high p21 expression as indicated by
staining intensity. This suggests that elevated ras expression may be important in the development of
adenomas, but that high levels need not be sustained in the conversion to invasive carcinoma.
Although the ras gene family has been studied
longer than any other group of cellular oncogenes,
there is still uncertainty over its role in authentic
human carcinogenesis. Ras genes code for GTP-
binding and GTP'ase enzyme activities of molecular
weight 21.000 daltons, referred to as p21 (Shih et
ai. 1979; Gibbs et al.. 1984; McGrath et al., 1984;
Sweet et al.. 1984), which appear to be located on
the inner face of the plasma membrane (Willingham
et al., 1980), and are probably normally involved in
the transduction of membrane-associated stimuli for
cell proliferation (Bishop, 1983; Kamata &
Feramisco, 1984). Activation of the genes by
mutation has been detected in approximately 15%
of a wide variety of spontaneous human tumours
and transformed cell lines in culture (Der et al.,
1982; Parada et al.. 1982; Pulciani et al., 1982;
Varmus, 1984). Raised levels of ras transcript have
also been identified in RNA extracted from several
types of human tumour (Spandidos & Kerr. 1984;
Slamon et al., 1984; Spandidos & Agnantis, 1984;
Spandidos et al.. 1985). Controversy remains,
however, over whether ras activation is a primary
event in carcinogenesis or appears during tumour
progression. At a more pragmatic level, it is quite
obscure whether the detection of ras expression in
pre-malignant lesions or malignant tumours would
provide useful diagnostic or prognostic information.
In this paper, we describe the use of the mono¬
clonal antibody Y13 259 in detection of ras p21 in
human colorectal neoplasms. We have confirmed
the ability of the antibody to detect enhanced levels
of ras expression by applying it in parallel to the
Correspondence: A.R.W. Williams.
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experimental neoplasm FHOST1, in which high




Tissues used included 21 adenocarcinomas of the
colon and rectum. 6 benign tubular adenomas of
the colon, and 7 specimens of colonic tissue
resected for non-neoplastic conditions (diverticular
disease or ulcerative colitis). The diagnosis in each
case was confirmed on paraffin sections. Specimens
were received fresh within minutes of resection in
the operating theatre. They were examined
immediately, samples of tissue taken (including
where possible the tumour/normal interface), placed
in plastic vials and 'snap' frozen in liquid nitrogen
where they were stored until required. Frozen
sections (6 fim) were cut, mounted on gelatine-
coated slides, fixed in acetone at room temperature
for 15min and air dried. As controls for immuno-
staining, two cell lines were maintained in culture as
previously described (Spandidos & Wilkie. 1984):
the transformed line FH05TI, which contains the
mutated T24 human Ha-ras oncogene inserted
within a high expression vector, and its parental,
untransformed Chinese hamster lung fibroblast
strain, here called CHL. FH05T1 cells were also
grown as tumours in nude mice. Frozen sections of
these tumours and normal mouse tissues were
prepared exactly as above. The cultured cells were
studied in cytocentrifuge preparations, or in frozen
sections of pellets in low melting temperature
agarose, fixed as above.
© The Macmillan Press Ltd., 1985
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Antibodies
The monoclonal antibody to p21 designated Y13
259 was prepared from the hybridoma cell lines as
previously described (Furth et al., 1982). Secondary
antisera used in a comparison of reagents and
staining methods were horseradish-peroxidase
(HRP)-conjugated rabbit anti-rat Ig (Dako), HRP-
conjugated sheep anti-rat Ig (Amersham), biotin-
conjugated rabbit anti-rat IgG (Vector), un¬
conjugated rabbit anti-rat Ig and monoclonal
peroxidase-anti-peroxidase complex (Sera Lab.).
Immunostaining
Sections were washed in TRIS-buffered saline,
pH 7.6 (TBS) and non-specific binding blocked by
application of normal human serum diluted 1 in 5
in TBS (NHS/TBS). Y13 259 diluted 1 in 100 in
NHS/TBS was applied for 1 h. After washing in
TBS and blocking as above, the appropriate
secondary antibody was applied at a dilution of 1 in
50 in NHS/TBS for 1 h. Anti-human tissue activity
was significantly diminished in secondary antibodies
by absorption with acetone-dried human liver tissue
and human immunoglobulins (Cohn fraction II,
Sigma). Sections treated with HRP-conjugated
secondary antibodies were washed in TBS and the
reaction developed with DAB solution (lmgml-1
diaminobenzidine (BDH) in 50mM TRIS-HC1
pH 7.60. containing 10 mM imidazole, activated
with H,02 immediately prior to use. Sections
incubated with biotinylated secondary antisera were
washed in TBS and further incubated for 30min
with biotinylated preformed complex of
streptavidin-HRP (Amersham) diluted 1 in 200 in
TBS. After final washing, the reaction was
developed as above. Negative control sections were
included for each case, and positive controls
(cytocentrifuge preparations of the FH05T1 cell
line) were used in each staining experiment.
Preliminary work comparing the indirect, PAP
and streptavidin-biotin methods showed highest
sensitivity with the latter method. In our hands, the
staining shown with Y13 259 in human tissues is
generally of relatively low intensity, and it is thus
important to minimise non-specific background
staining. The clear backgrounds and higher
dilutions of primary antibody afforded by the
amplified streptavidin-biotin method determined the
choice of this method in the main study.
Results
Experimental neoplasm
The transformed cell line FH05T1 showed strong
reactivity of all cells with Y13 259, both in cyto¬
centrifuge preparations and in frozen sections of cell
pellets. In contrast, the great majority of cells of the
parental strain from which it was derived (untrans-
formed Chinese hamster lung fibroblasts, termed
CHL), showed no reactivity. A small proportion
however, approximately 5%, showed strong specific
staining (Figures 1 and 2).
FH05T1 cells inoculated into nude mice pro¬
duced malignant tumours of fibrosarcomatous
appearance (to be described in detail elsewhere).
Frozen sections of such tumours showed strong
specific staining of all tumour cells with Y13 259,
whilst the adjacent murine tissues were negative
(Figure 3).
The reactivity of Y13 259 with this tumour was
completely lost in formalin-fixed paraffin-embedded
sections, and was not restored in any measure
by trypsinisation. Similarly, formaldehyde or
glutaraldehyde fixation of cytocentrifuge prepara¬
tions of the FH05T1 cell line abolished anti¬
body binding. Y13 259 is therefore not suitable for
use with routinely processed biopsy material.
Human colonic tissues
Positive staining of the intensity of the FHOSTl
tumour was not seen in any of the human colonic
tissues studied. In general, where positive staining
was detected, it was of low intensity, despite use of
the most sensitive peroxidase detection system
available to us.
The results of staining of 21 colo-rectal adeno¬
carcinomas, 6 colonic adenomas, their adjacent
uninvolved mucosa where available and 7 cases
of colonic resections for non-neoplastic conditions
are shown in Table 1. Staining of sections was
independently assessed by two observers and
graded as equivocal or negative (+/—); moderate
Table 1 Staining intensity of colonic tissues for Y13 259.
Number of cases -
staining intensity
Tissue + /— + + +
Carcinomas 15 4 2
Adenomas 0 1 5
Normal adjacent
to carcinoma 7 9 0
Normal adjacent
to adenoma 2 4 0
Normal non-neoplastic 4 3 0
Adenomas show a significantly greater intensity of
staining compared to carcinomas (P < 0.01) and all
normals (P< 0.002). (Four-fold Table Test). Carcinomas
show no significant difference in staining intensity from
normal mucosa.
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Figure 1 Transformed (FH05T1) cells - cyto-
centrifuge preparation. All cells show intensely positive











Figure 2 Parental untransformed Chinese hamster
lung fibroblasts (CHL) stained with Y13 259. Most
cells show no reactivity, but a small subpopulation
show intensely positive staining. ( x 320).
figure 3 Frozen section of advancing edge of FH05TI tumour in nude mouse. Tumour shows uniformly
intense staining (arrow); adjacent fibrous tissue and skeletal muscle (S) is negative. ( x 320).
690 A.R.W. WILLIAMS et al.
(+) or intense (+ + ). Agreement between observers
occurred in more than 75% of cases; where different
assessments were made, such cases did not affect
the statistical significance of the results. The Table
represents a consensus.
Normal colonic mucosa showed equivocal or
faintly positive reactivity of uniform distribution
with Y13 259 (Figure 4). No significant difference
was observed in the mucosa adjacent to neoplastic
lesions compared with mucosa from non-neoplastic
resections. Adenocarcinomas showed a variable
staining pattern; in 15, staining was absent or
equivocal, whilst 4 showed moderately strong
staining and 2 were graded as intense (Figure 5).
There was no correlation with the histological
pattern, depth of invasion or clinical stage of the
tumour. Where a difference was observed in
staining pattern between the carcinomas and the
adjacent mucosa, a sharp transition was not
observed. In contrast, 5 out of 6 colonic adenomas
showed intensely positive staining (Figure 6). The
interface between normal and neoplastic epithelium
in the adenomatous lesions did not show a sharp
Figure 4 Norma! colonic mucosa shows only very
faint staining. (Macrophages in the lamina propria
show endogenous peroxidase activity). ( x 160)
Figure 5 Adenocarcinoma of colon showing positive
staining. (This case shows the most intense degree of
staining; the majority of carcinomas are negative).
(x 160)
transition in reactivity; positive staining was often
most intense at the centre of the adenomas.
Discussion
The monoclonal antibody Y13 259 is one of a
series produced in rats bearing tumours induced by
the Harvey murine sarcoma virus (Furth et al..
1982). These authors showed it to precipitate p21
protein species encoded by both the Harvey and
Kirsten strains of the virus. There is close
homology of the protein products of viral and
cellular ras genes. Capon et al. (1983a) have shown
the viral and cellular p21 protein products to be
identical in all but three out of 189 amino acid
residues. Y13 259, traced on immunoblots by the
streptavidin-biotin method, binds to a single protein
band, with an apparent mol.wt of 21,000 on SDS-
PAGE, present in substantial quantities in ras-
transformed cells, and at much lower levels in
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Figure 6 Tubular adenoma of colon showing intense staining with Y13 259. (x 160)
untransformed cells (D.A. Spandidos and T.
Dimitrov. unpublished work). The antibody is thus
potentially useful in the detection of c-ras oncogene
expression in human tissues.
It was of great value in this study to have access
to a known positive control in the form of the
experimental neoplasm FH05T1. This transformed
cell line is known to express the mutated T24 Ha¬
ras oncogene at high levels; quantitation of
oncogene mRNA in dot blots indicated 20-60 fold
more Ha-ray message in the transformed cells
relative to the untransformed parental fibroblasts
(Spandidos & Wilkie. 1984). Whilst there is no
formal proof of the specificity of Y13 259 for ras
p21, we have established its greatly increased
reactivity with ray-transformed cells over their
untransformed parental cell strain.
Although increased transcription of activated ras
genes has been observed in certain neoplasms
(DeFeo et al.. 1981; Chang et al., 1982; McCoy et
al., 1983), mutation at specific positions (12 or 61)
in the amino acid coding sequence is the feature
most consistently observed in ras activation (Capon
et al., 1983a; b). It was therefore not surprising to
find that p21 expression in human tumours never
attained the artificially high levels seen in the
experimental tumour.
The presence of a subpopulation of CHL cells
strongly positive with Y13 259 may be related to
differential expression of ras at different stages in
the cell cycle (Catnpisi et al.. 1984). It is less likely
to represent contamination of CHL by FH05T1 or
spontaneous transformation of CHL cells, as the
proportion of ras positive CHL cells has not
changed after further passage in continuous culture.
The principal result of this study is the
consistently high level of p21 expression in
adenomas, whereas the carcinomas in general
showed lower staining intensity. As the great
majority of colo-rectal carcinomas are believed to
arise from adenomatous polyps (Morson &
Dawson, 1979), it would seem that the elevated p21
expression diminishes significantly as the lesions
evolve into invasive carcinomas.
An essentially similar conclusion was reached by
Spandidos and Kerr (1984), who reported increased
levels of RNA transcripts of Ki-ras and Ha-ras
oncogenes in a series of colonic adenomas and
adenocarcinomas, but noted higher expression of
ras mRNA in some adenomas compared with
corresponding carcinomas from the same patients.
A recent study employing the same antibody Y13
259 with immunoblotting techniques (Gallick et al.,
1985) also reached the conclusion that p21
expression tended to be greatest in the earlier stages
of colonic carcinomas.
The p21 proteins are thought to function as
transducers of signals from the extracellular
environment to the nucleus in a system intimately
involved in the control of cellular proliferation
(Hurley et al., 1984; Kamata and Feramisco, 1984).
Activation, even by mutation, of ras appears to
result in the delivery of a continuous signal rather
than a regulated one (Sweet at al., 1984). Ras
activation may oe an early event in the develop¬
ment of adenomas, which are known to show a
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shorter cell cycle time as well as expansion of the
proliferating compartment relative to the normal
mucosa (Bleiberg & Galand. 1976; Deschner &
Lipkin, 1976). Indeed, cycle times in adenomas are
shorter than those of carcinomas. A further
carcinogenic stimulus or stimuli may be required
for conversion of adenomas to invasive carcinomas,
with sustained elevations of ras expression perhaps
being no longer necessary. An analogous situation
of early ras activation has been described in the
context of chemical skin carcinogenesis in mice,
where c-Ha-ros has been found to be activated at
the stage of benign papilloma formation (Balmain
et al., 1984).
The findings of this study differ significantly
from those described by Thor et al. (1984), who
found ras p21 expression to correlate with the
depth of invasion of colonic carcinoma within the
bowel wall. Using different monoclonal antibodies
raised to synthetic peptides reflecting part of the
p21 protein structure, they found p21 expression in
normal colonic mucosa and colonic adenomas to be
negative or very low, whilst carcinomas expressed
relatively high levels. This was interpreted as indi¬
cating ras activation to be a late stage in the
development of colonic malignancy. The reasons
for this discrepancy are not clear, but the different
methods used in raising these antibodies suggest
they may have very different specificities from Y13
259.
It would be of great interest to determine
whether the elevated p21 expression detected in
adenomas is a product of the normal cellular
oncogene, or of the activated mutated gene. The
monoclonal antibodies currently available are
unable to distinguish between the mutated p2I
protein and the normal, but analysis of restriction
fragment polymorphism of DNA extracted from
tumours may be a more promising approach. Work
is currently proceeding in our laboratory to address
this question.
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Evaluation of a monoclonal antibody to ras peptide, RAP-5,
claimed to bind preferentially to cells of infiltrating
carcinomas
A. Robinson1, A.R.W. Williams1, J. Piris1, D.A. Spandidos2'3 & A.H. Wyilie1
1Department of Pathology, Edinburgh University Medical School, Teviot Place, Edinburgh EH8 9AG, UK;
2Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G6I 1BD, UK;
and 3Hellenic Institute Pasteur. Athens. Greece.
Summary RAP-5, a monoclonal antibody raised against a p21"" peptide, has been claimed to show
immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that
this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no
obvious relationship to infiltrative activity. RAP-5 bound to many different cell types, neoplastic and normal.
In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster
fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these
fibroblasts by insertion of the human mutated Hi-ras oncogene in a high expression vector. Another antibody
to p21"", Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocyto-
chemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell
lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in
human tissues.
Although the mutated form of the human Harvey
ras oncogene was the first transforming gene of
cellular origin to be identified (Der et al., 1982;
Parada et al.. 1982; Santos et al., 1982), the precise
role of ras oncogenes in human malignancy is far
from established. Ras genes code for a 21,000
dalton protein, p21r°s, which is located on the inner
face of the plasma membrane (Shih et al., 1979;
Willingham et al.. 1980, 1983), binds OTP and
possesses GTPase activity (Sweet et al., 1984; Gibbs
et al., 1984; McGrath et al., 1984). Mutations in
the vicinity of codons 12 and 61 of the ras genes
lead to products deficient in GTPase. but not GTP
binding activity, and these products in particular
have been associated with carcinogenesis. Thus,
insertion of mutated ras genes into cultured cells
confers upon them a transformed phenotype and
tumorigenicity in animals (Reddy et al., 1982;
Tabm et al., 1982; Taparowski et al., 1982); mutant
p21r°s introduced to cells by micro-injection can
also initiate proliferation and effect transient
phenotypic changes akin to transformation
(Feramisco et al.. 1984; Stacey & Kung, 1984); and
ras gene mutation at the critical sites has been
shown to be an early event in experimental
chemical carcinogenesis (Sukumar et al., 1983;
Balmain et al.. 1984). In around 15% of human
solid tumours, there is evidence for the presence of
mutated ras genes (reviewed by Weinberg, 1985).
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Amplification of ras genes has also been recorded
in such tumours, although it is rare (Pulciani et al.,
1985). Hyperexpression of ras mRNA, and raised
levels of p2ras (without necessarily implicating
mutation of the gene) have been reported in
primary human tumours in a variety of sites
(Slamon et al.. 1984; Spandidos and Agnantis,
1984; Spandidos et al., 1985; Tanaka et al., 1986;
Kurzrock et al., 1986). Some studies suggest that
ras expression increases in parallel with aggressive
behaviour in neoplasms of the human colon (Horan
Hand et al., 1984), breast (Ohuchi et al., 1986) and
prostate (Viola et al.. 1986), but the opposite result
has also been reported (Spandidos & Kerr, 1984;
Gallick et al.. 1985; Williams et al., 1985; Kerr et
al.. 1986).
Recently, a series of monoclonal antibodies
termed RAP I-5 has been raised against a synthetic
peptide, consisting of amino acids 10 - 17 of
mutated humans Ha-ras p21. In immuno¬
histochemical studies, these antibodies were claimed
to show striking preferential localisation to
infiltrative carcinoma cells, as compared to non-
infiltrative neoplasms and normal tissues. In this
paper, we examine the reactivity of RAP-5 with a
range of normal and pathological human tissues,
and with rodent cells lines in which widely
divergent levels of expression of human Ha-ras p21
had been achieved through genetic manipulation
(Spandidos & Wilkie, 1984). We have found these
cell lines, together with comparison with another
antibody (Y13-259) of proven specificity to p2\ra3
! The Macmillan Press Ltd., 1986
878 A. ROBINSON et at.
(Furth et al., 1982; Lacal & Aaronson. 1986), to be
particularly helpful in assessing the important
claims made for this new antibody.
Materials and methods
Fibroblast cell lines
CHL and FH05T1 were maintained in vitro as
described previously (Spandidos & Wilkie, 1984).
CHL cells were originally obtained by culture of
fibroblasts from Chinese hamster lung. FH05T1
cells were derived from CHL cells by transfection
with the plasmid pH05Tl, which contains the
mutated human Ha-ras (T24 bladder carcinoma cell
line) oncogene adjacent to the SV40 transcriptional
enhancer sequence. Cytocentrifuge preparations
were made from these cells after disruption of the
monolayers by gentle treatment with EDTA and
trypsin.
Human colorectal tissues
Tissues were obtained within minutes of surgical
removal. Some portions were immediately frozen in
liquid nitrogen and stored at — 80°C prior to
preparation of cryostat sections, whilst others were
fixed in 4% neutral buffered formaldehyde at room
temperature for processing in paraffin. In all,
frozen material was studied from normal colonic
mucosa (5 cases), colorectal adenomas (6) and
adenocarcinomas (6). Material from the 6 adeno¬
carcinomas was also processed in paraffin. For
comparison, formaldehyde fixed paraffin processed
material representing other normal and pathological
tissues was selected from departmental files: tonsil
(I), intradermal naevus (1), malignant melanoma of
skin (1), and bronchial carcinoid tumour (1).
Immunocytochemistry
Immunocytochemical analysis with RAP-5 and
Y13-259 was carried out on 5 /im cryostat sections
fixed for 15 min in either 4% neutral buffered
formaldehyde or acetone, using a streptavidin-
biotin immunoperoxidase method as described
previously (Williams et at., 1985). With RAP-5, the
same techniques were also applied to dewaxed,
rehydrated paraffin sections. Briefly, sections or
cytocentrifuge preparations were washed in Tris
buffered saline, (TBS - sodium chloride 150mM,
Tris HC1 10 mw, pH 7.6) and nonspecific binding
blocked by application of 10% normal rabbit serum
in TBS (NR-TBS). The primary antibody was
applied for 30min at room temperature at the
optimum dilution in NR-TBS. For RAP-5 this
dilution lay between 1:10,000 and 1:20,000, whilst
for Y13-259 the optimum dilution for use with
tissue sections was 1:100 and with cytocentrifuge
preparations 1:500. The sections were washed in
TBS. and incubated for 30 min at room temperature
in the second antibody. For RAP-5. this was sheep
anti-mouse immunoglobulin (Amersham Inter¬
national) and for Y13-259 goat anti-rat immuno¬
globulin (Sigma), both biotinylated and diluted
1:50 in NR-TBS. After further washing in TBS
the sections were incubated for 15min with
streptavidin-biotinylated horseradish peroxidase
complex (Amersham) diluted 1:200 in NR-TBS.
The reaction was developed after a final wash in
TBS. with diaminobenzidine solution (lmgmF1)
(BDH) in 50 mM Tris HC1 pH 7.6, containing 10 mM
imidazole activated immediately prior to use with
H,02. The sections were briefly counterstained with
haematoxylin, dehydrated and mounted.
Negative controls were included for each case,
consisting of sections treated identically to the
•others but with NR-TBS replacing the primary
antibody. Invariably, these gave no immuno¬
peroxidase reaction save oyer macrophages and
polymorphonuclear leukocytes within the tissues.
Immunoblots
These were prepared from lysates of CHL and
FH05T1 cells. Washed cell pellets were lysed in
lOOmM sodium chloride. lOmM Tris pH7.5, 0.1%
SDS, 1% NP40 at 4°C. Insoluble residue was
removed by centnfugation at 30,000 g for 30min
and the supernatants were denatured by heat im¬
mediately prior to electrophoresis. Approximately
20 pg of protein was loaded per track on 15%
polyacrylamide gels, blotted on nitrocellulose, and
detected by Indian ink (Hancock & Tsung, 1983),
or immunostaining. We used essentially the same
conditions for immunostaining of the nitrocellulose
filter as for the cytological preparations, with the
exception that the antibody dilutions used were
1:100 and 1:1000 for both Y13-259 and RAP-5.
Incubation was for 2 h at room temperature.
Results
Finding of RAPS and Y13-259 to human tissue
sections
We confirmed, in the present series of experiments,
our previous results on the staining pattern of Y13-
259 on acetone-fixed frozen sections of human
colorectal tissues. Normal mucosa and the
epithelium of most adenocarcinomas showed low
levels of reactivity, whilst in general adenomas
showed staining of greater intensity. We did not
observe specific staining in nonepithelial cell types.
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RAP-5, applied to formaldehyde-fixed frozen
sections of the same and other blocks showed a
different pattern: although normal epithelium
tended to stain at low levels, there were no
consistent differences between infiltrative and non-
infiltrative neoplasms. Infiltrative carcinomas some¬
times showed a moderate reaction, but sometimes
were negative, whilst non-infiltrative lesions also
gave positive reactions. Within individual tumours
there was considerable variation in the distribution
of positively staining cells, and in the intensity of
the reaction (Figure la. b). We frequently observed
moderate staining of the muscularis propria.
Serosal mesothelium also consistently gave a strong
reaction. In formaldehyde-fixed paraffin and frozen
sections of a variety of other tissues, RAP-5 gave
strongly positive reactions, notably in the cells of
an intradermal naevus, malignant melanoma, and
carcinoid tumour, but there was no obvious
relationship with aggressive activity (Figure 2a-c).
Although only single cases of these conditions were
studied, the results indicate that reactivity to RAP-5
is not restricted to epithelial cells or to cells
originating from any one germ layer.
Figure 1 Immunoperoxidase detection of RAP-5
binding to formaldehyde fixed paraffin sections of
human colonic adenoma (a) and infiltrative colonic
carcinoma (b). Heterogeneity of cellular staining is
evident in both the benign and malignant tumour.
( x 50, a; xl60,b).
Binding of RA P-5 and Y13-259 to proteins in
ra.s-expressing cell lines
As previously reported (Williams et al., 1985),
Y13-259 applied to acetone fixed cytocentrifuge
preparations of the rats-transformed cell line
FH05T1, yielded strong immunochemical staining
over all cells (Figure 3a), whereas less than 5% of
the parental, untransformed CHL fibroblasts gave
positive reactions. Analysis of the antibody binding
proteins on immunoblots, after SDS-polyacrylamide
gel electrophoresis, confirmed that Y13-259 at both
1:100 and 1:1000 dilution detected a single protein,
of apparent mol. wt 21 kd in FH05T1 cells (Figure
4a). In extracts of CHL cells the same binding
protein was either undetectable or present in much
•reduced quantity. Indian ink staining of the
nitrocellulose blots, or staining of unblotted poly-
acrylamide gels with kenacid blue showed that in
terms of proteins identifiable by these means the
extracts from FH05T1 and CHL cells were closely
similar.
In contrast with these results, immunocyto-
chemistry using RAP-5 as the primary antibody
revealed no differences between the CHL and
FH05T1 cells (Figure 3b, c). All cells of either type
were negative after acetone fixation, but after
fixation in formaldehyde gave strongly positive
staining over a wide range of dilutions down to
1:20,000. Analysis of the antibody binding proteins
was attempted on immunoblots. At dilutions of
1:1000 RAP-5 scarcely defined discrete protein
bands in gel tracks loaded with extracts of either
CHL or FH05T1 cells (Figure 4b). At tenfold
higher concentration, a number of proteins of a
wide range of molecular size appeared to bind to
the antibody; the majority of these were present in
similar quantity in FH05T1 and CHL extracts
(Figure 4c).
Discussion
RAP-5 is secreted by a hybridoma derived from
spleen cells of a mouse immunised with a ras
octapeptide linked to thyroglobulin (Horan Hand et
al., 1984). The octapeptide had the amino acid
sequence 10 - 17 of the mutated human (T24) Ha¬
ras p21, and selection of the hybridoma was based
upon preferential binding of its immunoglobulin to
the mutated as opposed to the non-mutated
peptide. In practice, however, RAP-5 was found by
its originators to detect epitopes present in a far
higher proportion of human tumours than are
associated with transforming mutations of the ras
gene family. It was assumed that cross-reaction
with non-mutated p21 was responsible. Specificity
of RAP-5 for p21 ras was adduced from
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Figure 2 Immunoperoxidase detection of RAP-5 binding to formaldehyde fixed paraffin sections of human
intradermal naevus (a), malignant melanoma of skin (b), and bronchial carcinoid tumour (c). The naevus and
tumour ceils show positive staining, with some heterogeneity, and positive cells are also identified in the
overlying epidermis (a & b) or respiratory epithelium (c). ( x 160).
EVALUATION OF AN ANTIBODY TO RAS PEPTIDE 881
Figure 3 Positive staining of cytocentrifuged FH05T1 cells by Y13-259 (a). Similarly treated CHL cells
consistently gave no staining. In contrast, both FH05T1 cells (b) and CHL cells (c) showed positive staining
with RAP-5. ( x 160).
Figure 4 Electrophoresis of proteins from FH05T1
(F) and CHL cells (C). In (a), an immunoblot stained
with Y13-259 at 1:100 dilution, a single band of 21 Kd
appears in the FH05T1 extract, but is absent from the
CHL extract. RAP-5 staining of a blot of identical
extracts, at 1:1000 dilution (b) or 1:100 dilution (c)
showed multiple reactive proteins in both FH05T1 and
CHL cells. For comparison, similarly loaded tracks in
the original polyacrylamide gel, stained with kenacid
blue, are shown (d) with the position of 14 Kd and
24 Kd marker proteins (->).
competition binding studies and from immunoblots,
although the concentrations of antibody used in the
latter were unexpectedly high. Published data on
RAP-5 do not yet include studies on a wide range
of neoplastic and normal tissues. The major interest
in this new antibody derived from the observation
that it detected heterogeneity within human breast,
colonic and prostatic neoplasms, preferentially
staining areas showing infiltration of adjacent
tissues, provided it was applied to sections fixed in
formaldehyde (Horan Hand et al., 1984: Thor et
al., 1984; Viola et al., 1985, 1986; Ohuehi et al.,
1986). There were obvious implications of great
fundamental and practical importance in this
suggestion.
The data presented in this paper demonstrate the
value of unequivocal biological test systems for
such novel and potentially exciting reagents.
FH05T1 cells and the parental CHL fibroblast line
differ from one another in the possession of a
mutated Ha-ras gene, in expression of the gene at
the level of transcription (a feature which we
confirmed in dot blots of RNA extracted from cells
of similar passage history to those described here),
in expression of a protein with the molecular size
expected of p21"". in availability of this protein for
detection by immunocytochemical methods, and in
the ability to generate rapidly growing aggressive
tumours in immune suppressed animals (Spandidos
& Wilkie, 1984; Spandidos, 1985). A reagent
capable of distinguishing aggressive from non-
infiitrative cells on the basis of ras expression ought
to discriminate between these two cell lines, but
RAP-5 did not. Rather, under the conditions
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described by its originators, it seemed to detect
proteins plentiful in both cells, and also in many
human cell types, both normal and neoplastic, of a
variety of embryological derivations. These results
do not exclude the possibility that RAP-5 may bind
to a ras peptide, but indicate that it also recognises
other widely distributed epitopes which are not
related to ras expression. A similar conclusion has
recently been reached on the basis of immunohisto-
chemical studies on human breast tissue (Ghosh et
al., 1986). Other antibodies raised against small
oncogene peptides have been shown in the past to
be capable of reaction with epitopes common to
many cellular proteins despite the appearances of
specificity in immunoabsorption studies (Nigg et
al., 1982).
The role of ras products in tumour aggression
remains undecided. In expenmental animals, cells
transformed by the mutated ras gene have been
shown to be capable of both infiltration and
metastasis (Spandidos & Wilkie, 1984; Muschel et
al., 1985; Thorgeirsson et al., 1985), but ras
expression does not always confer aggressive
properties. Normal ras genes are expressed physio¬
logically in non-dividing tissues (Spandidos &
Dimitrov, 1985), and in one phaeochromocvtoma
cell line insertion of the products of the mutated ras
gene led to differentiation and replication arrest
(Bar-Sagi & Feramisco, 1985). Several different
groups have presented evidence from animal
tumours and human colonic neoplasia that
activation (by mutation or hyperexpression) of the
ras gene is a feature of early rather than late
neoplasia (Sukumar et al., 1983; Balmain et al.,
1984; Williams et al.. 1985; Yuspa et al., 1985).
It seems probable that immunohistochemical
methods will remain important in attempts to
clarify the role of ras and other oncogenes in
human neoplasia. This paper highlights the value of
genetically modified cell lines in the critical
evaluation of antibodies raised against oncogene
proteins and peptides, and in particular casts
serious doubt on the usefulness of RAP-5 in
detection of human ras-coded, or ray-associated
proteins.
This work was supported by a grant from the Cancer
Research Campaign to AHW. We are grateful to Dr J.
Schlom for a generous gift of RAP-5 and to Dr E. Duvall
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1.3% w/v bisacrylamide in DDW
Separating gel (15%)
Mix: 15 ml soln. A
15 ml soln. E
0.5 ml 10% SDS
6.25 ml soln. B
13 ml DDW
0.25 ml 10% (w/v) ammonium persulphate (fresh)
Degas in vacuum chamber.
Add 20 ul Temed (tetramethylene diamine - BDH Chemicals)
Pour between very clean glass plates and overlay with 1ml.
DDW. Allow to set for 30 mins in warm room, or incubator.
Stacking gel (5%)
Mix: 2 ml soln. A
2 ml soln. E
0.2 ml 10% SDS
4.8 ml soln. C
16.8 ml DDW
0.2 ml 10% w/v ammonium persulphate
Degas, then add 20ul Temed. Pour off DDW overlay, then
layer stacking gel on to separating gel.
Insert comb, allow to set.
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APPENDIX 3
Preparation of PLPD fixative
For 400 ml:
150 ml 0.05 M phosphate buffer
50 ml 8% paraformaldehyde
0.43 g anhydrous sodium metaperiodate
2.74 g lysine HC1
5 g potassium dichromate
200 ml DDW
Phosphate Buffer
12.5 g disodium hydrogen orthophosphate anhydrous
(MW 142)
or
15.6 g disodium hydrogen orthophosphate dihydrate
(MW 178)
2 g sodium dihydrogen orthophosphate dihydrate
(MW 156)
Dissolve in 2 1 of DDW
To prepare 8% paraformaldehyde
For 200 ml:
16 g paraformaldehyde powder
1 ml 5M NaOH
to 200 ml with DDW
o
Filter and store in the dark at 4 C.
Fixation
Tissues should be trimmed to 5mm thickness. Fixation
o
is for a minimum of 18 hrs in the dark at 4 C. Fixed
tissues must be washed in running tap water
overnight to remove dichromate precipitate.
